title,url,time_published,summary,ticker,relevance_score,ticker_sentiment_score,ticker_sentiment_label
"If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/earnings/23/01/30357221/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-400-today,2023-01-10 16:32:50,"Gilead Sciences GILD has outperformed the market over the past 15 years by 1.85% on an annualized basis producing an average annual return of 9.05%. Currently, Gilead Sciences has a market capitalization of $109.52 billion.",GILD,0.980595,0.386944,Bullish
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities,https://www.globenewswire.com/news-release/2023/01/09/2585279/0/en/Nurix-Therapeutics-Advances-Promising-Targeted-Protein-Modulation-Pipeline-and-Outlines-2023-Strategic-Priorities.html,2023-01-09 13:35:00,Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform ...,GILD,0.053589,0.048,Neutral
"Atreca Appoints Philippe Bishop, MD as Chief Medical Officer - Atreca  ( NASDAQ:BCEL ) ",https://www.benzinga.com/pressreleases/23/01/g30331959/atreca-appoints-philippe-bishop-md-as-chief-medical-officer,2023-01-09 13:30:54,"SAN CARLOS, Calif., Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- Atreca, Inc. ( Atreca ) BCEL, a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the ...",GILD,0.041975,-0.070877,Neutral
"Atreca Appoints Philippe Bishop, MD as Chief Medical Officer",https://www.globenewswire.com/news-release/2023/01/09/2585273/0/en/Atreca-Appoints-Philippe-Bishop-MD-as-Chief-Medical-Officer.html,2023-01-09 13:30:00,"SAN CARLOS, Calif., Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- Atreca, Inc. ( Atreca ) ( NASDAQ: BCEL ) , a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today ...",GILD,0.042571,-0.070973,Neutral
"XBB.1.5, which makes up 28% of new COVID cases in the U.S., fuels worries about a winter wave",https://www.marketwatch.com/story/xbb-1-5-which-makes-up-28-of-new-covid-cases-in-the-u-s-fuels-worries-about-a-winter-wave-11673027050,2023-01-06 17:44:00,The highly transmissible subvariant of omicron has rapidly become one of the most dominant strains of the virus in the U.S.,GILD,0.09186,0.075893,Neutral
Can The No. 1 Pharma Stock Continue Its Blazing Run In 2023?,https://www.investors.com/news/technology/merck-stock-the-catalysts-that-could-drive-the-no-1-pharma-stock-further-in-2023/,2023-01-05 16:04:00,Merck Stock: The Catalysts That Could Drive The No. 1 Pharma ... Investor's Business Daily ...,GILD,0.068306,-0.122445,Neutral
Is Franklin U.S. Low Volatility High Dividend Index ETF  ( LVHD )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2035494/is-franklin-us-low-volatility-high-dividend-index-etf-lvhd-a-strong-etf-right-now,2023-01-05 11:20:08,Smart Beta ETF report for ...,GILD,0.115787,0.056737,Neutral
Gilead Sciences  ( GILD )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2035366/gilead-sciences-gild-gains-but-lags-market-what-you-should-know,2023-01-04 22:50:23,"Gilead Sciences (GILD) closed at $85.50 in the latest trading session, marking a +0.13% move from the prior day.",GILD,0.593484,0.342269,Somewhat-Bullish
Gilead's  ( GILD )  Application for Trodelvy Gets EMA Validation,https://www.zacks.com/stock/news/2035261/gileads-gild-application-for-trodelvy-gets-ema-validation,2023-01-04 16:45:00,Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.,GILD,0.209819,0.080105,Neutral
Gilead Sciences: Connecting Breast Cancer Education to Community: Equal Hope - Investing News Network,https://investingnews.com/gilead-sciences-connecting-breast-cancer-education-to-community-equal-hope/,2023-01-04 15:30:47,Gilead Sciences: Connecting Breast Cancer Education to Community: Equal Hope Investing News Network ...,GILD,0.13347,0.0,Neutral
AMGN: 2 Biotech Stocks to Buy Amid a Blazing Hot Run,https://stocknews.com/news/amgn-gild-2-biotech-stocks-to-buy-amid-a-blazing-hot-run/,2023-01-04 15:20:50,"After being thrust into the limelight during the pandemic, biotech stocks fell out of investors' radars as people got vaccinated and resumed their regular activities. However, with a rapidly aging population and the rise of sedentary lifestyles, diseases are on the rise, driving the demand for ...",GILD,0.296582,0.235756,Somewhat-Bullish
"Curebase Celebrates Year of Growth, Organizational Maturity",https://www.prnewswire.com/news-releases/curebase-celebrates-year-of-growth-organizational-maturity-301713148.html,2023-01-04 14:35:00,"SAN FRANCISCO, Jan. 4, 2023 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, capped off a successful 2022 with continued growth, maturity, and expansion of its footprint in the decentralized clinical trials ( DCT ) market.",GILD,0.064449,-0.050028,Neutral
European Medicines Agency Validates Marketing Authorization Application For TrodelvyÂ® For Pre-treated HR+/HER2- Metastatic Breast Cancer,https://investingnews.com/european-medicines-agency-validates-marketing-authorization-application-for-trodelvy-r-for-pre-treated-hr-her2-metastatic-breast-cancer/,2023-01-03 13:57:08,Application Based on Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Results from the Phase 3 TROPiCS-02 Study -,GILD,0.09358,0.036629,Neutral
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies - Investing News Network,https://investingnews.com/gilead-and-evoq-therapeutics-announce-collaboration-to-advance-immunotherapies/,2023-01-03 13:57:08,Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies Investing News Network ...,GILD,0.195025,0.080919,Neutral
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?,https://www.fool.com/investing/2023/01/02/better-large-cap-roche-holding-or-gilead-sciences/,2023-01-02 14:00:00,Which of these companies is better able to replace declining COVID-19-related sales?,GILD,0.100099,0.11487,Neutral
CSCO: 2 Nasdaq Stocks to Buy Now and Hold All of 2023,https://stocknews.com/news/csco-gild-2-nasdaq-stocks-to-buy-now-and-hold-all-of/,2023-01-20 17:31:08,CSCO: 2 Nasdaq Stocks to Buy Now and Hold All of ...,GILD,0.31282,0.187815,Somewhat-Bullish
SK bioscience Appoints New Executives to Accelerate New Growth Strategies,https://www.prnewswire.com/news-releases/sk-bioscience-appoints-new-executives-to-accelerate-new-growth-strategies-301726445.html,2023-01-20 12:00:00,SK bioscience Appoints New Executives to Accelerate New Growth ... PR ...,GILD,0.061631,0.039,Neutral
Active vs. Passive Investing: Which Strategy Is Right for You?,https://www.thestreet.com/investing/active-vs-passive-investing-15017234,2023-01-19 23:40:00,"Some investors like to buy and hold, while others choose to a more hands-on approach, watching the market, buying, selling, and capitalizing on short-term profits.",GILD,0.030064,0.15095,Somewhat-Bullish
"Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023",https://investingnews.com/gilead-sciences-to-release-fourth-quarter-full-year-2022-financial-results-on-thursday-february-2-2023/,2023-01-19 21:25:41,"Gilead Sciences, Inc. ( Nasdaq: GILD ) announced today that its fourth quarter and full year 2022 financial results and full year 2023 financial guidance will be released on Thursday, February 2 after the market closes. At 4:30 p.m.",GILD,0.70749,0.236952,Somewhat-Bullish
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million,https://investingnews.com/the-robert-a-winn-diversity-in-clinical-trials-award-program-established-by-the-bristol-myers-squibb-foundation-to-expand-with-amgen-s-commitment-of-8-million/,2023-01-19 13:49:51,Amgen Joins Gilead Sciences as a Program Supporter Applications Now Open for Physicians and Medical Students The Robert A.,GILD,0.125134,0.258142,Somewhat-Bullish
GILD: 2 Biotech Stocks to Buy up in 2023 and 1 to Avoid Like the Plague,https://stocknews.com/news/gild-uthr-bngo-2-biotech-stocks-to-buy-up-in-2023-and-1/,2023-01-19 12:59:27,GILD: 2 Biotech Stocks to Buy up in 2023 and 1 to Avoid Like the ... ...,GILD,0.376572,0.168678,Somewhat-Bullish
ABBV: 3 Safe High-Dividend Stocks to Buy Right Now,https://stocknews.com/news/abbv-gild-mpx-3-safe-high-dividend-stocks-to-buy-right-now/,2023-01-18 14:19:50,"The December CPI marked the sixth-straight monthly decline, as prices rose 6.5% annually, down from 7.1% in November 2022. However, Simona Mocuta, Chief economist at State Street Global Advisors, said, ""We know that we won't get the same kind of support from gasoline prices, so don't expect the ...",GILD,0.320557,0.087128,Neutral
3 Stocks That Beat the S&P During the Great Recession,https://www.fool.com/investing/2023/01/18/stocks-that-beat-sp-500-during-great-recession/,2023-01-18 11:35:00,These stocks could be safe places to store your money if a recession takes place this year.,GILD,0.167322,-0.006041,Neutral
Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2040413/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know,2023-01-17 22:50:20,"Gilead Sciences (GILD) closed at $85.41 in the latest trading session, marking a -1% move from the prior day.",GILD,0.697241,0.216899,Somewhat-Bullish
VRTX: The No. 1 Biotech Stock to Buy for 2023,https://stocknews.com/news/vrtx-gild-biib-uthr-the-no-1-biotech-stock-to-buy-for-2023/,2023-01-17 14:02:08,VRTX: The No. 1 Biotech Stock to Buy for ...,GILD,0.083107,0.09299,Neutral
Should SPDR Russell 1000 Yield Focus ETF  ( ONEY )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2039882/should-spdr-russell-1000-yield-focus-etf-oney-be-on-your-investing-radar,2023-01-17 11:20:09,Style Box ETF report for ONEY ...,GILD,0.118647,0.067448,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2039887/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-01-17 11:20:08,Smart Beta ETF report for ...,GILD,0.12013,0.062124,Neutral
Mark Zuckerberg On Elon Musk's Approach To Twitter Content Moderation: 'It's Going To Be Very Interesting...',https://www.benzinga.com/news/22/12/29917668/mark-zuckerberg-on-elon-musks-approach-to-twitter-content-moderation-its-going-to-be-very-1,2023-01-17 01:34:08,Meta Platforms Inc META CEO Mark Zuckerberg commented on Twitter CEO Elon Musk's approach to content moderation on Twitter at DealBook Summit in November 2022.,GILD,0.16171,-0.019738,Neutral
Is iShares Select Dividend ETF  ( DVY )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2039439/is-ishares-select-dividend-etf-dvy-a-strong-etf-right-now,2023-01-16 11:20:08,Smart Beta ETF report for ...,GILD,0.113329,0.060706,Neutral
GILD: 2 Biotech Stocks Under $100 to Buy Now,https://stocknews.com/news/gild-cort-2-biotech-stocks-under-100-to-buy-now/,2023-01-13 19:40:34,"The biotech industry has thrived amid the pandemic. Moreover, the National Biotechnology and Biomanufacturing Initiative of the Biden-Harris Administration is expected to fuel the industry's future expansion.",GILD,0.499789,0.171304,Somewhat-Bullish
HMC: These 3 Stocks Pay You to Own Them,https://stocknews.com/news/hmc-gild-sire-these-3-stocks-pay-you-to-own-them/,2023-01-13 13:38:51,"Inflation closed out 2022 in a modest retreat, with the consumer price index ( CPI ) accelerating 6.5% year-over-year in December, down from 7.1% in November and a 9.1% peak hit in June last year. Despite the significant slowdown in price increases, inflation continues to hover way above the ...",GILD,0.311237,0.13809,Neutral
"After Ditching Promising Drug, Everest Medicines Bets on mRNA - Gilead Sciences  ( NASDAQ:GILD ) , Pfizer  ( NYSE:PFE ) ",https://www.benzinga.com/23/01/30388310/after-ditching-promising-drug-everest-medicines-bets-on-mrna,2023-01-12 13:21:20,"Everest Medicines is staking its future on mRNA vaccines, which it will produce in a new $130 facility that recently began operations in Zhejiang province The company will have to compete with many other domestic drug makers shelling out big bucks to develop mRNA vaccines with strong support from ...",GILD,0.082251,0.02407,Neutral
Gilead Sciences  ( GILD )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2038141/gilead-sciences-gild-gains-but-lags-market-what-you-should-know,2023-01-11 22:50:19,"In the latest trading session, Gilead Sciences (GILD) closed at $87.19, marking a +0.06% move from the previous day.",GILD,0.640349,0.433565,Bullish
Peering Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/01/30371101/peering-into-gilead-sciencess-recent-short-interest,2023-01-11 15:14:12,"Gilead Sciences's GILD short percent of float has fallen 15.71% since its last report. The company recently reported that it has 14.76 million shares sold short, which is 1.18% of all regular shares that are available for trading.",GILD,0.221819,0.083071,Neutral
Top Dividend Stock: Gilead Sciences Nears Buy Point Ahead of Earnings,https://www.investors.com/research/the-income-investor/top-dividend-stock-gilead-sciences-nears-buy-point-ahead-of-earnings/,2023-01-11 15:08:00,Top Dividend Stock: Gilead Sciences Nears Buy Point Ahead of ... Investor's Business Daily ...,GILD,0.276909,0.410199,Bullish
2 Unstoppable Stocks That Could Beat the Market Again In 2023,https://www.fool.com/investing/2023/01/11/2-unstoppable-stocks-that-could-beat-the-market-ag/,2023-01-11 13:45:00,"Thankfully, it's not too late to buy these stocks.",GILD,0.515543,0.401999,Bullish
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2037707/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-01-11 11:20:09,Sector ETF report for ...,GILD,0.136113,0.07192,Neutral
Why Gilead  ( GILD )  is Poised to Beat Earnings Estimates Again,https://www.zacks.com/stock/news/2046442/why-gilead-gild-is-poised-to-beat-earnings-estimates-again,2023-01-30 17:10:11,Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,GILD,0.16849,0.033717,Neutral
Will Eylea and Dupixent Fuel Regeneron's  ( REGN )  Q4 Earnings?,https://www.zacks.com/stock/news/2046381/will-eylea-and-dupixent-fuel-regenerons-regn-q4-earnings,2023-01-30 16:03:00,Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.,GILD,0.139265,0.070365,Neutral
"Global Pharmaceutical Drug Delivery Market worth $2,206.5 billion by 2026 - Exclusive Report by MarketsandMarketsâ¢",https://www.benzinga.com/pressreleases/23/01/g30622827/global-pharmaceutical-drug-delivery-market-worth-2-206-5-billion-by-2026-exclusive-report-by-marke,2023-01-30 14:30:00,"Chicago, Jan. 30, 2023 ( GLOBE NEWSWIRE ) -- According to the new market research report ""Pharmaceutical Drug Delivery Market Size, Growth by Route of Administration ( Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes ) , Application ( Cancer, Diabetes ) , ...",GILD,0.087503,0.021576,Neutral
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma,https://investingnews.com/kite-and-arcellx-close-agreement-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma/,2023-01-30 14:27:49,"Kite, a Gilead Company ( NASDAQ: GILD ) , and Arcellx, Inc. ( NASDAQ: ACLX ) , today announced the closing of the companies' previously announced global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of ...",GILD,0.132186,0.120825,Neutral
Should iShares Select Dividend ETF  ( DVY )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2046052/should-ishares-select-dividend-etf-dvy-be-on-your-investing-radar,2023-01-30 11:20:06,Style Box ETF report for ...,GILD,0.123209,0.068541,Neutral
Jobs report to give further clues about where economy is headed | Business,https://www.cnn.com/2023/01/29/investing/stocks-week-ahead,2023-01-29 12:17:00,Jobs report to give further clues about where economy is headed ...,GILD,0.057907,-0.067965,Neutral
Jobs report to give further clues about where economy is headed | Business,https://www.cnn.com/2023/01/29/investing/stocks-week-ahead/index.html,2023-01-29 12:17:00,Jobs report to give further clues about where economy is headed ...,GILD,0.057907,-0.067965,Neutral
"Investing Action Plan - January Wrap: Apple, OPEC, Exxon And The Fed",https://www.investors.com/research/investing-action-plan/stock-market-investing-action-plan-january-wrap-apple-opec-exxon-and-the-fed/,2023-01-27 23:20:00,"Investing Action Plan - January Wrap: Apple, OPEC, Exxon And ... Investor's Business Daily ...",GILD,0.032916,0.047876,Neutral
"If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today",https://www.benzinga.com/news/earnings/23/01/30608259/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-400-today,2023-01-27 19:32:06,"Gilead Sciences GILD has outperformed the market over the past 15 years by 1.47% on an annualized basis producing an average annual return of 8.95%. Currently, Gilead Sciences has a market capitalization of $105.06 billion.",GILD,0.980595,0.386944,Bullish
Regeneron  ( REGN )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?,https://www.zacks.com/stock/news/2045515/regeneron-regn-expected-to-beat-earnings-estimates-can-the-stock-move-higher,2023-01-27 15:00:12,Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,GILD,0.088472,0.038117,Neutral
Should Franklin U.S. Low Volatility High Dividend Index ETF  ( LVHD )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2045270/should-franklin-us-low-volatility-high-dividend-index-etf-lvhd-be-on-your-investing-radar,2023-01-27 11:20:06,Style Box ETF report for ...,GILD,0.11894,0.064126,Neutral
Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2045034/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know,2023-01-26 22:45:22,"Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.",GILD,0.633079,0.283215,Somewhat-Bullish
Gilead Sciences  ( GILD )  Earnings Expected to Grow: Should You Buy?,https://www.zacks.com/stock/news/2044810/gilead-sciences-gild-earnings-expected-to-grow-should-you-buy,2023-01-26 15:01:14,Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,GILD,0.101582,0.084349,Neutral
Could Gilead Sciences Stock Help You Become a Millionaire?,https://www.fool.com/investing/2023/01/26/could-gilead-sciences-stock-help-you-become-a-mill/,2023-01-26 13:55:00,Does Gilead have enough growth potential to become a market-beating investment?,GILD,0.256314,0.457744,Bullish
GILD: 1 Biotech Stock to Buy in January 2023 and 1 to Sell,https://stocknews.com/news/gild-stok-1-biotech-stock-to-buy-in-january-2023-and-1/,2023-01-25 13:21:02,"The biotech industry thrived and drew much attention during the pandemic years due to the production of new life-saving drugs, vaccines, and therapeutics. The bioscience industry's economic impact on the U.S. economy amounted to $2.9 trillion in 2021.",GILD,0.553402,0.3018,Somewhat-Bullish
Gilead Sciences  ( GILD )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2043606/gilead-sciences-gild-gains-as-market-dips-what-you-should-know,2023-01-24 22:50:23,"Gilead Sciences (GILD) closed the most recent trading day at $84.02, moving +0.95% from the previous trading session.",GILD,0.633079,0.349328,Somewhat-Bullish
Gilead  ( GILD )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2043538/gilead-gild-to-report-q4-earnings-whats-in-the-cards,2023-01-24 18:53:00,Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.,GILD,0.169676,0.0,Neutral
GILD: 1 High-Yield Dividend Stock You Can Count on in 2023,https://stocknews.com/news/gild-uthr-vrtx-biib-1-high-yield-dividend-stock-you-can-count-on-in-2023/,2023-01-24 14:55:48,GILD: 1 High-Yield Dividend Stock You Can Count on in ...,GILD,0.587401,0.435219,Bullish
GILD: 3 Top-Rated Stocks to Buy for the Long Haul,https://stocknews.com/news/gild-biib-audc-3-top-rated-stocks-to-buy-for-the-long-haul/,2023-01-24 12:27:54,"Aggressive rate hikes by the Fed to curb sky-high inflation last year had resulted in massive selloffs, but it did have its intended effect. Inflation eased for the sixth consecutive time in December. CPI increased by 6.5% year-over-year and dipped 0.1% over the prior month, in line with the Dow ...",GILD,0.379531,0.239081,Somewhat-Bullish
GILD: Get the Most Bang for Your Buck With These 3 Stocks,https://stocknews.com/news/gild-kro-bvh-get-the-most-bang-for-your-buck-with-these-3/,2023-01-23 19:07:40,"While hopes of a sharp decline in inflation helped the market make a good start to the year, a sharper-than-expected decline in retail sales during the holiday month and a third consecutive month of decline in industrial activity have been an unpleasant reminder about the double-edged nature of ...",GILD,0.391311,0.163839,Somewhat-Bullish
GILD or GMAB: Which Is the Better Value Stock Right Now?,https://www.zacks.com/stock/news/2042763/gild-or-gmab-which-is-the-better-value-stock-right-now,2023-01-23 16:40:14,GILD vs. GMAB: Which Stock Is the Better Value Option?,GILD,0.7414,0.593263,Bullish
Gilead  ( GILD )  Gains 21% in a Year: Will the Trend Continue?,https://www.zacks.com/stock/news/2042729/gilead-gild-gains-21-in-a-year-will-the-trend-continue,2023-01-23 15:20:00,Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.,GILD,0.224903,0.108841,Neutral
Should You Invest in the VanEck Biotech ETF  ( BBH ) ?,https://www.zacks.com/stock/news/2042463/should-you-invest-in-the-vaneck-biotech-etf-bbh,2023-01-23 11:20:08,Sector ETF report for ...,GILD,0.133841,0.071297,Neutral
3 Smart Stocks to Buy if a Recession Is on the Way,https://www.fool.com/investing/2023/01/21/3-smart-stocks-to-buy-if-a-recession-is-on-the-way/,2023-01-21 11:55:00,Their products will enjoy strong demand regardless of what happens with the economy.,GILD,0.169676,-0.087774,Neutral
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update,https://www.globenewswire.com/news-release/2023/02/09/2605512/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2022-Financial-Results-and-Provides-a-Corporate-Update.html,2023-02-09 21:15:00,Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies ...,GILD,0.085997,0.020712,Neutral
GILD: 3 High-Value Stocks to Buy and Hold for a Lifetime,https://stocknews.com/news/gild-stla-bvh-3-high-value-stocks-to-buy-and-hold-for-a-lifetime/,2023-02-09 17:18:25,"The Fed raised its interest rates by 25 basis points at the first Federal Open Market Committee ( FOMC ) meeting of 2023, bringing the federal funds rate to a target range of 4.5% to 4.75%.",GILD,0.3426,0.24131,Somewhat-Bullish
Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/02/30839751/kites-tecartus-car-t-cell-therapy-demonstrates-durable-overall-survival-benefit-in-leukemia-setti,2023-02-09 17:17:32,"Kite, a Gilead Sciences Inc GILD company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus ( brexucabtagene autoleucel ) .",GILD,0.501398,0.170037,Somewhat-Bullish
"Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update",https://www.zacks.com/stock/news/2052486/biotech-stock-roundup-amgn-gild-bmy-regns-q4-results-kprx-up-on-study-update,2023-02-09 17:00:00,"Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.",GILD,0.128135,0.1827,Somewhat-Bullish
Regenerative Medicine Market Growth Report  ( $37.48 Billion )  Lead by Increasing Adoption of Gene Therapies | The Insight Partners,https://www.benzinga.com/pressreleases/23/02/g30833795/regenerative-medicine-market-growth-report-37-48-billion-lead-by-increasing-adoption-of-gene-thera,2023-02-09 14:08:00,"New York, Feb. 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Regenerative Medicine Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Cell-Based Immunotherapy and Cell Therapy Products, Tissue-Engineered Products, ...",GILD,0.030408,0.100066,Neutral
Starburst Unveils Inaugural Data Rebel and Partner Award Winners at Datanova Conference,https://www.prnewswire.com/in/news-releases/starburst-unveils-inaugural-data-rebel-and-partner-award-winners-at-datanova-conference-301742770.html,2023-02-09 14:00:00,Starburst Unveils Inaugural Data Rebel and Partner Award Winners ... PR ...,GILD,0.062271,0.031158,Neutral
Starburst Unveils Inaugural Data Rebel and Partner Award Winners at Datanova Conference,https://www.prnewswire.com/news-releases/starburst-unveils-inaugural-data-rebel-and-partner-award-winners-at-datanova-conference-301742770.html,2023-02-09 14:00:00,Starburst Unveils Inaugural Data Rebel and Partner Award Winners ... PR ...,GILD,0.062271,0.031158,Neutral
Starburst Unveils Inaugural Data Rebel and Partner Award Winners at Datanova Conference,https://www.newswire.ca/news-releases/starburst-unveils-inaugural-data-rebel-and-partner-award-winners-at-datanova-conference-844575743.html,2023-02-09 14:00:00,Starburst Unveils Inaugural Data Rebel and Partner Award Winners ... Canada ...,GILD,0.062271,0.031158,Neutral
GILD: 1 Dividend Stock You'll Be Thankful to Own in 2023,https://stocknews.com/news/gild-vrtx-biib-uthr-1-dividend-stock-youll-be-thankful-to-own-in-2023/,2023-02-09 13:53:09,GILD: 1 Dividend Stock You'll Be Thankful to Own in ...,GILD,0.598987,0.369852,Bullish
Mind the Gap: Understanding the 3 Types of Price Gaps,https://www.zacks.com/commentary/2051869/mind-the-gap-understanding-the-3-types-of-price-gaps,2023-02-09 13:40:00,Large price gaps can mark the end of a major price moves or be the signature of a future winning stock. Andrew Rocco explains the difference through historical examples.,GILD,0.094762,0.062846,Neutral
2 Biotech Stocks That Could Make You Richer,https://www.fool.com/investing/2023/02/09/2-biotech-stocks-that-could-make-you-richer/,2023-02-09 13:00:00,Patience will pay off with these two stocks.,GILD,0.518879,0.304016,Somewhat-Bullish
Kite's TecartusÂ® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia,https://investingnews.com/kite-s-tecartus-r-car-t-cell-therapy-demonstrates-overall-survival-benefit-in-three-year-follow-up-of-pivotal-zuma-3-trial-in-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia/,2023-02-09 12:35:27,"Kite, a Gilead Company ( Nasdaq: GILD ) , today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus Â® ( brexucabtagene autoleucel ) .",GILD,0.066002,0.078428,Neutral
"2023 CALIFORNIA CONFERENCE FOR WOMEN TO FOCUS ON LEADERSHIP, CONNECTION, AND BEING A FORCE FOR CHANGE",https://www.benzinga.com/pressreleases/23/02/n30821811/2023-california-conference-for-women-to-focus-on-leadership-connection-and-being-a-force-for-chang,2023-02-08 20:29:00,"SANTA CLARA, Feb. 8, 2023 /PRNewswire/ -- Leaders from corporate America, the media, sports, arts, and Hollywood will come together this Women's History Month to discuss women leading together to be a force for positive change in 2023. They include the former CEO of IBM Ginny Rometty.",GILD,0.051551,0.15847,Somewhat-Bullish
"Physicians' Education Resource Announces 40th Annual Miami Breast Cancer Conference Scheduled for March 2-5, 2023",https://www.benzinga.com/pressreleases/23/02/g30818618/physicians-education-resource-announces-40th-annual-miami-breast-cancer-conference-scheduled-for-m,2023-02-08 17:27:34,"CRANBURY, N.J., Feb. 08, 2023 ( GLOBE NEWSWIRE ) -- Physicians' Education ResourceÂ®, LLC ( PERÂ® ) , a top educational resource for health care professionals across all specialties to advance patient care, today announced it will host its 40th Annual Miami Breast Cancer ConferenceÂ® at the ...",GILD,0.072876,0.155301,Somewhat-Bullish
"2028 Immuno-Oncology Market Report Puts Limelight on Market Size, Share, Growth Opportunities, Factors and Trends Influencing the Industry | Xcellent Insights",https://www.benzinga.com/pressreleases/23/02/g30764491/2028-immuno-oncology-market-report-puts-limelight-on-market-size-share-growth-opportunities-factor,2023-02-07 14:19:55,"Pune, Feb. 07, 2023 ( GLOBE NEWSWIRE ) -- The global Immuno-Oncology Market Size was USD 43698.02 million in 2021 and is expected to register a robust revenue CAGR of 15.05% during the forecast period.",GILD,0.041181,0.0,Neutral
Is SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2050743/is-spdr-portfolio-sp-500-high-dividend-etf-spyd-a-strong-etf-right-now,2023-02-07 11:20:06,Smart Beta ETF report for ...,GILD,0.116067,0.066855,Neutral
GILD: 3 Must-Have Dividend Stocks for 2023,https://stocknews.com/news/gild-vlo-arc-3-must-have-dividend-stocks-for-2023/,2023-02-07 08:27:59,GILD: 3 Must-Have Dividend Stocks for ...,GILD,0.277608,0.135822,Neutral
Gilead's  ( GILD )  Breast Cancer Drug Trodelvy Gets FDA Nod,https://www.zacks.com/stock/news/2050554/gileads-gild-breast-cancer-drug-trodelvy-gets-fda-nod,2023-02-06 18:27:00,"Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.",GILD,0.323785,0.036229,Neutral
"Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL",https://www.zacks.com/stock/news/2050425/biotech-stocks-q4-earnings-due-on-feb-7-vrtx-incy-and-exel,2023-02-06 15:30:00,"Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.",GILD,0.108466,0.041372,Neutral
Drug companies face COVID cliff in 2023 as sales set to plummet,https://www.reuters.com/business/healthcare-pharmaceuticals/drug-companies-face-covid-cliff-2023-sales-set-plummet-2023-02-06/,2023-02-06 11:08:02,"[1/3] Empty vials of Pfizer-BioNTech coronavirus disease ( COVID-19 ) children's vaccines are pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., May 19, 2022. REUTERS/Hannah Beier/File Photo",GILD,0.051999,0.0,Neutral
Is Gilead Sciences a Good Stock to Buy Now?,https://www.fool.com/investing/2023/02/06/is-gilead-sciences-a-good-stock-to-buy-now/,2023-02-06 10:41:00,"Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward.",GILD,0.405963,0.349046,Somewhat-Bullish
10 Companies That Boosted Their Dividends This Week,https://www.barrons.com/articles/gilead-sciences-cigna-valero-dividend-stocks-51675455571,2023-02-04 08:00:00,Old Dominion Freight Line and 9 More Companies That Raised Their Stock Dividends ...,GILD,0.9973,0.246359,Somewhat-Bullish
"Ford, Starbucks fall; Clorox, Gilead Sciences rise",https://apnews.com/article/technology-stocks-and-bonds-financial-markets-alphabet-inc-clorox-co-8e74bd1a2e74d25920cb7dfb5e1777a5,2023-02-03 21:27:02,"Ford, Starbucks fall. Clorox, Gilead Sciences rise The Associated Press - en ...",GILD,0.340915,0.0,Neutral
Gilead  ( GILD )  Q4 Earnings & Sales Top on Biktarvy & Oncology,https://www.zacks.com/stock/news/2049797/gilead-gild-q4-earnings-sales-top-on-biktarvy-oncology,2023-02-03 21:16:00,Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.,GILD,0.167032,0.289211,Somewhat-Bullish
"Market Rally Powers Higher On Tame Fed, Meta: Weekly Review",https://www.investors.com/news/market-rally-powers-higher-on-tame-fed-meta-earnings-apple-google-amazon/,2023-02-03 18:43:00,"The stock market rally marched higher as the Fed took a slightly more dovish stance, even though it said rate hikes will continue. Friday's superhot jobs report failed to derail the uptrend. Big earnings or guidance continued to be mixed, but Meta Platforms ( META ) skyrocketed on cost cuts, ...",GILD,0.040864,-0.175455,Somewhat-Bearish
Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/02/30711002/gilead-sciences-trovelvy-scores-fda-approval-for-advancedmetastatic-breast-cancer-setting,2023-02-03 17:54:22,The FDA has approved Gilead Sciences Inc's GILD Trodelvy ( sacituzumab govitecan-hziy ) for adult patients with advanced or metastatic breast cancer.,GILD,0.485711,0.193575,Somewhat-Bullish
U.S. FDA Approves TrodelvyÂ® in Pre-treated HR+/HER2- Metastatic Breast Cancer - Investing News Network,https://investingnews.com/u-s-fda-approves-trodelvy-r-in-pre-treated-hr-her2-metastatic-breast-cancer/,2023-02-03 15:50:55,U.S. FDA Approves TrodelvyÂ® in Pre-treated HR+/HER2- Metastatic Breast Cancer Investing News Network ...,GILD,0.077887,0.074516,Neutral
Gilead's breast cancer drug secures U.S. FDA approval for expanded use,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-expanded-use-gileads-breast-cancer-drug-2023-02-03/,2023-02-03 15:40:00,U.S. FDA approves expanded use of Gilead's breast cancer drug ...,GILD,0.214937,0.056028,Neutral
AIDS Memorial Quilt Heads to New Orleans and Baton Rouge to Change the Pattern and End HIV in Black and Brown Communities,https://www.benzinga.com/pressreleases/23/02/g30706018/aids-memorial-quilt-heads-to-new-orleans-and-baton-rouge-to-change-the-pattern-and-end-hiv-in-blac,2023-02-03 13:30:00,"NEW ORLEANS & BATON ROUGE, LA, Feb. 03, 2023 ( GLOBE NEWSWIRE ) -- Louisiana has the fourth highest HIV diagnoses rates in the country, so beginning on Feb. 7, National Black HIV/AIDS Awareness Day, sections of the AIDS Memorial Quilt honoring Black and Brown lives lost to HIV and AIDS will ...",GILD,0.15697,0.13332,Neutral
"S&P 500 Futures Fall in Premarket Trading; Bill.com Holdings, Atlassian Lag",https://www.barrons.com/articles/s-p-500-futures-fall-in-premarket-trading-bill-com-holdings-atlassian-lag-01675427448,2023-02-03 12:30:00,"S&P 500 Futures Fall in Premarket Trading. Bill.com Holdings, Atlassian Lag ...",GILD,0.866386,0.021216,Neutral
Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?,https://www.fool.com/investing/2023/02/03/is-gilead-sciences-stock-a-buy-strongest-results/,2023-02-03 10:51:00,Gilead's strongest growth since 2015 comes with an asterisk.,GILD,0.24847,0.158325,Somewhat-Bullish
Gilead  ( GILD )  Reports Q4 Earnings: What Key Metrics Have to Say,https://www.zacks.com/stock/news/2049307/gilead-gild-reports-q4-earnings-what-key-metrics-have-to-say,2023-02-03 09:26:00,"Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",GILD,0.079921,0.072117,Neutral
Gilead Sciences  ( GILD )  Q4 2022 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/02/02/gilead-sciences-gild-q4-2022-earnings-call-transcr/,2023-02-03 02:00:23,"GILD earnings call for the period ending December 31, 2022.",GILD,0.004354,0.113874,Neutral
Gilead Sciences  ( GILD )  Tops Q4 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2049063/gilead-sciences-gild-tops-q4-earnings-and-revenue-estimates,2023-02-02 22:35:15,"Gilead (GILD) delivered earnings and revenue surprises of 11.33% and 12.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",GILD,0.139669,0.096236,Neutral
Why Gilead Sciences  ( GILD )  Shooting Higher After Hours? - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/earnings/23/02/30698999/why-gilead-sciences-stock-is-trading-higher-after-hours,2023-02-02 22:27:17,"Gilead Sciences Inc GILD shares are trading higher in Thursday's after-hours session after the company reported better-than-expected results, issued strong guidance, and raised its dividend.",GILD,0.43852,0.527368,Bullish
"Stocks making the biggest moves after hours: Apple, Amazon, Ford and more",https://www.cnbc.com/2023/02/02/stocks-making-big-moves-after-hours-aapl-amzn-f.html,2023-02-02 22:24:55,"Several major U.S. companies reported disappointing results for their latest quarters, including a decline in sales for Apple.",GILD,0.056275,0.230994,Somewhat-Bullish
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership,https://www.globenewswire.com/news-release/2023/02/02/2600997/18362/en/Amarin-Mails-Letter-to-Shareholders-Highlighting-New-Board-and-Superior-Leadership.html,2023-02-02 21:30:00,Significantly Refreshed Board Overseeing Successful Execution of Amarin's Transformation Plan to Drive Short- and Long-Term Value. Outmatches Sarissa's Slate in Every Critical Area ...,GILD,0.023981,0.112426,Neutral
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership - Amarin Corp  ( NASDAQ:AMRN ) ,https://www.benzinga.com/pressreleases/23/02/g30697704/amarin-mails-letter-to-shareholders-highlighting-new-board-and-superior-leadership,2023-02-02 21:30:00,Significantly Refreshed Board Overseeing Successful Execution of Amarin's Transformation Plan to Drive Short- and Long-Term Value; Outmatches Sarissa's Slate in Every Critical Area Chairman Per Wold-Olsen Brings Critical Experience and Leadership Releases Additional Board Videos Available at ...,GILD,0.022881,0.14492,Neutral
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend - Investing News Network,https://investingnews.com/gilead-sciences-announces-2-7-percent-increase-in-first-quarter-2023-dividend/,2023-02-02 21:21:03,Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend Investing News Network ...,GILD,0.721785,0.383343,Bullish
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results - Investing News Network,https://investingnews.com/gilead-sciences-announces-fourth-quarter-and-full-year-2022-financial-results/,2023-02-02 21:21:03,Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results Investing News Network ...,GILD,0.052714,0.07601,Neutral
Gilead profit beats Street expectations on COVID and HIV sales,https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-profit-beats-street-expectations-covid-hiv-sales-2023-02-02/,2023-02-02 21:12:00,"Feb 2 ( Reuters ) - Gilead Sciences Inc ( GILD.O ) on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer drugs, while COVID-19 antiviral Veklury had sales that were double Wall Street estimates.",GILD,0.137671,0.009196,Neutral
"Gilead's Unexpectedly Bullish Outlook - Cancer, HIV Remain Key",https://www.investors.com/news/technology/gild-stock-gilead-earnings-q4-2022/,2023-02-02 21:00:00,GILD Stock: Gilead Issues Unexpectedly Bullish Outlook After ... Investor's Business Daily ...,GILD,0.490988,0.371325,Bullish
BHP: 2 Stocks to Help Jump-Start Your Passive Income in 2023,https://stocknews.com/news/bhp-gild-2-stocks-to-help-jump-start-your-passive-income-in-2023/,2023-02-02 18:22:01,BHP: 2 Stocks to Help Jump-Start Your Passive Income in ...,GILD,0.321207,0.126845,Neutral
ABBV: These 3 Dividend Stocks Are Worth Investing In,https://stocknews.com/news/abbv-gild-sire-these-3-dividend-stocks-are-worth-investing-in/,2023-02-02 16:19:05,"The U.S. Gross Domestic Product ( GDP ) increased at a 2.9% annualized rate in the fourth quarter of 2022, exceeding the Dow Jones forecast of 2.8%. Increases in consumer spending, government spending, private inventory investment, and nonresidential fixed investment drove the fourth-quarter ...",GILD,0.277433,0.210115,Somewhat-Bullish
An Increase In Investments In The R&D Of Autoimmune Disease Drugs Is Expected To Drive The Autoimmune Treatment Market As Per The Business Research Company's Autoimmune Treatment Global Market Report 2023,https://www.benzinga.com/pressreleases/23/02/g30671480/an-increase-in-investments-in-the-r-d-of-autoimmune-disease-drugs-is-expected-to-drive-the-autoimm,2023-02-01 16:30:00,"LONDON, Feb. 01, 2023 ( GLOBE NEWSWIRE ) -- The Business Research Company's research on the ""Autoimmune Treatment Market"" forecasts the global autoimmune treatment market size to grow from $6 billion in 2022 to $6.8 billion in 2023 at a compound annual growth rate ( CAGR ) of more than 12%.",GILD,0.050572,0.059946,Neutral
"Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others",https://www.zacks.com/stock/news/2047789/drugbiotech-stocks-q4-earnings-due-on-feb-2-gild-mrk-others,2023-02-01 15:44:00,Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2.,GILD,0.214557,-0.001653,Neutral
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer,https://investingnews.com/gilead-awards-7-6-million-in-grants-to-advance-health-equity-in-breast-cancer/,2023-02-01 13:54:24,"Toward Health Equity Oncology Grant â¢ Supports Initiatives to Break the Cycle of Health Inequity - Gilead Sciences, Inc. ( Nasdaq: GILD ) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity ( THE ) Oncology Grantâ¢.",GILD,0.301686,0.33278,Somewhat-Bullish
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings,https://www.zacks.com/stock/news/2047559/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings,2023-02-01 13:50:07,Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.,GILD,0.266828,0.235712,Somewhat-Bullish
Why Gilead  ( GILD )  Might Surprise This Earnings Season,https://www.zacks.com/stock/news/2047537/why-gilead-gild-might-surprise-this-earnings-season,2023-02-01 13:32:00,Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,GILD,0.812724,0.583932,Bullish
"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",https://www.benzinga.com/general/biotech/23/01/30648889/february-pdufa-catalysts-biotech-investors-must-know-sanofis-bleeding-disorder-drug-regenerons-tw,2023-01-31 19:33:01,"The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year. NME approvals assume importance as the metric is an indicator of ...",GILD,0.067727,-0.240173,Somewhat-Bearish
Incyte  ( INCY )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2047086/incyte-incy-to-report-q4-earnings-whats-in-the-cards,2023-01-31 15:31:00,Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.,GILD,0.16171,0.076954,Neutral
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders,https://www.benzinga.com/pressreleases/23/01/g30640967/amarin-files-definitive-proxy-materials-and-mails-letter-to-shareholders,2023-01-31 13:24:38,"Urges Shareholders to Vote ""AGAINST"" Sarissa's Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months - New Strategy, New Leadership Team and Significantly Refreshed Board.",GILD,0.018743,0.089586,Neutral
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders,https://www.globenewswire.com/news-release/2023/01/31/2598450/18362/en/Amarin-Files-Definitive-Proxy-Materials-and-Mails-Letter-to-Shareholders.html,2023-01-31 13:24:00,"Urges Shareholders to Vote ""AGAINST"" Sarissa's Proposals on the WHITE Proxy Card ...",GILD,0.015353,0.087576,Neutral
"If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/earnings/23/02/30964753/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-2-100-today,2023-02-17 19:02:31,"Gilead Sciences GILD has outperformed the market over the past 20 years by 8.18% on an annualized basis producing an average annual return of 16.34%. Currently, Gilead Sciences has a market capitalization of $105.38 billion.",GILD,0.980595,0.386944,Bullish
"The Zacks Analyst Blog Highlights Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences",https://www.zacks.com/stock/news/2056015/the-zacks-analyst-blog-highlights-tesla-eli-lilly-bank-of-america-qualcomm-and-gilead-sciences,2023-02-17 16:39:00,"Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences are part of the Zacks top Analyst Blog.",GILD,0.716023,0.0,Neutral
"TrodelvyÂ® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer - Investing News Network",https://investingnews.com/trodelvy-r-demonstrates-positive-efficacy-treating-both-platinum-ineligible-and-rapidly-progressing-post-platinum-metastatic-urothelial-cancer/,2023-02-17 14:30:00,"TrodelvyÂ® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer Investing News Network ...",GILD,0.061473,0.048159,Neutral
GILD: The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid,https://stocknews.com/news/gild-uthr-jazz-bngo-the-3-hottest-biotech-stocks-to-own-in-2023-and/,2023-02-16 18:33:32,"Despite macro uncertainties, the biotech industry has fared relatively well over the past year thanks to consistent breakthroughs and inelastic demand. Along with increasing opportunities to serve an aging population, the Biden Administration's National Biotechnology and Biomanufacturing ...",GILD,0.287481,0.098936,Neutral
"Top Analyst Reports for Tesla, Eli Lilly & Bank of America",https://www.zacks.com/research-daily/2055447/top-analyst-reports-for-tesla-eli-lilly-bank-of-america,2023-02-16 16:00:00,"Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Eli Lilly and Company (LLY) and Bank of America Corporation (BAC).",GILD,0.123844,0.09851,Neutral
5 Least-Hurt Biotech ETFs of the Last Week,https://www.zacks.com/stock/news/2054858/5-least-hurt-biotech-etfs-of-the-last-week,2023-02-15 18:00:00,"Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.",GILD,0.121343,0.207713,Somewhat-Bullish
GILD: 3 Genius Dividend Stocks to Buy Now and Hold Forever,https://stocknews.com/news/gild-hmc-syy-3-genius-dividend-stocks-to-buy-now-and-hold-forever/,2023-02-14 16:36:03,"The Federal Reserve has been steadily increasing interest rates to draw money out of the economy and ease inflationary pressures. Inflation slowed down in December 2022 to an annual rate of 6.5% and is expected to tick down to 6.2% in January, continuing the disinflation trend that began last ...",GILD,0.281261,0.157093,Somewhat-Bullish
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 - Investing News Network,https://investingnews.com/gilead-demonstrates-transformative-potential-impact-of-antiviral-innovation-at-croi-2023/,2023-02-14 14:11:36,Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 Investing News Network ...,GILD,0.097128,0.104594,Neutral
"Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday - Belden  ( NYSE:BDC ) , Cadence Design Sys  ( NASDAQ:CDNS ) ",https://www.benzinga.com/news/23/02/30895885/lattice-semiconductor-to-rally-33-here-are-10-other-analyst-forecasts-for-tuesday,2023-02-14 12:30:08,"Goldman Sachs boosted the price target for Kaiser Aluminum Corporation KALU from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares rose 1.7% to close at $85.33 on Monday. Needham raised the price target for Cadence Design Systems, Inc.",GILD,0.195814,0.215754,Somewhat-Bullish
"Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote ""AGAINST"" All of Sarissa's Proposals - Amarin Corp  ( NASDAQ:AMRN ) ",https://www.benzinga.com/pressreleases/23/02/g30891615/leading-independent-proxy-advisory-firm-glass-lewis-recommends-that-amarin-shareholders-vote-again,2023-02-14 00:47:44,"Glass Lewis Recognizes that Change Led by Amarin's New Board is Already Underway, and Sarissa Representation is Not Warranted Report Notes that Sarissa's Underqualified Slate of Nominees Include ""Redundant"" Skillsets Amarin Board Urges Shareholders to Vote ""AGAINST"" Sarissa's Proposals on the ...",GILD,0.025166,0.052092,Neutral
"Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Amarin Shareholders Vote ""AGAINST"" All of Sarissa's Proposals",https://www.globenewswire.com/news-release/2023/02/14/2607198/18362/en/Leading-Independent-Proxy-Advisory-Firm-Glass-Lewis-Recommends-that-Amarin-Shareholders-Vote-AGAINST-All-of-Sarissa-s-Proposals.html,2023-02-14 00:47:00,"Glass Lewis Recognizes that Change Led by Amarin's New Board is Already Underway, and Sarissa Representation is Not Warranted ...",GILD,0.026415,0.019443,Neutral
"Regenerative Medicine Market to Surpass USD 153.05 Billion by 2029, With 26.3% CAGR",https://www.benzinga.com/pressreleases/23/02/g30874563/regenerative-medicine-market-to-surpass-usd-153-05-billion-by-2029-with-26-3-cagr,2023-02-13 12:45:47,"Pune, India, Feb. 13, 2023 ( GLOBE NEWSWIRE ) -- The regenerative medicine market size was valued at USD 23.65 billion in 2021. The market is expected to grow from USD 29.86 billion in 2022 to USD 153.05 billion by 2029 with a CAGR of 26.3% during the forecast period.",GILD,0.039548,0.033177,Neutral
Antifungal Drugs Market Report will Surpass USD 25.04 Billion by 2030 at a CAGR of 4.2% Till 2030 : GreyViews,https://www.benzinga.com/pressreleases/23/02/g30860017/antifungal-drugs-market-report-will-surpass-usd-25-04-billion-by-2030-at-a-cagr-of-4-2-till-2030-g,2023-02-10 19:00:00,"Pune India, Feb. 10, 2023 ( GLOBE NEWSWIRE ) -- Antifungal Drugs Market Size By Drug Class ( Allylamines, Azoles, Polyenes, Echinocandins, and Others ) , By Route of Administration ( Parenteral, Oral and Topical ) , By Indication ( Candidiasis, Dermatophytosis, Aspergillosis and Others ) , ...",GILD,0.064449,0.132162,Neutral
Gilead  ( GILD )  Kite Reports Positive Data on CAR T-Cell Therapy,https://www.zacks.com/stock/news/2052947/gilead-gild-kite-reports-positive-data-on-car-t-cell-therapy,2023-02-10 16:03:00,Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.,GILD,0.137671,0.145248,Neutral
PFE: 2 COVID-19 Stocks That are Still Darlings in 2023,https://stocknews.com/news/pfe-gild-2-covid-19-stocks-that-are-still-darlings-in-2023/,2023-02-28 17:31:18,PFE: 2 COVID-19 Stocks That are Still Darlings in ...,GILD,0.358521,0.247184,Somewhat-Bullish
Pulmonary Arterial Hypertension Market Worth  ( $10.88 Billion by 2028 )  Lead by Asia Pacific Region  ( 6.5% CAGR )  - Global Report by The Insight Partners,https://www.benzinga.com/pressreleases/23/02/g31091255/pulmonary-arterial-hypertension-market-worth-10-88-billion-by-2028-lead-by-asia-pacific-region-6-5,2023-02-28 14:03:29,"New York, Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Pulmonary Arterial Hypertension Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs [Endothelin Receptor Antagonists ( ERAs ) , Prostacyclin and ...",GILD,0.021087,0.076814,Neutral
"These 13 beaten-down stocks offer a 'margin of safety' from a possible credit shock, according to a top-1% fund manager",https://www.businessinsider.com/13-cheap-stocks-to-buy-recession-interest-rates-credit-shock-2023-2,2023-02-28 13:05:00,13 Undervalued Stocks to Buy in a Recession: Top-1% Fund Manager - Business Insider ...,GILD,0.071677,0.214791,Somewhat-Bullish
JNJ: The 4 Best Forever Stocks to Buy in February 2023,https://stocknews.com/news/jnj-gild-stla-cah-pltr-the-4-best-forever-stocks-to-buy-in-february-2023/,2023-02-27 16:32:54,JNJ: The 4 Best Forever Stocks to Buy in February ...,GILD,0.253778,0.095294,Neutral
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?,https://www.zacks.com/stock/news/2059096/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe,2023-02-27 11:20:09,Sector ETF report for ...,GILD,0.133841,0.071297,Neutral
3 Stocks to Buy Right Now That Are Cash Cows,https://www.fool.com/investing/2023/02/25/3-stocks-to-buy-right-now-that-are-cash-cows/,2023-02-25 11:25:00,"If cash is king, these three stocks should wear crowns.",GILD,0.163631,0.082121,Neutral
WHO panel is reviewing whether COVID vaccines need to be updated,https://www.marketwatch.com/story/who-panel-is-reviewing-whether-covid-vaccines-need-updating-as-agency-monitors-7-omicron-subvariants-3ff416a8,2023-02-24 16:40:00,"Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand.",GILD,0.081691,-0.001034,Neutral
Is Invesco S&P 500 High Dividend Low Volatility ETF  ( SPHD )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2058561/is-invesco-sp-500-high-dividend-low-volatility-etf-sphd-a-strong-etf-right-now,2023-02-24 11:20:04,Smart Beta ETF report for ...,GILD,0.114956,0.066606,Neutral
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows - Pfizer  ( NYSE:PFE ) ,https://www.benzinga.com/news/large-cap/23/02/31022960/gskpfizer-backed-viiv-healthcares-hiv-treatment-at-par-with-gileads-study-shows,2023-02-23 13:43:36,"ViiV Healthcare, majority-owned by GSK Plc GSK, Pfizer Inc PFE, and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable regimen Cabenuva ( cabotegravir, rilpivirine [CAB+RPV LA] ) compared against complete daily oral regimen Biktarvy ( ...",GILD,0.305058,0.0,Neutral
GILD: It's Time to Buy Up These 3 Growth Stocks In 2023,https://stocknews.com/news/gild-jazz-door-its-time-to-buy-up-these-3-growth-stocks-in/,2023-02-23 12:53:34,GILD: It's Time to Buy Up These 3 Growth Stocks In ...,GILD,0.32478,0.23467,Somewhat-Bullish
"4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates",https://www.zacks.com/stock/news/2057943/4-drug-biotech-stocks-poised-to-beat-q4-earnings-estimates,2023-02-23 12:46:00,"We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.",GILD,0.046907,0.097373,Neutral
Should Invesco S&P 500 High Dividend Low Volatility ETF  ( SPHD )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2057910/should-invesco-sp-500-high-dividend-low-volatility-etf-sphd-be-on-your-investing-radar,2023-02-23 11:20:03,Style Box ETF report for ...,GILD,0.120733,0.067941,Neutral
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV,https://investingnews.com/gilead-presents-positive-proof-of-concept-data-for-investigational-combination-regimen-of-lenacapavir-with-broadly-neutralizing-antibodies-as-a-potential-twice-yearly-approach-for-the-treatment-of-hiv/,2023-02-22 17:07:27,Study Demonstrates the Potential of Lenacapavir in Combination with Broadly Neutralizing HIV Antibodies Teropavimab and Zinlirvimab -,GILD,0.166551,0.104726,Neutral
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill,https://www.reuters.com/business/healthcare-pharmaceuticals/gsks-viiv-says-study-shows-its-long-acting-hiv-shot-effective-gileads-daily-pill-2023-02-22/,2023-02-22 16:08:00,GSK's ViiV says study shows its long-acting HIV shot as effective as ... ...,GILD,0.100729,0.091522,Neutral
Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/02/31005994/gilead-sciences-touts-encouraging-data-from-real-world-studies-of-its-flagship-covid-19-treatment,2023-02-22 14:37:26,Gilead Sciences Inc GILD announced data from three retrospective real-world Veklury ( remdesivir ) studies for COVID-19 treatment.,GILD,0.410059,0.191612,Somewhat-Bullish
Kite Completes Acquisition of Tmunity - Investing News Network,https://investingnews.com/kite-completes-acquisition-of-tmunity/,2023-02-22 14:23:22,Kite Completes Acquisition of Tmunity Investing News Network ...,GILD,0.226477,0.120834,Neutral
This Recession-Proof Company Has a Best-in-Class Dividend,https://www.fool.com/investing/2023/02/22/this-recession-proof-company-has-a-best-in-class-d/,2023-02-22 12:30:00,"Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group.",GILD,0.139265,-0.114321,Neutral
"VekluryÂ® Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients",https://investingnews.com/veklury-r-reduced-risk-of-mortality-in-hospitalized-covid-19-patients-across-all-variant-time-periods-in-a-real-world-study-of-more-than-500000-hospitalized-patients/,2023-02-21 22:59:30,"Real-World Evidence from Clinical Practice Demonstrates Use of Veklury was Associated with a Statistically Significant Reduction in Mortality in an Overall Patient Population, Including Immunocompromised Patients -",GILD,0.142565,0.081246,Neutral
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies,https://investingnews.com/gilead-presents-new-data-from-hiv-cure-research-program-and-collaborations-exploring-novel-investigational-combinations-and-strategies/,2023-02-21 20:21:33,Innovative Investigational Approaches Include Targeting of the HIV Viral Reservoir and Enhancing Immune Response in the Absence of Antiretroviral Therapy -,GILD,0.207826,0.125778,Neutral
How Are Biotech ETFs Reacting to Q4 Earnings Releases?,https://www.zacks.com/stock/news/2057067/how-are-biotech-etfs-reacting-to-q4-earnings-releases,2023-02-21 19:21:00,The latest earnings from some of the big biotech players came in at mixed this reporting season.,GILD,0.096671,0.294335,Somewhat-Bullish
AMGN: 3 Biotech Stocks to Buy in 2023 That Could Help Set You up for Life,https://stocknews.com/news/amgn-gild-uthr-3-biotech-stocks-to-buy-in-2023-that-could-help/,2023-02-21 14:03:17,AMGN: 3 Biotech Stocks to Buy in 2023 That Could Help Set You up ... ...,GILD,0.285829,0.211241,Somewhat-Bullish
Is Global X SuperDividend U.S. ETF  ( DIV )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2056634/is-global-x-superdividend-us-etf-div-a-strong-etf-right-now,2023-02-21 11:20:06,Smart Beta ETF report for DIV ...,GILD,0.113866,0.063033,Neutral
Gilead  ( GILD )  Reports Positive Data From Urothelial Cancer Study,https://www.zacks.com/stock/news/2056487/gilead-gild-reports-positive-data-from-urothelial-cancer-study,2023-02-20 16:53:00,Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.,GILD,0.111747,-0.021746,Neutral
Should SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2056184/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar,2023-02-20 11:20:07,Style Box ETF report for ...,GILD,0.122894,0.068464,Neutral
5 Best ETFs Tracking CRISPR Gene Editing,https://www.fool.com/investing/stock-market/market-sectors/healthcare/genomics-stocks/crispr-etfs/,2023-03-10 20:45:33,These exchange-traded funds track companies in this biotech space.,GILD,0.130926,0.061935,Neutral
GILD: 4 Strong Buy Stocks to Buy in March 2023,https://stocknews.com/news/gild-hca-mck-lyts-cvs-4-strong-buy-stocks-to-buy-in-march-2023/,2023-03-10 17:55:45,GILD: 4 Strong Buy Stocks to Buy in March ...,GILD,0.217568,0.100174,Neutral
"Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields - Gilead Sciences  ( NASDAQ:GILD ) , Amgen  ( NASDAQ:AMGN ) ",https://www.benzinga.com/news/23/03/31295242/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-delivering-high-dividend-yie,2023-03-10 13:36:13,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",GILD,0.10607,0.0,Neutral
Gilead Sciences  ( GILD )  Stock Moves -1.55%: What You Should Know,https://www.zacks.com/stock/news/2063802/gilead-sciences-gild-stock-moves--155-what-you-should-know,2023-03-09 22:45:25,"In the latest trading session, Gilead Sciences (GILD) closed at $78.96, marking a -1.55% move from the previous day.",GILD,0.641573,0.198783,Somewhat-Bullish
Why Shares of MacroGenics Jumped Thursday,https://www.fool.com/investing/2023/03/09/why-shares-of-macrogenics-jumped-thursday/,2023-03-09 20:59:00,The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.,GILD,0.131643,0.202812,Somewhat-Bullish
Anti-Viral Therapies Market Growth  ( $82.92 Billion by 2028 )  Driven by Branded Drugs Segment during  ( 2022-2028 )  - Global Report by The Insight Partners,https://www.benzinga.com/pressreleases/23/03/g31276388/anti-viral-therapies-market-growth-82-92-billion-by-2028-driven-by-branded-drugs-segment-during-20,2023-03-09 13:46:17,"New York, March 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Generic Drugs and Branded Drugs ) , Mechanism of Action ( Nucleotide Polymerase ...",GILD,0.02493,0.067196,Neutral
Is Franklin U.S. Low Volatility High Dividend Index ETF  ( LVHD )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2063344/is-franklin-us-low-volatility-high-dividend-index-etf-lvhd-a-strong-etf-right-now,2023-03-09 11:20:09,Smart Beta ETF report for ...,GILD,0.11123,0.062494,Neutral
Is IQ Chaikin U.S. Large Cap ETF  ( CLRG )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2063354/is-iq-chaikin-us-large-cap-etf-clrg-a-strong-etf-right-now,2023-03-09 11:20:06,Smart Beta ETF report for ...,GILD,0.114956,0.057692,Neutral
"Factbox: What's in Biden's budget: taxes on buybacks, rail safety, childcare",https://www.reuters.com/markets/rates-bonds/whats-bidens-budget-taxes-buybacks-rail-safety-childcare-2023-03-08/,2023-03-08 23:48:00,"Factbox: What's in Biden's budget: taxes on buybacks, rail safety ... ...",GILD,0.046273,0.130138,Neutral
"Antifungal Drugs Market Worth  ( $13.99 Billion by 2028 )  at 3.3% CAGR - Global Analysis by Therapeutic Indication  ( Aspergillosis, Dermatophytosis, Candidiasis ) ",https://www.benzinga.com/pressreleases/23/03/g31257180/antifungal-drugs-market-worth-13-99-billion-by-2028-at-3-3-cagr-global-analysis-by-therapeutic-ind,2023-03-08 13:59:36,"New York, March 08, 2023 ( GLOBE NEWSWIRE ) -- Latest Research Report by The Insight Partners, ""Antifungal Drugs Market Size, Share, Growth, Value and Global Forecast to 2028 - Global Analysis by Infection Type ( Superficial Fungal Infection and Systemic Fungal Infection ) , Drug Type ( ...",GILD,0.033098,0.098384,Neutral
GILD: 3 Stocks with Tremendous Growth Potential in 2023,https://stocknews.com/news/gild-coke-ooma-ko-3-stocks-with-tremendous-growth-potential-in-2023/,2023-03-08 08:11:15,GILD: 3 Stocks with Tremendous Growth Potential in ...,GILD,0.303175,0.198935,Somewhat-Bullish
BMY: 2 Dividend Stocks That Could Pay You for the Rest of Your Life,https://stocknews.com/news/bmy-gild-jnj-2-dividend-stocks-that-could-pay-you-for-the-rest/,2023-03-07 17:23:48,"Investors' confidence has taken a hit due to macroeconomic issues. As bear-market risks remain, I think it is ideal to invest in quality dividend stocks, Bristol-Myers Squibb Company ( BMY ) and Gilead Sciences, Inc. ( GILD ) , that can ensure a steady income source.",GILD,0.253646,0.186817,Somewhat-Bullish
2 Healthcare Stocks That Could Help Set You Up for Life,https://www.fool.com/investing/2023/03/07/2-healthcare-stocks-could-help-set-you-up-for-life/,2023-03-07 14:37:00,Even seemingly boring businesses can deliver solid returns over long periods.,GILD,0.495877,0.58638,Bullish
A Look Into Gilead Sciences' Debt - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/03/31221891/a-look-into-gilead-sciences-debt,2023-03-06 17:01:45,"Shares of Gilead Sciences Inc. GILD moved lower by 9.56% in the past three months. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has.",GILD,0.3007,-0.157037,Somewhat-Bearish
Peering Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/03/31220356/peering-into-gilead-sciencess-recent-short-interest,2023-03-06 15:45:24,"Gilead Sciences's GILD short percent of float has risen 3.28% since its last report. The company recently reported that it has 15.76 million shares sold short, which is 1.26% of all regular shares that are available for trading.",GILD,0.221819,0.155473,Somewhat-Bullish
Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2061733/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know,2023-03-03 22:45:26,"Gilead Sciences (GILD) closed the most recent trading day at $81.07, moving +1.82% from the previous trading session.",GILD,0.668563,0.327787,Somewhat-Bullish
GILD: 1 Resilient Growth Stock to Buy Now and Hold Forever,https://stocknews.com/news/gild-vrtx-biib-incy-1-resilient-growth-stock-to-buy-now-and-hold-forever/,2023-03-03 17:05:02,"After a brutal 2022, growth stocks are expected to stage a recovery amid cooling inflation, the Fed's downshift on monetary policy tightening, and recent economic data, including strong retail sales and job growth, hinting at the possibility of the economy getting a soft landing.",GILD,0.59404,0.358087,Bullish
GILD: The 3 Best Biotech Stocks to Buy for Under $100,https://stocknews.com/news/gild-incy-taipy-the-3-best-biotech-stocks-to-buy-for-under-100/,2023-03-03 15:05:17,GILD: The 3 Best Biotech Stocks to Buy for Under ...,GILD,0.391311,0.237799,Somewhat-Bullish
Jim Cramer's stock picks: Investors can now bet on or against them through two new funds | The Financial Express,https://www.financialexpress.com/investing-abroad/featured-stories/jim-cramers-stock-picks-investors-can-now-bet-on-or-against-them-through-two-new-funds/2999013/,2023-03-03 14:31:00,Jim Cramer's stock picks: Investors can now bet on or against them ... The Financial Express ...,GILD,0.102013,0.0,Neutral
"Thousands of Women, Dozens of Top Employers Gather in Silicon Valley to Discuss Women in the Workplace",https://www.benzinga.com/pressreleases/23/03/n31151581/thousands-of-women-dozens-of-top-employers-gather-in-silicon-valley-to-discuss-women-in-the-workpl,2023-03-02 02:47:00,"SANTA CLARA,Calif., March 1, 2023 /PRNewswire/ -- Amid layoffs, economic headwinds, and backsliding on women's rights in many parts of the world, thousands of people from dozens of top employers gathered today to address women in the workplace at the 2023 California Conference for Women.",GILD,0.076602,0.161138,Somewhat-Bullish
Gilead  ( GILD )  Exercises Option to License Nurix's Candidate,https://www.zacks.com/stock/news/2068682/gilead-gild-exercises-option-to-license-nurixs-candidate,2023-03-21 18:47:00,Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader molecule NX 0479.,GILD,0.137671,-0.117264,Neutral
GILD: 3 Dividend Paying Stocks to Buy in March,https://stocknews.com/news/gild-cvs-mo-osh-3-dividend-paying-stocks-to-buy-in-march/,2023-03-21 14:18:51,"While the stock market has had a strong start to the year, macroeconomic concerns will likely keep it under pressure in the short term.",GILD,0.362946,0.232872,Somewhat-Bullish
Kite's YescartaÂ® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma,https://investingnews.com/kite-s-yescarta-r-car-t-cell-therapy-demonstrates-a-statistically-significant-improvement-in-overall-survival-for-initial-treatment-of-relapsed-refractory-large-b-cell-lymphoma/,2023-03-21 14:11:45,"Kite, a Gilead Company ( Nasdaq: GILD ) , today announced the primary overall survival ( OS ) analysis results of the Phase 3 ZUMA-7 study.",GILD,0.05387,0.072982,Neutral
Nurix's  ( NRIX )  Stock Up Due to License Option Exercise by Gilead,https://www.zacks.com/stock/news/2068549/nurixs-nrix-stock-up-due-to-license-option-exercise-by-gilead,2023-03-21 14:05:00,Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.,GILD,0.128135,-0.065329,Neutral
"What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? - BioRestorative Therapies  ( NASDAQ:BRTX ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/23/03/31438097/what-is-autologous-cell-based-therapy-the-treatment-revolutionizing-regenerative-medicine-that-co,2023-03-21 13:07:08,Autologous cell based therapies are personalized therapies using your own cells to target a disease or disorder. Personalized therapies targeting cancer such CAR-T cell therapies have generated impressive clinical results with complete remission rates in B-acute lymphoblastic leukemia in over ...,GILD,0.09989,0.203818,Somewhat-Bullish
"Strength Seen in Nurix Therapeutics, Inc.  ( NRIX ) : Can Its 5.7% Jump Turn into More Strength?",https://www.zacks.com/stock/news/2068270/strength-seen-in-nurix-therapeutics-inc-nrix-can-its-57-jump-turn-into-more-strength,2023-03-21 07:49:00,"Nurix Therapeutics, Inc. (NRIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",GILD,0.103331,0.076203,Neutral
GILD: 3 Nasdaq Stocks That Could Carry Your Portfolio for Years,https://stocknews.com/news/gild-vrtx-adsk-3-nasdaq-stocks-that-could-carry-your-portfolio-for-years/,2023-03-20 19:46:36,"Nasdaq components Gilead Sciences, Inc. ( GILD ) , Vertex Pharmaceuticals Incorporated ( VRTX ) , and Autodesk, Inc.'s ( ADSK ) ever-improving performance could translate into impressive returns in the long run. In this piece, I have discussed several reasons I am bullish on these stocks despite ...",GILD,0.335928,0.326397,Somewhat-Bullish
"First Republic Bank's stock plummets and Peloton's stock falls while New York Community Bank shares soar, and other stocks on the move",https://www.marketwatch.com/story/new-york-community-bank-shares-surge-and-foot-lockers-stock-gains-but-first-republics-stock-hit-by-s-p-downgrade-b51e92d3,2023-03-20 15:56:00,NYCB stock benefits from news it is snapping up some assets of failed Signature Bank.,GILD,0.28387,0.044546,Neutral
"Gilead Exercises First License Option Under Agreement With Nurix Therapeutics - Nurix Therapeutics  ( NASDAQ:NRIX ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/23/03/31420626/gilead-exercises-first-license-option-under-agreement-with-nurix-therapeutics,2023-03-20 14:17:29,"Gilead Sciences Inc GILD has exercised its option to license Nurix Therapeutics Inc's NRIX investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration.",GILD,0.410059,-0.064556,Neutral
"Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479",https://investingnews.com/gilead-exercises-option-to-license-nurix-s-irak4-targeted-protein-degrader-development-candidate-nx-0479/,2023-03-20 13:07:21,-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee --,GILD,0.113169,0.001163,Neutral
"Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479",https://www.globenewswire.com/news-release/2023/03/20/2630267/0/en/Gilead-Exercises-Option-to-License-Nurix-s-IRAK4-Targeted-Protein-Degrader-Development-Candidate-NX-0479.html,2023-03-20 12:30:00,-- IRAK4 Program Represents the First of Up to Five Degrader Programs Within the 2019 Discovery Collaboration Agreement -- -- Nurix to Receive a $20 Million Option Fee ...,GILD,0.091772,0.001076,Neutral
Gilead Sciences Unusual Options Activity - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/markets/options/23/03/31402802/gilead-sciences-unusual-options-activity,2023-03-17 18:45:56,"Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences GILD. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",GILD,0.737923,0.308104,Somewhat-Bullish
"Sensex gains 355 pts, Nifty ends at 17,100, VIX slumps 9%",https://www.business-standard.com/article/news-cm/sensex-gains-355-pts-nifty-ends-at-17-100-vix-slumps-9-123031700798_1.html,2023-03-17 10:22:00,"Sensex gains 355 pts, Nifty ends at 17100, VIX slumps 9%s Business Standard ...",GILD,0.035138,0.004932,Neutral
"Indices trade with minor gains, metal stocks shine",https://www.business-standard.com/article/news-cm/indices-trade-with-minor-gains-metal-stocks-shine-123031700671_1.html,2023-03-17 09:04:00,"The domestic equity barometers pared losses and traded with minor gains in mid-afternoon trade. The Nifty traded above the 17,000 level after hitting day's low of 16,958.15 in afternoon trade. Realty, IT and metal stocks advanced while media, auto and FMCG stocks declined.",GILD,0.076847,0.04934,Neutral
Gilead Sciences  ( GILD )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2066960/gilead-sciences-gild-gains-but-lags-market-what-you-should-know,2023-03-16 21:45:24,"Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.",GILD,0.556576,0.303418,Somewhat-Bullish
Gilead  ( GILD )  Gains 34% in 12 Months: Will the Trend Sustain?,https://www.zacks.com/stock/news/2066925/gilead-gild-gains-34-in-12-months-will-the-trend-sustain,2023-03-16 16:10:00,Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.,GILD,0.130571,0.088325,Neutral
Gilead Sciences  ( GILD )  Stock Moves -0.15%: What You Should Know,https://www.zacks.com/stock/news/2066402/gilead-sciences-gild-stock-moves--015-what-you-should-know,2023-03-15 21:50:21,"In the latest trading session, Gilead Sciences (GILD) closed at $79.65, marking a -0.15% move from the previous day.",GILD,0.659949,0.128837,Neutral
First Drugs Facing Medicare Price Penalty Named,https://www.wsj.com/articles/first-drugs-facing-medicare-price-penalty-named-by-u-s-6453e7d9,2023-03-15 16:24:00,"U.S. health officials listed 27 medications whose prices rose faster than inflation, triggering rebates under a new federal law.",GILD,0.371523,-0.171126,Somewhat-Bearish
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines - AbbVie  ( NYSE:ABBV ) ,https://www.benzinga.com/general/biotech/23/03/31357344/drug-companies-raising-prices-greater-than-inflation-us-government-mulling-imposing-fines,2023-03-15 12:30:10,"Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly on the government's Medicare health program.",GILD,0.290607,-0.472091,Bearish
HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook,https://www.globenewswire.com/news-release/2023/03/15/2627479/0/en/HOOKIPA-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-2023-Outlook.html,2023-03-15 11:00:00,"NEW YORK and VIENNA, March 15, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter ...",GILD,0.016096,0.080771,Neutral
Is SPDR Russell 1000 Yield Focus ETF  ( ONEY )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2065878/is-spdr-russell-1000-yield-focus-etf-oney-a-strong-etf-right-now,2023-03-15 10:20:08,Smart Beta ETF report for ONEY ...,GILD,0.113866,0.059703,Neutral
"US to impose inflation fines on first set of drugs, lowering costs",https://www.reuters.com/business/healthcare-pharmaceuticals/us-impose-inflation-fines-first-set-drugs-lowering-costs-2023-03-15/,2023-03-15 09:05:00,"WASHINGTON, March 15 ( Reuters ) - The U.S. government will subject 27 drugs to inflation penalties, it announced on Wednesday, meaning people on Medicare will pay less out-of-pocket by $2 to as high as $390 per average dose starting April 1.",GILD,0.12165,-0.138131,Neutral
GILD: 2 Smart Dividend Stocks to Buy Now for Steady Gains,https://stocknews.com/news/gild-mo-2-smart-dividend-stocks-to-buy-now-for-steady-gains/,2023-03-14 13:55:52,"While the stock market has seen a solid start to the year, macroeconomic concerns are expected to keep the market under pressure in the near term. With volatility expected to remain, I think dividend-paying stocks Gilead Sciences, Inc. ( GILD ) and Altria Group, Inc. ( MO ) could be worth buying ...",GILD,0.467372,0.241156,Somewhat-Bullish
"Global Antiviral Therapies Market Predicted to Generate a Revenue of $66,016.5 Million, Growing at a CAGR of 3.1% over the 2020-2027 Timeframe [208-Pages] | Explicated by Research Dive",https://www.benzinga.com/pressreleases/23/03/g31339569/global-antiviral-therapies-market-predicted-to-generate-a-revenue-of-66-016-5-million-growing-at-a,2023-03-14 13:05:00,"New York, USA, March 14, 2023 ( GLOBE NEWSWIRE ) -- According to a report published by Research Dive, the global antiviral therapies market is projected to garner a revenue of $66,016.5 million and rise at a CAGR of 3.1% throughout the estimated period from 2020 to 2027.",GILD,0.068502,0.0,Neutral
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2065154/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-03-14 10:20:11,Sector ETF report for ...,GILD,0.135347,0.071708,Neutral
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements,https://www.globenewswire.com/news-release/2023/03/13/2625713/0/en/Enochian-BioSciences-Achieves-Full-Compliance-with-NASDAQ-Filing-Requirements.html,2023-03-13 12:30:00,"LOS ANGELES, March 13, 2023 ( GLOBE NEWSWIRE ) -- ( NASDAQ: ENOB ) . Enochian BioSciences Inc. ( the Company ) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms ...",GILD,0.109455,0.157191,Somewhat-Bullish
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements - Enochian BioSciences  ( NASDAQ:ENOB ) ,https://www.benzinga.com/pressreleases/23/03/g31318724/enochian-biosciences-achieves-full-compliance-with-nasdaq-filing-requirements,2023-03-13 12:30:00,"LOS ANGELES, March 13, 2023 ( GLOBE NEWSWIRE ) -- ENOB. Enochian BioSciences Inc. ( the Company ) announced that it has achieved full compliance with NASDAQ filing requirements.",GILD,0.105604,0.155186,Somewhat-Bullish
Should IQ Chaikin U.S. Large Cap ETF  ( CLRG )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2064527/should-iq-chaikin-us-large-cap-etf-clrg-be-on-your-investing-radar,2023-03-13 10:20:09,Style Box ETF report for ...,GILD,0.12546,0.065631,Neutral
Everest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on Company,https://www.prnewswire.com/news-releases/everest-medicines-announces-silicon-valley-bank-developments-have-minimal-impact-on-company-301769704.html,2023-03-12 23:43:00,Everest Medicines Announces Silicon Valley Bank Developments ... PR ...,GILD,0.082677,0.032603,Neutral
"Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis - GSK  ( NYSE:GSK ) , Pfizer  ( NYSE:PFE ) ",https://www.benzinga.com/general/biotech/23/03/31609651/texas-judge-obstructs-affordable-act-coverage-mandate-for-some-cancer-screenings-prophylaxis,2023-03-31 14:47:01,"A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV ( PrEP ) , at no cost to patients.",GILD,0.294093,0.055333,Neutral
"COVID Remains A Global Threat - NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All - AstraZeneca  ( NASDAQ:AZN ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/23/03/31608814/covid-remains-a-global-threat-nanoviricides-set-to-begin-clinical-trials-for-pan-coronavirus-drug,2023-03-31 13:29:55,"Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. As a result, there are still high rates of hospitalizations and COVID remains many times more deadly than influenza.",GILD,0.092569,-0.028047,Neutral
"ImmuneOnco Banks On Cutting-edge Cancer Drugs To Attract IPO Cash - AbbVie  ( NYSE:ABBV ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/markets/penny-stocks/23/03/31608710/immuneonco-banks-on-cutting-edge-cancer-drugs-to-attract-ipo-cash,2023-03-31 13:23:56,"ImmuneOnco's main product pipeline is a cancer drug targeting a promising protein pathway, the first such drug to enter clinical tests in China, with more intensive trials due in the fourth quarter Eli Lilly ranks as the company's biggest institutional investor after six rounds of financing",GILD,0.067536,0.091222,Neutral
Should Franklin U.S. Low Volatility High Dividend Index ETF  ( LVHD )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2072829/should-franklin-us-low-volatility-high-dividend-index-etf-lvhd-be-on-your-investing-radar,2023-03-31 10:20:07,Style Box ETF report for ...,GILD,0.121037,0.064599,Neutral
USFDA approves Lupin's tablets for Hepatitis B infection treatment | The Financial Express,https://www.financialexpress.com/healthcare/pharma-healthcare/usfda-approves-lupins-tablets-for-hepatitis-b-infection-treatment/3028562/,2023-03-31 09:55:00,USFDA approves Lupin's tablets for Hepatitis B infection treatment The Financial Express ...,GILD,0.377142,0.0,Neutral
"IGM Biosciences, Inc.  ( IGMS )  Reports Q4 Loss, Misses Revenue Estimates",https://www.zacks.com/stock/news/2072686/igm-biosciences-inc-igms-reports-q4-loss-misses-revenue-estimates,2023-03-30 22:05:05,"IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 22.22% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",GILD,0.209365,0.0,Neutral
"Texas judge blocks Obamacare coverage mandate for PrEP, cancer screening",https://www.reuters.com/business/healthcare-pharmaceuticals/texas-judge-blocks-obamacare-coverage-mandate-prep-cancer-screening-2023-03-30/,2023-03-30 14:40:00,"Texas judge blocks Obamacare coverage mandate for PrEP, cancer ... ...",GILD,0.174587,0.130925,Neutral
"Arcellx, Inc.  ( ACLX )  Reports Q4 Loss, Misses Revenue Estimates",https://www.zacks.com/stock/news/2072068/arcellx-inc-aclx-reports-q4-loss-misses-revenue-estimates,2023-03-29 21:25:06,"Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",GILD,0.212425,0.0,Neutral
Is It Time to Buy These Ultra-Cheap Dividend Stocks?,https://www.fool.com/investing/2023/03/29/is-it-time-to-buy-these-ultra-cheap-dividend-stock/,2023-03-29 20:00:00,"These two biopharma stocks aren't exciting growth plays, but they are reliable income vehicles.",GILD,0.195814,0.073154,Neutral
Why Are Cathie Wood's Ark ETFs Still Trailing Nasdaq Stocks? - ARK Innovation ETF  ( ARCA:ARKK ) ,https://www.benzinga.com/markets/cryptocurrency/23/03/31550425/why-are-cathie-woods-ark-etfs-still-trailing-nasdaq-stocks,2023-03-29 19:42:58,"From their all-time highs towards the end of 2021, tech stocks have suffered a significant blow from the Federal Reserve's interest rate hike cycle. The sectors and industries that, before and during the pandemic, were the big winners in the wake of historically low borrowing costs, subsequently ...",GILD,0.204072,0.171828,Somewhat-Bullish
GILD: 3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry,https://stocknews.com/news/gild-vrtx-biib-crsp-sage-3-of-the-best-stocks-in-1-of-wall-streets/,2023-03-29 14:59:32,"The biotech industry thrived during the pandemic with rising demand for drugs, therapies, and vaccines. However, various macroeconomic and regulatory challenges have hampered the industry's growth since last year, prompting massive layoffs and shutdowns.",GILD,0.267626,0.178621,Somewhat-Bullish
"Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run",https://www.fool.com/investing/2023/03/29/up-463-this-sizzling-growth-stock-could-have-a-lot/,2023-03-29 11:45:00,Viking Therapeutics stock might in the midst of a historic run.,GILD,0.047278,0.05616,Neutral
Gilead Sciences  ( GILD )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2071582/gilead-sciences-gild-gains-as-market-dips-what-you-should-know,2023-03-28 21:50:20,"Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.",GILD,0.603594,0.23282,Somewhat-Bullish
"Bunge, Gilead Sciences And A Famous Chocolate Maker On CNBC's 'Final Trades' - Bunge  ( NYSE:BG ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/23/03/31506228/bunge-gilead-sciences-and-a-famous-chocolate-maker-on-cnbcs-final-trades,2023-03-27 12:34:36,"On CNBC's ""Halftime Report Final Trades,"" JP Morgan Private Bank's Anastasia Amoroso said she is sticking with Invesco QQQ Trust QQQ. Stephen Weiss of Short Hills Capital Partners named Bunge Limited BG. ""I think it trades between 90 and 100,"" he added.",GILD,0.524949,0.404345,Bullish
Should You Invest in the VanEck Biotech ETF  ( BBH ) ?,https://www.zacks.com/stock/news/2070609/should-you-invest-in-the-vaneck-biotech-etf-bbh,2023-03-27 10:20:08,Sector ETF report for ...,GILD,0.136113,0.07192,Neutral
"Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves",https://www.prnewswire.com/news-releases/everest-medicines-receives-full-upfront-payment-from-gilead-for-trodelvy-related-transaction-boosting-pro-forma-cash-reserves-301781641.html,2023-03-27 00:19:00,Everest Medicines Receives Full Upfront Payment from Gilead for ... PR ...,GILD,0.075635,0.089906,Neutral
"Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves",https://www.prnewswire.com/apac/news-releases/everest-medicines-receives-full-upfront-payment-from-gilead-for-trodelvy-related-transaction-boosting-pro-forma-cash-reserves-301781645.html,2023-03-27 00:15:00,Everest Medicines Receives Full Upfront Payment from Gilead for ... PR ...,GILD,0.075635,0.089906,Neutral
"Gordon Moore, credited for bringing PCs to millions of homes, dies at 94",https://www.business-standard.com/article/international/gordon-moore-credited-for-bringing-pcs-to-millions-of-homes-dies-at-94-123032500346_1.html,2023-03-25 07:58:00,Gordon Moore came up with the 'Moore's Law' that would push semiconductor companies to put billions of dollars into research and develop the industry at breakneck speed ...,GILD,0.052226,0.0,Neutral
"Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval",https://www.zacks.com/stock/news/2069798/biotech-stock-roundup-alt-obesity-data-gild-exercises-option-incy-drug-approval,2023-03-23 17:51:00,Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.,GILD,0.068797,-0.130733,Neutral
GILD: 2 Biotech Stocks to Buy Hand Over Fist in March,https://stocknews.com/news/gild-vrtx-2-biotech-stocks-to-buy-hand-over-fist-in-march/,2023-03-23 17:24:52,"Despite macroeconomic challenges, the biotech industry has been performing relatively well. Government initiatives, rapid technology breakthroughs, and inelastic demand for healthcare are fostering the growth of the biotech industry.",GILD,0.41608,0.365139,Bullish
Is iShares Select Dividend ETF  ( DVY )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2069414/is-ishares-select-dividend-etf-dvy-a-strong-etf-right-now,2023-03-23 10:20:08,Smart Beta ETF report for ...,GILD,0.113062,0.060653,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2069416/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-03-23 10:20:07,Smart Beta ETF report for ...,GILD,0.122894,0.068464,Neutral
Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2069298/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know,2023-03-22 21:50:25,"Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.",GILD,0.608634,0.172566,Somewhat-Bullish
Gilead  ( GILD )  Announces OS Data on Yescarta From ZUMA-7 Study,https://www.zacks.com/stock/news/2069257/gilead-gild-announces-os-data-on-yescarta-from-zuma-7-study,2023-03-22 18:38:00,Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.,GILD,0.110717,0.20835,Somewhat-Bullish
GILD: 3 Stocks to Buy Now for More Potential Upside,https://stocknews.com/news/gild-teva-mgnx-3-stocks-to-buy-now-for-more-potential-upside/,2023-03-22 16:38:42,The recent banking sector turmoil has soared investor anxieties and raised the odds of an impending recession.,GILD,0.321673,0.128735,Neutral
Gilead Sciences' Debt Overview - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/03/31460358/gilead-sciences-debt-overview,2023-03-22 16:16:25,"Shares of Gilead Sciences Inc. GILD fell by 7.40% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.",GILD,0.281153,-0.111064,Neutral
National AIDS Memorial Quilt Stops in Memphis to Break the Stigma and Change the Pattern Around AIDS in Black and Brown Communities,https://www.benzinga.com/pressreleases/23/03/g31460051/national-aids-memorial-quilt-stops-in-memphis-to-break-the-stigma-and-change-the-pattern-around-ai,2023-03-22 16:03:31,"MEMPHIS, Tenn., March 22, 2023 ( GLOBE NEWSWIRE ) -- Memphis ranks eighth in the nation for new HIV cases per year among large cities in the United States, according to the Infectious Disease Society of America.",GILD,0.096671,0.05561,Neutral
A Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today,https://www.fool.com/investing/2023/03/22/a-bull-market-is-coming-load-up-on-3-cheap-stocks/,2023-03-22 14:07:00,These stocks are all trading at less than 12 times their future profits.,GILD,0.158173,0.00404,Neutral
Should SPDR Russell 1000 Yield Focus ETF  ( ONEY )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2068839/should-spdr-russell-1000-yield-focus-etf-oney-be-on-your-investing-radar,2023-03-22 10:20:07,Style Box ETF report for ONEY ...,GILD,0.121037,0.068013,Neutral
Four Elements Of Healthcare Industry Leadership: China Summit,https://www.forbes.com/sites/forbeschina/2023/03/22/four-elements-of-healthcare-industry-leadership-forbes-china-summit/,2023-03-22 04:56:00,"""Healthcare can often be a very conservative industry because it's an industry that deals with very long timetables. However, playing it too safe and too careful can leave you behind competitors,"" Forbes Senior Editor Alex Knapp believes.",GILD,0.042876,-0.06925,Neutral
"U.S.-China Collaboration Could Cut Development Time, Cost For New Cancer Treatments",https://www.forbes.com/sites/forbeschina/2023/03/22/us-china-collaboration-could-cut-development-time-cost-for-new-cancer-treatments/,2023-03-22 04:10:51,"The world's current system for developing cancer drugs is unsustainable, Memorial Sloan Kettering oncologist Dr. Bob Li believes.",GILD,0.053153,0.0,Neutral
Harness Uncertainty To Overcome It In Today's Business World: China Summit,https://www.forbes.com/sites/forbeschina/2023/03/21/harness-uncertainty-to-overcome-it-in-todays-business-world-forbes-china-summit/,2023-03-22 00:54:42,"In today's uncertain times, business leaders should focus on what is certain in their environment as a key approach to success, University of Michigan Business Professor told a Forbes China gathering last week ...",GILD,0.06697,0.0,Neutral
"If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today",https://www.fool.com/investing/2023/04/10/if-you-invested-10000-in-gilead-sciences-in-2013/,2023-04-10 13:15:00,Would you have been better off investing in the S&P 500?,GILD,0.169676,0.142574,Neutral
3 Dividend Stocks Billionaires Seem to Love,https://www.fool.com/investing/2023/04/09/3-dividend-stocks-billionaires-seem-to-love/,2023-04-09 11:30:00,It sometimes pays to follow the lead of successful people.,GILD,0.399416,0.324225,Somewhat-Bullish
Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2075894/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now,2023-04-07 10:20:11,Smart Beta ETF report for ...,GILD,0.113866,0.060813,Neutral
Post-Pandemic Potential: Analysts Eye InflaRx COVID-19 Antibody For Market Breakthrough - InflaRx  ( NASDAQ:IFRX ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/04/31702239/post-pandemic-potential-analysts-eye-inflarx-covid-19-antibody-for-market-breakthro,2023-04-06 17:49:48,"On Wednesday, the FDA granted emergency-use authorization to InflaRx NV's IFRX monoclonal antibody for hospitalized COVID patients when initiated within 48 hours of receiving artificial life support. Vilobelimab will be sold under Gohibic.",GILD,0.350564,0.232312,Somewhat-Bullish
6 Reasons to Buy Gilead Sciences Stock,https://www.fool.com/investing/2023/04/06/6-reasons-to-buy-gilead-sciences-stock/,2023-04-06 12:15:00,The healthcare stock could be a solid pillar to build your portfolio around.,GILD,0.127795,0.267925,Somewhat-Bullish
Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith's Story - Investing News Network,https://investingnews.com/gilead-sciences-overcoming-covid-19-in-early-2020-keith-s-story/,2023-04-05 12:58:45,Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith's Story Investing News Network ...,GILD,0.343279,0.0,Neutral
"Gilead details promising early COVID antiviral data, setting up larger studies",https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-details-promising-early-covid-antiviral-data-setting-up-larger-studies-2023-04-04/,2023-04-04 22:34:00,"Gilead details promising early COVID antiviral data, setting up larger ... ...",GILD,0.081552,0.092739,Neutral
Gilead Sciences  ( GILD )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2073994/gilead-sciences-gild-gains-but-lags-market-what-you-should-know,2023-04-03 21:50:20,"In the latest trading session, Gilead Sciences (GILD) closed at $83.24, marking a +0.33% move from the previous day.",GILD,0.603594,0.248627,Somewhat-Bullish
Should iShares Select Dividend ETF  ( DVY )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2073520/should-ishares-select-dividend-etf-dvy-be-on-your-investing-radar,2023-04-03 10:20:10,Style Box ETF report for ...,GILD,0.122269,0.068311,Neutral
CIO Leadership: HMG Strategy to Recognize Visionary Leaders at the 2023 New Jersey CIO Executive Leadership Summit on May 18,https://www.benzinga.com/pressreleases/23/04/g31919657/cio-leadership-hmg-strategy-to-recognize-visionary-leaders-at-the-2023-new-jersey-cio-executive-le,2023-04-20 16:20:44,"WESTPORT, Conn., April 20, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is excited to be recognizing four exemplary global business technology leaders for their visionary ...",GILD,0.02212,0.0,Neutral
Gilead Sciences  ( GILD )  Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release,https://www.zacks.com/stock/news/2082075/gilead-sciences-gild-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q1-release,2023-04-20 14:03:14,Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,GILD,0.102013,-0.001099,Neutral
"Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade",https://www.investors.com/research/options/get-income-on-gilead-stock-or-buy-it-at-a-discount-with-this-option-trade/,2023-04-20 14:00:00,"Get Income On Gilead Stock, Or Buy It At A Discount With This ... Investor's Business Daily ...",GILD,0.136499,-0.17248,Somewhat-Bearish
Will Gilead  ( GILD )  Beat Estimates Again in Its Next Earnings Report?,https://www.zacks.com/stock/news/2081494/will-gilead-gild-beat-estimates-again-in-its-next-earnings-report,2023-04-19 16:10:13,Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,GILD,0.176502,0.153808,Somewhat-Bullish
Gilead Sciences: Breaking Down Barriers To Access in HIV and Beyond: A Perspective,https://investingnews.com/gilead-sciences-breaking-down-barriers-to-access-in-hiv-and-beyond-a-perspective/,2023-04-19 13:20:30,"When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit. Health equity and access are more than goals or ambitions - they're woven into the fabric of who we are and what we do.",GILD,0.137671,0.0,Neutral
Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2080758/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know,2023-04-18 22:00:19,"In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.",GILD,0.588876,0.193727,Somewhat-Bullish
PCSA: Why Insiders Are Aggressively Buying This Under $1 Stock,https://stocknews.com/news/pcsa-gild-otsky-alxn-why-insiders-are-aggressively-buying-this-under-1-stock/,2023-04-18 19:09:14,"Insider buying activity for Processa Pharmaceuticals, Inc. ( PCSA ) indicates confidence in the company's growth prospects. Insiders have been net buyers of 5.4% shares of the company over the past six months.",GILD,0.195814,0.193092,Somewhat-Bullish
VekluryÂ® Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations,https://investingnews.com/veklury-r-efficacy-and-safety-profile-further-demonstrated-in-vulnerable-patient-populations/,2023-04-16 08:57:06,"Phase 3 Clinical Trial Demonstrated the Safety Profile of Veklury in Patients with Severe Renal Impairment - - Real-World Evidence Demonstrated Veklury Reduced COVID-19- Associated Mortality and Readmission Rates in Immunocompromised Patients Across All Variants of Concern, Including Omicron -",GILD,0.138331,0.010279,Neutral
3 Dividend Stocks to Buy and Hold for the Next Decade,https://www.fool.com/investing/2023/04/15/3-dividend-stocks-to-buy-and-hold-for-the-next-dec/,2023-04-15 10:14:00,Long-term investors looking for income should especially like these stocks.,GILD,0.165883,0.125557,Neutral
"Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023",https://investingnews.com/gilead-sciences-to-release-first-quarter-2023-financial-results-on-thursday-april-27-2023/,2023-04-13 20:42:28,"Gilead Sciences, Inc. ( Nasdaq: GILD ) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2023 ...",GILD,0.742397,0.212227,Somewhat-Bullish
1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy,https://www.fool.com/investing/2023/04/13/ai-investments-top-stocks-to-buy/,2023-04-13 09:50:00,These companies are leading the way in using AI in healthcare.,GILD,0.051003,0.0,Neutral
Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2077884/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know,2023-04-12 22:00:24,"Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.",GILD,0.70749,0.22206,Somewhat-Bullish
Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV,https://investingnews.com/gilead-sciences-4-questions-global-experts-convene-to-identify-key-measures-to-long-term-success-in-hiv/,2023-04-12 13:16:18,Dr. Jeffrey Lazarus was studying at New York University in the late 1980s when he saw first-hand the devastation of the HIV epidemic.,GILD,0.076115,0.0,Neutral
Could Gilead Sciences Stock Help You Become a Millionaire?,https://www.fool.com/investing/2023/04/12/could-gilead-sciences-stock-help-be-millionaire/,2023-04-12 09:31:00,The company's dominant HIV therapies and growing oncology pipeline are delivering.,GILD,0.112269,0.122525,Neutral
P/E Ratio Insights for Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/04/31753993/pe-ratio-insights-for-gilead-sciences,2023-04-11 18:15:40,"In the current session, the stock is trading at $82.91, after a 0.38% increase. Over the past month, Gilead Sciences Inc. GILD stock increased by 3.94%, and in the past year, by 33.60%.",GILD,0.433523,0.120975,Neutral
A Look Into Gilead Sciences' Debt - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/04/31752657/a-look-into-gilead-sciences-debt,2023-04-11 18:01:33,"Shares of Gilead Sciences Inc. GILD decreased by 3.87% in the past three months. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.",GILD,0.36472,0.015832,Neutral
Is SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2076692/is-spdr-portfolio-sp-500-high-dividend-etf-spyd-a-strong-etf-right-now,2023-04-11 10:20:08,Smart Beta ETF report for ...,GILD,0.114137,0.066424,Neutral
Gilead Sciences  ( GILD )  Q1 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/04/28/gilead-sciences-gild-q1-2023-earnings-call-transcr/,2023-04-28 19:34:03,"GILD earnings call for the period ending March 31, 2023.",GILD,0.004207,0.084776,Neutral
Gilead Sciences  ( GILD )  Q1 2023 Earnings Call Transcript,https://moneymorning.com/investing/gilead-sciences-gild-q1-2023-earnings-call-transcript/,2023-04-28 19:34:03,"Hello, everyone, and welcome to the first quarter 2023 Gilead Sciences earnings conference call. My name is Nadia, and I'll be coordinating the call today. [Operator instructions] I will now hand over to your host, Jacquie Ross, vice president, investor relations, to begin. Jacquie, please go ...",GILD,0.256538,0.391413,Bullish
"Gilead's  ( GILD )  Q1 Earnings Miss, Veklury Sales Plunge",https://www.zacks.com/stock/news/2087119/gileads-gild-q1-earnings-miss-veklury-sales-plunge,2023-04-28 17:07:00,Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.,GILD,0.173958,-0.007492,Neutral
Why Gilead Sciences  ( GILD )  Stock Is Falling Today - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/04/32080628/why-gilead-sciences-stock-is-falling-today,2023-04-28 14:29:03,"Gilead Sciences Inc GILD reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury ( remdesivir ) sales, partially offset by increased sales in HIV and Oncology.",GILD,0.514619,0.125269,Neutral
Government Drug Price Curbs Could Sound A Death Knell For Industry,https://www.investors.com/news/technology/biotech-stocks-brace-for-the-worst-as-government-drug-price-negotiations-loom/,2023-04-28 12:00:00,Biotech Stocks Brace For The Worst As Government Drug Price ... Investor's Business Daily ...,GILD,0.027118,0.052088,Neutral
Gilead Sciences  ( GILD )  Q1 Earnings and Revenues Lag Estimates,https://www.zacks.com/stock/news/2086455/gilead-sciences-gild-q1-earnings-and-revenues-lag-estimates,2023-04-27 21:45:15,"Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",GILD,0.137671,0.11699,Neutral
Futures: Amazon Erases Gains On Cloud Fears; These Techs Dive,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amazon-continues-earnings-surge-for-tech-titans-but-cloudflare-snap-plunge/,2023-04-27 21:32:00,"Futures: Amazon Jumps On Earnings, But These Techs Plunge Investor's Business Daily ...",GILD,0.046184,-0.156323,Somewhat-Bearish
"Stocks making the biggest moves after hours: Amazon, Intel, Snap, Pinterest and more",https://www.cnbc.com/2023/04/27/stocks-making-the-biggest-moves-after-hours-amazon-intel-snap-pinterest-and-more.html,2023-04-27 21:19:38,These are the stocks posting the largest moves in extended trading.,GILD,0.068112,-0.09095,Neutral
"Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighs",https://www.marketwatch.com/story/gilead-shares-fall-after-mixed-results-as-weaker-covid-19-drug-remand-weighs-353bd3f4,2023-04-27 21:18:00,Gilead Sciences Inc. on Thursday cut one of its profit forecasts and reported first-quarter profit that missed expectations.,GILD,0.47672,-0.220754,Somewhat-Bearish
Gilead Sciences Announces First Quarter 2023 Financial Results - Investing News Network,https://investingnews.com/gilead-sciences-announces-first-quarter-2023-financial-results/,2023-04-27 20:53:31,Gilead Sciences Announces First Quarter 2023 Financial Results Investing News Network ...,GILD,0.082848,0.034946,Neutral
"Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger",https://www.investors.com/news/technology/gild-stock-gilead-earnings-amgen-stock-amgen-earnings-q1-2023/,2023-04-27 20:17:00,"GILD Stock: Cancer Treatments Surge, But Profit Questions Linger Investor's Business Daily ...",GILD,0.469457,-0.124062,Neutral
Gilead profit misses Wall Street expectations as COVID drug sales decline,https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-profit-misses-wall-street-expectations-covid-drug-sales-decline-2023-04-27/,2023-04-27 20:10:00,Gilead profit misses Wall Street expectations as COVID drug sales ... ...,GILD,0.204072,-0.043191,Neutral
REGN: A Prescription for Success: Check Out This Strong Pharmaceutical Stock This Week,https://stocknews.com/news/regn-biib-gild-vnda-a-prescription-for-success-check-out-this-strong-pharmaceutical-stock/,2023-04-27 15:54:46,REGN: A Prescription for Success: Check Out This Strong ... ...,GILD,0.150592,0.228145,Somewhat-Bullish
P/E Ratio Insights for Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/04/32049564/pe-ratio-insights-for-gilead-sciences,2023-04-27 15:00:46,"In the current market session, Gilead Sciences Inc. GILD stock price is at $82.75, after a 1.18% decrease. However, over the past month, the company's stock increased by 1.60%, and in the past year, by 39.45%.",GILD,0.428632,0.068711,Neutral
"Debt Limit Bill Heads To Senate To Be Rejected - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ",https://www.benzinga.com/economics/macro-economic-events/23/04/32046950/debt-limit-bill-heads-to-senate-to-be-rejected,2023-04-27 13:33:02,"House passed a bill to increase debt ""ceiling"" by $1.5 TRILLION. Almost zero chance it passes through Senate. In 230 years, America has never defaulted on its debt aside from Nixon, FDR, Lincoln. Speaker Kevin McCarthy passed his debt limit bill through the House yesterdayâ¦barely.",GILD,0.082677,0.0,Neutral
What Does Gilead Sciences' Debt Look Like? - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/04/32046283/what-does-gilead-sciences-debt-look-like,2023-04-27 13:16:23,"Over the past three months, shares of Gilead Sciences Inc. GILD moved lower by 0.44%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.",GILD,0.273807,-0.085346,Neutral
Alarming Rates of HIV and AIDS among Houston's Blacks and Hispanics Bring National AIDS Memorial Quilt to the City,https://www.benzinga.com/pressreleases/23/04/g32045937/alarming-rates-of-hiv-and-aids-among-houstons-blacks-and-hispanics-bring-national-aids-memorial-qu,2023-04-27 13:04:33,"HOUSTON, April 27, 2023 ( GLOBE NEWSWIRE ) -- The statistics tell the story, and there's a serious HIV crisis in Houston and even more specifically among Blacks and Hispanics. That's why the National AIDS Memorial Quilt is making a stop in Houston May 3-7.",GILD,0.099271,0.044402,Neutral
Morning Bid: Fresh spur from Meta and Europe's banks,https://www.reuters.com/markets/europe/global-markets-view-usa-2023-04-27/,2023-04-27 10:05:38,"A look at the day ahead in U.S. and global markets from Mike Dolan The Big Tech earnings season is going some way to justifying the striking outperformance of its mega cap shares this year, with Meta Platforms the latest to impress overnight and Amazon ( AMZN.O ) advancing ahead of its readout on ...",GILD,0.048919,0.035546,Neutral
Better Buy: Pfizer vs. Gilead,https://moneymorning.com/investing/better-buy-pfizer-vs-gilead/,2023-04-27 09:30:00,"You may not immediately think of growth when you think of big-pharma companies. Smaller biotech players often steal the show when they introduce a first product or report positive clinical-trial news. But bigger, more established companies actually can bring you a fair share of growth -- and ...",GILD,0.160633,0.076379,Neutral
Better Buy: Pfizer vs. Gilead,https://www.fool.com/investing/2023/04/27/better-buy-pfizer-vs-gilead/,2023-04-27 09:30:00,Pfizer and Gilead look cheap right now.,GILD,0.103554,0.062779,Neutral
"$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/earnings/23/04/32025028/100-invested-in-this-stock-20-years-ago-would-be-worth-1-400-today,2023-04-26 21:32:05,"Gilead Sciences GILD has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 14.24%. Currently, Gilead Sciences has a market capitalization of $104.58 billion.",GILD,0.980595,0.386944,Bullish
"Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More",https://www.zacks.com/stock/news/2084870/drugbiotech-stocks-q1-earnings-due-apr-27-lly-abbv-more,2023-04-26 13:28:00,Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.,GILD,0.263942,0.095222,Neutral
CIO Leadership: HMG Strategy to Recognize Visionary Leaders at the 2023 Florida CIO Executive Leadership Summit on May 11,https://www.benzinga.com/pressreleases/23/04/g31997215/cio-leadership-hmg-strategy-to-recognize-visionary-leaders-at-the-2023-florida-cio-executive-leade,2023-04-25 19:08:03,"WESTPORT, Conn., April 25, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is excited to be recognizing four exemplary global business technology leaders for their visionary ...",GILD,0.02214,0.0,Neutral
3 Biotech Stocks To Watch Today,https://stockmarket.com/featured/3-biotech-stocks-to-watch-today-2023-04-25,2023-04-25 17:00:00,"The biotechnology sector is a highly innovative and dynamic industry that is constantly evolving. Biotech companies develop and produce drugs, therapies, and other products that are designed to improve health outcomes for patients.",GILD,0.338119,-0.038845,Neutral
Incyte  ( INCY )  Earnings Expected to Grow: What to Know Ahead of Next Week's Release,https://www.zacks.com/stock/news/2084210/incyte-incy-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release,2023-04-25 14:01:27,Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,GILD,0.088472,0.038117,Neutral
This Supercharged Dividend King Stock Might Soon Run Out of Steam,https://www.fool.com/investing/2023/04/25/this-supercharged-dividend-king-stock-may-soon-run/,2023-04-25 13:45:00,"Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.",GILD,0.038223,0.001966,Neutral
2 Excellent Dividend Stocks to Buy for Less Than $100,https://www.fool.com/investing/2023/04/25/2-excellent-dividend-stocks-to-buy-for-less-than-1/,2023-04-25 11:45:00,Both companies are steals at current levels.,GILD,0.631144,0.518169,Bullish
Gilead Sciences Releases Inaugural ESG Impact Report,https://investingnews.com/gilead-sciences-releases-inaugural-esg-impact-report/,2023-04-24 21:53:40,"Gilead Sciences recently released its inaugural Environmental, Social and Governance ( ESG ) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior year",GILD,0.84035,0.55457,Bullish
Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead,https://www.zacks.com/commentary/2083214/big-tech-earnings-economic-numbers-3-ways-to-survive-the-week-ahead,2023-04-24 11:27:00,"Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.",GILD,0.155451,0.0,Neutral
Will HIV and Oncology Propel Gilead's  ( GILD )  Q1 Earnings?,https://www.zacks.com/stock/news/2082974/will-hiv-and-oncology-propel-gileads-gild-q1-earnings,2023-04-21 16:55:00,Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.,GILD,0.267315,0.203694,Somewhat-Bullish
"B - Berkshire Hathaway Inc. Common Stock  ( NYSE:BRK/A ) , Berkshire Hathaway Inc. New Common Stock  ( NYSE:BRK/B ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/04/31929561/berkshire-hathaway-gilead-sciences-vertex-pharmaceuticals-and-a-break-out-casino-stock-f,2023-04-21 11:59:32,"On CNBC's ""Halftime Report Final Trades,"" Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. GILD, which has 7% free cash flow yield and a 3.6% dividend yield. ""I think it will continue to be a good name to own this year,"" she added.",GILD,0.673107,0.332993,Somewhat-Bullish
"CIO Leadership: HMG Strategy to Recognize Visionary Leaders at Upcoming Executive Leadership Summits in Silicon Valley, Florida, New Jersey and New York",https://www.benzinga.com/pressreleases/23/05/g32321548/cio-leadership-hmg-strategy-to-recognize-visionary-leaders-at-upcoming-executive-leadership-summit,2023-05-10 16:35:36,"WESTPORT, Conn., May 10, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling business technology executives to reimagine the enterprise and reshape the business world, is excited to be recognizing distinguished executives for their visionary leadership at four ...",GILD,0.016205,0.0,Neutral
Biotech ETFs Pop on M&A Resurgence,https://www.zacks.com/stock/news/2093665/biotech-etfs-pop-on-ma-resurgence,2023-05-10 16:33:00,2023 could be a year of heightened biotech dealmaking activity ...,GILD,0.199859,0.13748,Neutral
Gilead Emphasizes Unique Ways To Hire Top Talent,https://investingnews.com/gilead-emphasizes-unique-ways-to-hire-top-talent/,2023-05-10 12:53:09,"When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities. As he perused pharmaceutical companies' job postings, he kept a look out for diversity in leadership, the potential for personal career growth and a commitment to helping ...",GILD,0.102013,0.0,Neutral
Your Wednesday Briefing,https://www.nytimes.com/2023/05/10/briefing/trump-civil-case-liable.html,2023-05-10 05:00:01,"A Manhattan jury found Donald Trump liable for sexually abusing and defaming the former magazine writer E. Jean Carroll and awarded her $5 million in damages. More than a dozen women have accused the former president of sexual misconduct over the years, but this is the only allegation to be ...",GILD,0.02671,0.037909,Neutral
Gilead Sciences prevails in US government lawsuit over HIV drug patents,https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-sciences-prevails-us-government-lawsuit-over-hiv-drug-patents-2023-05-09/,2023-05-09 16:48:19,Gilead Sciences prevails in US government lawsuit over HIV drug ... ...,GILD,0.099066,-0.06513,Neutral
"Gilead Sciences didn't violate government patents on HIV prevention treatment, jury finds",https://www.cnbc.com/2023/05/09/gilead-did-not-violate-patents-hiv-prevention-drug.html,2023-05-09 16:43:29,The U.S. government had sued Gilead in 2019 arguing that the company was profiting off CDC patents.,GILD,0.214937,-0.211727,Somewhat-Bearish
U.S. Loses Key Case on Rights to H.I.V.-Prevention Drugs,https://www.nytimes.com/2023/05/09/business/prep-hiv-aids-gilead.html,2023-05-09 16:24:55,A federal jury in Delaware on Tuesday found that the federal government did not have an ownership claim to lucrative drugs to prevent H.I.V. that are sold by the pharmaceutical company Gilead Sciences.,GILD,0.056943,0.11995,Neutral
U.S. Loses Key Case on Rights to H.I.V.-Prevention Drugs,https://www.nytimes.com/2023/05/09/business/prep-hiv-aids-gilead.html,2023-05-09 16:24:55,A federal jury in Delaware on Tuesday found that the federal government did not have an ownership claim to lucrative drugs to prevent H.I.V. that are sold by the pharmaceutical company Gilead Sciences.,GILD,0.035189,0.114777,Neutral
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera,https://investingnews.com/gilead-strengthens-early-pipeline-in-oncology-and-inflammation-through-the-acquisition-of-xinthera/,2023-05-09 13:22:11,"Acquisition of XinThera Provides Gilead with Precision Small Molecules Focused on PARP1 and MK2 Inhibitors - Gilead Sciences, Inc. ( Nasdaq: GILD ) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego.",GILD,0.218817,0.058356,Neutral
Ahmad Goree Named New Leader of Dallas Southern Pride,https://www.prnewswire.com/news-releases/ahmad-goree-named-new-leader-of-dallas-southern-pride-301818351.html,2023-05-08 15:11:00,More than 10K people expected to attend the 2023 Juneteenth Unity Weekend Celebration event June 15-20 in Dallas,GILD,0.048919,0.403679,Bullish
Ahmad Goree Named New Leader of Dallas Southern Pride,https://www.benzinga.com/pressreleases/23/05/n32267196/ahmad-goree-named-new-leader-of-dallas-southern-pride,2023-05-08 15:11:00,More than 10K people expected to attend the 2023 Juneteenth Unity Weekend Celebration event June 15-20 in Dallas,GILD,0.046907,0.403304,Bullish
Rates Have Risen: Here Are 5 Stocks With Little Debt,https://www.forbes.com/sites/johndorfman/2023/05/08/moderna-teradyne-rates-risen-here-are-5-stocks-with-little-debt/,2023-05-08 15:09:40,"Interest rates are about five percentage points higher than they were a year ago. For stock pickers, that means that debt once again matters. Here are five stocks that fit the bill.",GILD,0.057352,-0.136597,Neutral
"American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades' - Chevron  ( NYSE:CVX ) , American Express  ( NYSE:AXP ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/05/32258109/american-express-gilead-sciences-and-this-us-oil-giant-on-cnbcs-final-trades,2023-05-08 12:16:54,"On CNBC's ""Halftime Report Final Trades,"" Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. GILD is a very defensive, steady growth play. ""It is cheap, cheap, cheap,"" he added.",GILD,0.538389,0.238776,Somewhat-Bullish
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock,https://www.fool.com/investing/2023/05/06/this-incredible-growth-stock-has-all-the-hallmarks/,2023-05-06 17:00:00,"Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets.",GILD,0.045054,0.009005,Neutral
2 Magnificent Dividend Stocks to Buy Before the Next Recession,https://www.fool.com/investing/2023/05/05/2-magnificent-dividend-stocks-to-buy-before-next/,2023-05-05 13:45:00,The healthcare sector is a good place to find recession-proof stocks.,GILD,0.442082,0.15084,Somewhat-Bullish
CHMP Adopts Positive Opinion Recommending HepcludexÂ® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus,https://investingnews.com/chmp-adopts-positive-opinion-recommending-hepcludex-r-for-full-marketing-authorization-for-the-treatment-of-hepatitis-delta-virus/,2023-05-04 11:52:50,"Gilead Sciences, Inc. ( Nasdaq: GILD ) today announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion for Hepcludex Â® ( bulevirtide ) for the treatment of adults with chronic HDV and compensated liver ...",GILD,0.366061,0.289601,Somewhat-Bullish
Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years,https://www.fool.com/investing/2023/05/04/gilead-sciences-stock-has-only-done-this-in-1-of-t/,2023-05-04 11:50:00,Should you buy Gilead Sciences stock despite its poor track record?,GILD,0.479258,0.393674,Bullish
Insmed Reports First Quarter 2023 Financial Results and Provides Business Update,https://www.prnewswire.com/news-releases/insmed-reports-first-quarter-2023-financial-results-and-provides-business-update-301815538.html,2023-05-04 11:30:00,Insmed Reports First Quarter 2023 Financial Results and Provides ... PR ...,GILD,0.008868,0.06747,Neutral
CIO Leadership: HMG Strategy to Recognize Visionary Leaders at the 2023 Silicon Valley CISO & Technology Executive Leadership Summit on May 11,https://www.benzinga.com/pressreleases/23/05/g32194108/cio-leadership-hmg-strategy-to-recognize-visionary-leaders-at-the-2023-silicon-valley-ciso-technol,2023-05-03 17:39:51,"WESTPORT, Conn., May 03, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to be recognizing four exemplary global business technology leaders for their visionary ...",GILD,0.020903,0.0,Neutral
"Advanced Therapy Medicinal Products Market to Reach USD 24 Billion by 2032, Driven by Rising Prevalence of Chronic Diseases and Individualized Treatment Demand",https://markets.businessinsider.com/news/stocks/advanced-therapy-medicinal-products-market-to-reach-usd-24-billion-by-2032-driven-by-rising-prevalence-of-chronic-diseases-and-individualized-treatment-demand-1032286877,2023-05-03 14:24:37,"Advanced Therapy Medicinal Products ( ATMPs ) Market By Product Type ( Gene Therapies, Cell Therapies, Tissue-Engineered Product ) , By End-use ( Hospitals, Clinics, Research Institutes, Others ) , By Region Forecast To 2032",GILD,0.208644,0.159918,Somewhat-Bullish
Here's 1 Magnificent Reason to Buy Vertex Pharmaceuticals Stock,https://www.fool.com/investing/2023/05/03/heres-1-magnificent-reason-to-buy-vertex-pharmaceu/,2023-05-03 14:15:00,The bull case for the cystic fibrosis treatment maker is as strong as ever.,GILD,0.058047,0.115984,Neutral
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts,https://investingnews.com/gilead-remains-steadfast-in-support-for-hepatitis-c-elimination-efforts/,2023-05-03 11:48:45,"The recent national conversation on hepatitis C ( HCV ) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination.",GILD,0.2842,0.162446,Somewhat-Bullish
The Fed could deliver the final rate hike of a historically aggressive cycle today. Here's what to know.,https://www.businessinsider.com/fed-rate-hike-explained-policy-central-bank-may-cycle-markets-2023-5,2023-05-03 10:10:00,Fed Rate Hike Explained: Historically Aggressive Cycle Could End ... - Business Insider ...,GILD,0.041251,0.0,Neutral
Gilead Sciences battles U.S. government in court over HIV prevention patent,https://www.cnbc.com/2023/05/02/gilead-government-trial-hiv-prevention-drug.html,2023-05-02 18:46:58,The U.S. claims Gilead's drugs Truvada and Descovy infringe on CDC patents.,GILD,0.102013,-0.158588,Somewhat-Bearish
"Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More",https://www.zacks.com/stock/news/2088427/biotechdrug-stocks-q1-earnings-due-may-3-uthr-pcrx-more,2023-05-02 17:32:00,"Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.",GILD,0.04497,-0.053922,Neutral
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine - Johnson & Johnson  ( NYSE:JNJ ) ,https://www.benzinga.com/general/biotech/23/05/32165424/johnson-johnson-ignites-car-t-ambitions-with-licensing-pact-with-cellular-biomedicine,2023-05-02 16:14:29,"Johnson & Johnson's JNJ pharma unit Janssen entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc to develop, manufacture and commercialize next-generation chimeric antigen receptor ( CAR ) T-cell therapies for B-cell malignancies.",GILD,0.303175,0.0,Neutral
Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/05/32160672/gilead-vs-cdc-the-1b-showdown-over-hiv-drug-profits,2023-05-02 16:08:45,Gilead Sciences Inc GILD is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help prevent the disease. It generated sales of $147 million in 2022 compared to $371 million a year ago.,GILD,0.436009,0.341901,Somewhat-Bullish
"Gilead, US square off in billion-dollar HIV drug patent trial",https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-us-square-off-billion-dollar-hiv-drug-patent-trial-2023-05-02/,2023-05-02 09:03:00,May 2 ( Reuters ) - Gilead Sciences Inc ( GILD.O ) is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.,GILD,0.101154,0.071245,Neutral
3 Relatively Safe Stocks to Buy if a Recession Is on the Way,https://www.fool.com/investing/2023/05/20/3-relatively-safe-stocks-to-buy-if-a-recession-is/,2023-05-20 10:14:00,"If the economy falters, these stocks should hold up better than most.",GILD,0.214937,0.045511,Neutral
Why CymaBay Therapeutics Stock Nose-Dived This Week,https://www.fool.com/investing/2023/05/19/why-cymabay-therapeutics-stock-nose-dived-this-wee/,2023-05-19 21:59:16,Investors did not warmly greet the latest news from the biotech.,GILD,0.140896,0.064497,Neutral
Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer,https://www.newswire.ca/news-releases/eupraxia-pharmaceuticals-announces-appointment-of-dr-mark-kowalski-as-chief-medical-officer-872724205.html,2023-05-18 11:00:00,Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark ... Canada ...,GILD,0.028456,-0.092164,Neutral
Visionary Leadership: Going Beyond Protection to Make Security a Competitive Advantage Will Fuel the Discussion at the 2023 Silicon Valley CISO & Technology Executive Leadership Summit on June 1,https://www.benzinga.com/pressreleases/23/05/g32447563/visionary-leadership-going-beyond-protection-to-make-security-a-competitive-advantage-will-fuel-th,2023-05-17 15:02:59,"WESTPORT, Conn., May 17, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is excited to be hosting its 2023 Silicon Valley CISO & Technology Executive Leadership Summit at the ...",GILD,0.021274,0.0,Neutral
A Look Into Gilead Sciences' Debt - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/05/32426480/a-look-into-gilead-sciences-debt,2023-05-16 15:46:46,"Shares of Gilead Sciences Inc. GILD decreased by 7.18% in the past three months. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has.",GILD,0.295867,-0.020668,Neutral
Abortion pill case heads back to federal appeals court: What's at stake,https://www.marketwatch.com/story/abortion-pill-case-heads-back-to-federal-appeals-court-whats-at-stake-b3155343,2023-05-16 15:23:00,"Case threatens to ""wreak havoc"" on drug development and approval, drugmakers say ...",GILD,0.098456,-0.118628,Neutral
Arcus  ( RCUS )  & Gilead Re-Collaborate for Inflammatory Diseases,https://www.zacks.com/stock/news/2095860/arcus-rcus-gilead-re-collaborate-for-inflammatory-diseases,2023-05-16 13:31:00,"Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.",GILD,0.28387,0.091311,Neutral
"Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday - Clene  ( NASDAQ:CLNN ) , Absolute Software  ( NASDAQ:ABST ) ",https://www.benzinga.com/news/23/05/32419925/gilead-sciences-to-rally-around-28-here-are-10-other-analyst-forecasts-for-tuesday,2023-05-16 12:24:50,"Morgan Stanley raised the price target for DraftKings Inc. DKNG from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close at $23.49 on Monday. Keefe, Bruyette & Woods boosted the price target for Selective Insurance Group, Inc.",GILD,0.279015,0.487841,Bullish
The Allogeneic Cell Therapy Market is expected to hit USD 1.72 Bn by 2029 at a CAGR of 24.5 percent - says Maximize Market Research,https://www.benzinga.com/pressreleases/23/05/g32418357/the-allogeneic-cell-therapy-market-is-expected-to-hit-usd-1-72-bn-by-2029-at-a-cagr-of-24-5-percen,2023-05-16 11:33:16,"Pune, May 16, 2023 ( GLOBE NEWSWIRE ) -- A global healthcare research and business-consulting firm, Maximize Market Research, has published a market intelligence report on the ""Allogeneic Cell Therapy Market"".",GILD,0.020509,0.408049,Bullish
Aspergillosis Treatment Market is to reach USD 3569.72 Mn by 2029 at a growth rate of 5.4 percent over the forecast period,https://www.benzinga.com/pressreleases/23/05/g32416515/aspergillosis-treatment-market-is-to-reach-usd-3569-72-mn-by-2029-at-a-growth-rate-of-5-4-percent-,2023-05-16 10:16:55,"Pune, May 16, 2023 ( GLOBE NEWSWIRE ) -- Maximize Market Research, a global Healthcare market research firm has published a competitive intelligence and market research report on the ""Aspergillosis Treatment Market"". The Aspergillosis Treatment Market size was valued at USD 2470.30 Mn in 2022.",GILD,0.031159,0.133497,Neutral
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation,https://investingnews.com/gilead-sciences-and-arcus-biosciences-expand-partnership-to-include-research-programs-in-inflammation/,2023-05-15 12:55:12,Gilead to Have Early Option to Exclusively License Drug Candidates Against up to Four Targets for Inflammatory Diseases -,GILD,0.144448,0.067664,Neutral
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2095065/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-05-15 10:20:09,Sector ETF report for ...,GILD,0.137671,0.072354,Neutral
Should IQ Chaikin U.S. Large Cap ETF  ( CLRG )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2095060/should-iq-chaikin-us-large-cap-etf-clrg-be-on-your-investing-radar,2023-05-15 10:20:09,Style Box ETF report for ...,GILD,0.125789,0.069184,Neutral
Is SPDR Russell 1000 Yield Focus ETF  ( ONEY )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2095071/is-spdr-russell-1000-yield-focus-etf-oney-a-strong-etf-right-now,2023-05-15 10:20:08,Smart Beta ETF report for ONEY ...,GILD,0.114956,0.061034,Neutral
Looking Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/05/32369915/looking-into-gilead-sciencess-recent-short-interest,2023-05-12 17:45:28,"Gilead Sciences's GILD short percent of float has risen 8.73% since its last report. The company recently reported that it has 15.25 million shares sold short, which is 1.37% of all regular shares that are available for trading.",GILD,0.221819,0.155473,Somewhat-Bullish
"CAGR of 5.6%, Red Biotechnology Market Expected to Surpass USD 609.6 Billion by 2031 - Exclusive Study by TMR",https://www.benzinga.com/pressreleases/23/05/g32362861/cagr-of-5-6-red-biotechnology-market-expected-to-surpass-usd-609-6-billion-by-2031-exclusive-study,2023-05-12 12:30:00,"Wilmington, Delaware, United States, May 12, 2023 ( GLOBE NEWSWIRE ) -- The global red biotechnology market size stood at USD 357.2 Bn in 2021 and is anticipated to surpass value of USD 609.6 Bn by 2031. The global industry is anticipated to expand at a CAGR of 5.6% between 2022 and 2031.",GILD,0.044551,-0.157838,Somewhat-Bearish
Is IQ Chaikin U.S. Large Cap ETF  ( CLRG )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2094534/is-iq-chaikin-us-large-cap-etf-clrg-a-strong-etf-right-now,2023-05-12 10:20:05,Smart Beta ETF report for ...,GILD,0.113329,0.066247,Neutral
Gilead Sciences Stock: Bear vs. Bull,https://www.fool.com/investing/2023/05/12/gilead-sciences-stock-bear-vs-bull/,2023-05-12 09:30:00,The S&P 500 has outperformed Gilead over the past five years.,GILD,0.115509,0.082309,Neutral
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/05/11/2666554/0/en/HOOKIPA-Pharma-Reports-First-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html,2023-05-11 11:01:00,"NEW YORK and VIENNA, May 11, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023.",GILD,0.030998,0.038253,Neutral
Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments.,https://www.barrons.com/articles/pfizer-merck-effector-cancer-treatment-data-a1cfbbd8,2023-05-26 15:42:00,"Pfizer, Merck, eFFECTOR and Other Drugmakers Released New Cancer Treatment Data ...",GILD,0.151064,-0.059666,Neutral
Pfizer's  ( PFE )  COVID-19 Oral Treatment Gets FDA Nod in Adults,https://www.zacks.com/stock/news/2100448/pfizers-pfe-covid-19-oral-treatment-gets-fda-nod-in-adults,2023-05-26 15:08:00,"Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.",GILD,0.1331,0.124314,Neutral
Gilead's  ( GILD )  Veklury Gets Positive CHMP View for Extended Use,https://www.zacks.com/stock/news/2100280/gileads-gild-veklury-gets-positive-chmp-view-for-extended-use,2023-05-26 14:30:00,"Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.",GILD,0.231332,0.032137,Neutral
Why Roche's 'Meaningful' Results Sent Another Biotech Flying,https://www.investors.com/news/technology/rcus-stock-roars-higher-on-roche-meaningful-results-in-a-new-cancer-class/,2023-05-26 14:27:00,RCUS Stock Roars Higher On Roche's 'Meaningful' Results In A ... Investor's Business Daily ...,GILD,0.137278,0.0,Neutral
CIO Leadership: How Pending SEC Cyber Regulations Will Impact CXOs and the Board Will Power the Discussion at the 2023 New York CISO & Technology Executive Leadership Summit on June 15,https://www.benzinga.com/pressreleases/23/05/g32578469/cio-leadership-how-pending-sec-cyber-regulations-will-impact-cxos-and-the-board-will-power-the-dis,2023-05-25 15:39:19,"WESTPORT, Conn., May 25, 2023 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 digital platform for enabling technology executives to reimagine the enterprise and reshape the business world, is excited to be hosting its 2023 New York CISO & Technology Executive Leadership Summit at The Harvard ...",GILD,0.028254,0.0,Neutral
Adverum Biotechnologies Announces New Executive Leadership Roles,https://www.globenewswire.com/news-release/2023/05/25/2675941/32452/en/Adverum-Biotechnologies-Announces-New-Executive-Leadership-Roles.html,2023-05-25 10:30:00,"- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor ...",GILD,0.02692,0.043135,Neutral
Adverum Biotechnologies Announces New Executive Leadership Roles - Adverum Biotechnologies  ( NASDAQ:ADVM ) ,https://www.benzinga.com/pressreleases/23/05/g32569208/adverum-biotechnologies-announces-new-executive-leadership-roles,2023-05-25 10:30:00,"- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor - - Star Seyedkazemi, Pharm.D., chief development officer, expands her responsibilities to lead Adverum's clinical development, medical affairs and pharmacovigilance teams -",GILD,0.025596,0.04281,Neutral
CytoDyn Announces President Takes Medical Leave of Absence - CytoDyn  ( OTC:CYDY ) ,https://www.benzinga.com/pressreleases/23/05/g32563519/cytodyn-announces-president-takes-medical-leave-of-absence,2023-05-24 21:05:07,"Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor VANCOUVER, Washington, May 24, 2023 ( GLOBE NEWSWIRE ) -- CytoDyn Inc.",GILD,0.031696,0.038658,Neutral
CytoDyn Announces President Takes Medical Leave of Absence,https://www.globenewswire.com/news-release/2023/05/24/2675727/19782/en/CytoDyn-Announces-President-Takes-Medical-Leave-of-Absence.html,2023-05-24 21:05:00,Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor ...,GILD,0.022925,0.036874,Neutral
TRIBECA FESTIVAL ANNOUNCES 2023 TRIBECA X SPEAKER LINEUP; OFFICIAL SELECTIONS FOR TRIBECA X AWARD,https://www.benzinga.com/pressreleases/23/05/n32559246/tribeca-festival-announces-2023-tribeca-x-speaker-lineup-official-selections-for-tribeca-x-award,2023-05-24 18:00:00,KEYNOTE CONVERSATIONS WITH DIANE VON FURSTENBERG; GE'S LINDA BOFF AND GENERAL MOTORS' ALAN WEXLER TUBI'S MARK ROTBLAT IN CONVERSATION WITH VAYNERMEDIA'S GARY VAYNERCHUK. AL ROKER IN CONVERSATION WITH JOHN DEERE'S MARA DOWNING. GRINDR'S GEORGE ARISON IN CONVERSATION WITH GILEAD SCIENCES' ALEX ...,GILD,0.071677,0.03337,Neutral
Should SPDR Russell 1000 Yield Focus ETF  ( ONEY )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2098829/should-spdr-russell-1000-yield-focus-etf-oney-be-on-your-investing-radar,2023-05-24 10:20:07,Style Box ETF report for ONEY ...,GILD,0.12013,0.067797,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2098310/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-05-23 10:20:08,Smart Beta ETF report for ...,GILD,0.123526,0.068619,Neutral
Global Biotechnology Market Size & Share to Surpass $2772.7 Billion by 2030 | Vantage Market Research,https://www.benzinga.com/pressreleases/23/05/g32509392/global-biotechnology-market-size-share-to-surpass-2772-7-billion-by-2030-vantage-market-research,2023-05-22 14:21:22,"WASHINGTON, May 22, 2023 ( GLOBE NEWSWIRE ) -- The Global Biotechnology Market is valued at USD 1094.6 Billion in 2022 and is projected to reach a value of USD 2772.7 Billion by 2030 at a CAGR ( Compound Annual Growth Rate ) of 14.2% over the forecast period 2023-2030.",GILD,0.025008,0.0,Neutral
2 Top Biotech Stocks to Buy in June,https://www.fool.com/investing/2023/06/09/2-top-biotech-stocks-to-buy-in-june/,2023-06-09 14:15:00,Both companies have solid therapy franchises and continue to expand their horizons.,GILD,0.145437,0.227388,Somewhat-Bullish
Gilead Sciences Shows Rising Relative Strength; Still Shy Of Key Threshold,https://www.investors.com/ibd-data-stories/gilead-sciences-shows-rising-relative-strength-still-shy-of-key-threshold/,2023-06-09 07:00:00,Gilead Sciences Shows Rising Relative Strength. Still Shy Of Key ... Investor's Business Daily ...,GILD,0.639616,0.641536,Bullish
"GILD: Buy, Hold or Sell? Gilead Sciences Inc.  ( GILD )  and Moderna Inc.  ( MRNA ) ",https://stocknews.com/news/gild-mrna-buy-hold-or-sell-gilead-sciences-inc-gild-and-moderna/,2023-06-08 15:45:12,"GILD: Buy, Hold or Sell? Gilead Sciences Inc. ( GILD ) and Moderna ... ...",GILD,0.381463,0.205174,Somewhat-Bullish
Gilead Sciences  ( GILD )  Stock Moves -0.16%: What You Should Know,https://www.zacks.com/stock/news/2105402/gilead-sciences-gild-stock-moves--016-what-you-should-know,2023-06-07 21:50:11,"Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session.",GILD,0.610329,0.203207,Somewhat-Bullish
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/earnings/23/06/32739292/heres-how-much-1000-invested-in-gilead-sciences-20-years-ago-would-be-worth-today,2023-06-06 14:30:33,"Gilead Sciences GILD has outperformed the market over the past 20 years by 5.38% on an annualized basis producing an average annual return of 12.94%. Currently, Gilead Sciences has a market capitalization of $95.57 billion.",GILD,0.980595,0.386944,Bullish
"Gilead  ( GILD ) , Arcus Announce Results From Mid-Stage NSCLC Study",https://www.zacks.com/stock/news/2104052/gilead-gild-arcus-announce-results-from-mid-stage-nsclc-study,2023-06-05 18:59:00,Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.,GILD,0.096866,-0.085809,Neutral
"ASCO News Comes Fast And Furious: ImmunoGen, Day One Surge",https://www.investors.com/news/technology/imgn-stock-why-this-perfectly-rated-biotech-just-soared-again/,2023-06-05 14:49:00,"IMGN Stock: Why This Perfectly Rated Biotech Just Soared, Again Investor's Business Daily ...",GILD,0.139265,-0.065717,Neutral
Sir Elton John Joins Forces with Donatella Versace and Other Notable Philanthropists to Announce $125 Million Rocket Fund to End AIDS For All,https://www.benzinga.com/pressreleases/23/06/n32715769/sir-elton-john-joins-forces-with-donatella-versace-and-other-notable-philanthropists-to-announce-1,2023-06-05 13:30:00,Stars lead the charge on social media to let their 'Inner Elton' out and take a stand for equality by encouraging everyone to be their true selves,GILD,0.04076,0.124807,Neutral
3 Dividend Stocks You Can Buy Without Any Hesitation,https://www.fool.com/investing/2023/06/03/3-dividend-stocks-you-can-buy-without-hesitation/,2023-06-03 10:14:00,The choices are easy with these stocks.,GILD,0.386211,0.370954,Bullish
Why The Biotech Buying Bonanza Will Likely Continue,https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/,2023-06-02 17:17:00,Biotech Stocks Are In A 'Blistering' M&A Climate. The FTC Could ... Investor's Business Daily ...,GILD,0.031529,0.089095,Neutral
BNGO: Is Now the Time to Buy Bionano Genomics  ( BNGO ) ?,https://stocknews.com/news/bngo-alks-biib-gild-is-now-the-time-to-buy-bionano-genomics-bngo/,2023-06-01 17:56:05,"Bionano Genomics, Inc. ( BNGO ) is a genome analysis software provider that enables genomics labs to analyze and interpret data across a range of platforms. The company's revenue saw a significant jump in the recent past, increasing at CAGRs of 46.4% and 25.3% over the past three and five years, ...",GILD,0.140485,0.219421,Somewhat-Bullish
2 Large Cap Biotech Stocks To Watch Right Now,https://stockmarket.com/featured/2-large-cap-biotech-stocks-to-watch-right-now-2023-05-31,2023-05-31 20:29:15,The biotechnology sector is a rapidly evolving and highly exciting area of the market. The sector focuses on the use of living organisms to make products or run processes. This sector is at the forefront of scientific advancement.,GILD,0.24289,0.026505,Neutral
Should You Invest in the VanEck Biotech ETF  ( BBH ) ?,https://www.zacks.com/stock/news/2101737/should-you-invest-in-the-vaneck-biotech-etf-bbh,2023-05-31 10:20:06,Sector ETF report for ...,GILD,0.134968,0.071604,Neutral
Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co.  ( MRK ) ,https://www.forbes.com/sites/johnbuckingham/2023/06/19/big-pharma-vs-washingtonan-opportunity-to-buy-merck--co-mrk/,2023-06-19 23:34:34,"Warren Buffett states, ""Uncertainty is the friend of the buyer of long-term values,"" and Washington represents a big question mark these days for the pharma sector.",GILD,0.051886,0.033,Neutral
Anti-Ageing Drugs Market to Amass Notable Gains by 2029 Says Brandessence Market Research,https://www.prnewswire.com/news-releases/anti-ageing-drugs-market-to-amass-notable-gains-by-2029-says-brandessence-market-research-301851923.html,2023-06-15 14:01:00,"LONDON, June 15, 2023 /PRNewswire/ -- The body undergoes numerous changes as people age. They eventually start showing signs of ageing and become susceptible to numerous diseases.",GILD,0.023933,0.100746,Neutral
The Antitrust Loophole That Keeps Generic Drugs Off the Market,https://www.theatlantic.com/ideas/archive/2023/06/pharmaceutical-generic-drugs-pay-for-delay/674410/,2023-06-15 11:00:00,Pay for Delay: Big Pharma's Most Maddening Business Tactic The Atlantic ...,GILD,0.024801,-0.023173,Neutral
Biomarkers Market to Grow Significantly by 2029- Brandessence Market Research,https://www.prnewswire.com/news-releases/biomarkers-market-to-grow-significantly-by-2029--brandessence-market-research-301851886.html,2023-06-15 10:40:00,"LONDON, June 15, 2023 /PRNewswire/ -- Biomarkers are referred to as a type of measurable biological indicators or characteristics found in body tissues or fluids like blood.",GILD,0.023861,0.109009,Neutral
Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2107888/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know,2023-06-13 22:00:22,"Gilead Sciences (GILD) closed the most recent trading day at $78.45, moving +0.76% from the previous trading session.",GILD,0.481177,0.340516,Somewhat-Bullish
"Dallas Southern Pride Announces the 2023 Juneteenth Unity Weekend Celebration, June 16-18",https://www.benzinga.com/pressreleases/23/06/n32834051/dallas-southern-pride-announces-the-2023-juneteenth-unity-weekend-celebration-june-16-18,2023-06-13 12:55:48,"More than 10K people expected to attend star-studded event that will feature some of the biggest names in hip-hop and entertainment. DALLAS, June 13, 2023 /PRNewswire/ -- Dallas Southern Pride will host its highly anticipated annual Juneteenth Unity Weekend Celebration, June 16-18, 2023.",GILD,0.082111,0.229532,Somewhat-Bullish
"Cancer Biologics Market Set to Surpass USD 185.0 Bn by 2031 Driven by Increasing Cancer Prevalence and Biotechnology Innovations, Reveals TMR Study",https://www.benzinga.com/pressreleases/23/06/g32831132/cancer-biologics-market-set-to-surpass-usd-185-0-bn-by-2031-driven-by-increasing-cancer-prevalence,2023-06-13 10:30:00,"Wilmington, Delaware, United States, June 13, 2023 ( GLOBE NEWSWIRE ) -- The global cancer biologics market was valued at US$ 94.5 Bn in 2022. It is projected to expand at a CAGR of 7.7% from 2023 to 2031.",GILD,0.043264,0.0,Neutral
"Arvinas, Inc.  ( ARVN )  Moves 17.5% Higher: Will This Strength Last?",https://www.zacks.com/stock/news/2107394/arvinas-inc-arvn-moves-175-higher-will-this-strength-last,2023-06-13 08:51:00,"Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",GILD,0.276909,-0.098204,Neutral
"GILD: 2 Game-Changing Biotech Stocks, 1 to Sell Now",https://stocknews.com/news/gild-regn-ttnp-rcus-2-game-changing-biotech-stocks-1-to-sell-now/,2023-06-12 15:23:55,"Progress in the personalized medicines sector and the adoption of new avenues for biotechnology applications are boosting the biotech industry. However, concerns such as economic slowdowns and geopolitical risks might hamper its growth.",GILD,0.342329,0.236632,Somewhat-Bullish
"Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns",https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-rises-fda-panel-backs-alzheimers-drug-easing-safety-concerns-2023-06-12/,2023-06-12 10:26:14,"Biogen rises as FDA panel backs Alzheimer's drug, easing safety ... ...",GILD,0.155451,0.00944,Neutral
Looking Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/06/33067299/looking-into-gilead-sciencess-recent-short-interest,2023-06-29 20:15:43,"Gilead Sciences's GILD short percent of float has fallen 9.32% since its last report. The company recently reported that it has 16.32 million shares sold short, which is 1.46% of all regular shares that are available for trading.",GILD,0.221819,0.083071,Neutral
Gilead Sciences' Debt Overview - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/06/33065015/gilead-sciences-debt-overview,2023-06-29 18:02:06,"Over the past three months, shares of Gilead Sciences Inc. GILD decreased by 7.28%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.",GILD,0.277958,-0.021616,Neutral
Hepatitis C cure is not reaching overwhelming majority of patients due to financial barriers,https://www.cnbc.com/2023/06/29/hepatitis-c-cure-isnt-reaching-patients-due-to-cost-cdc-says.html,2023-06-29 17:47:37,Hepatitis C is often referred to as the silent killer because the initial infection has few to no symptoms.,GILD,0.05833,0.049974,Neutral
"$11M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - AlloVir  ( NASDAQ:ALVR ) , Augusta Gold  ( OTC:AUGG ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/06/33055165/11m-bet-on-this-healthcare-stock-check-out-these-3-penny-stocks-insiders-are-aggressivel,2023-06-29 10:15:25,"The Dow Jones closed lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.",GILD,0.122894,0.187089,Somewhat-Bullish
2 Medical Stocks to Consider Buying in June,https://www.zacks.com/stock/news/2114516/2-medical-stocks-to-consider-buying-in-june,2023-06-29 00:08:00,"With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.",GILD,0.275867,-0.120834,Neutral
Ominous Death Cross Forms On Gilead Sciences's Chart - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/markets/23/06/33044412/ominous-death-cross-forms-on-gilead-sciencess-chart,2023-06-28 14:48:05,"If history is any guide, there may be trouble ahead for shares of Gilead Sciences GILD. A so-called ""death cross"" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions.",GILD,0.561184,-0.458171,Bearish
BNGO: Should You Watch Bionano Genomics  ( BNGO )  this Week?,https://stocknews.com/news/bngo-alks-gild-biib-should-you-watch-bionano-genomics-bngo-this-week/,2023-06-27 16:22:38,"Genomic testing equipment manufacturer Bionano Genomics, Inc. ( BNGO ) is gaining traction with its third-generation optical mapping solution, Saphyr, which offers advanced capabilities crucial for genome research.",GILD,0.084722,0.207885,Somewhat-Bullish
GILD: 3 Biotech Stocks With Some Major Value in Them,https://stocknews.com/news/gild-biib-alks-rcus-dnli-3-biotech-stocks-with-some-major-value-in-them/,2023-06-27 12:14:56,The biotech sector assumes a crucial role in propelling the advancement of healthcare by spearheading the creation of innovative therapies and technologies aimed at addressing unmet medical requirements.,GILD,0.288214,-0.032922,Neutral
"BJ's Wholesale Club, Verint Systems And 2 Other Stocks Insiders Are Selling - BJ's Wholesale Club  ( NYSE:BJ ) , Arcus Biosciences  ( NYSE:RCUS ) ",https://www.benzinga.com/news/23/06/33020762/bjs-wholesale-club-verint-systems-and-2-other-stocks-insiders-are-selling,2023-06-27 11:58:28,"The S&P 500 closed lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.",GILD,0.097854,-0.212307,Somewhat-Bearish
Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2113303/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know,2023-06-26 22:00:21,"Gilead Sciences (GILD) closed the most recent trading day at $76.56, moving -1.17% from the previous trading session.",GILD,0.532556,0.224336,Somewhat-Bullish
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,2023-06-26 21:01:00,Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline ... PR ...,GILD,0.041791,0.034859,Neutral
Gilead  ( GILD )  Breast Cancer Drug Gets Positive CHMP Opinion,https://www.zacks.com/stock/news/2113218/gilead-gild-breast-cancer-drug-gets-positive-chmp-opinion,2023-06-26 16:48:00,Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.,GILD,0.087185,-0.017889,Neutral
2 Low-Priced Stocks That Could Make You Richer,https://www.fool.com/investing/2023/06/26/2-low-priced-stocks-that-could-make-you-richer/,2023-06-26 14:15:00,These two low-priced healthcare stocks could skyrocket within the next 12 months.,GILD,0.051774,0.066592,Neutral
Our early-adopters index examines how corporate America is deploying AI,https://www.economist.com/business/2023/06/25/our-early-adopters-index-examines-how-corporate-america-is-deploying-ai,2023-06-25 18:49:27,"T are having a bumper year. Despite a recent wobble, the share price of the Big Five-Alphabet, Amazon, Apple, Meta and Microsoft-has jumped by 60% since January, when measured in an equally weighted basket ( see chart 1 ) . The price of shares in one big chipmaker, Nvidia, has tripled and in ...",GILD,0.022347,0.068325,Neutral
Big Pharma Vs. Washington-An Opportunity To Buy Bristol Myers,https://www.forbes.com/sites/johnbuckingham/2023/06/23/big-pharma-vs-washington-an-opportunity-to-buy-bristol-myers/,2023-06-23 22:27:12,"After all, news broke on Friday that Bristol Myers Squibb has sued Uncle Sam over a Medicare price renegotiation program in the Inflation Reduction Act (IRA) that was ...",GILD,0.043738,0.032788,Neutral
"Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director",https://www.prnewswire.com/news-releases/mirati-therapeutics-appoints-industry-veteran-carol-gallagher-pharmd-as-new-independent-director-301861168.html,2023-06-23 20:00:00,"SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.Â® ( NASDAQ: MRTX ) , a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.",GILD,0.054483,0.016926,Neutral
Gilead Sciences  ( GILD )  Announces Positive HDV Treatment Data,https://www.zacks.com/stock/news/2112576/gilead-sciences-gild-announces-positive-hdv-treatment-data,2023-06-23 16:58:00,"Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.",GILD,0.129168,-0.138049,Neutral
"Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/23/06/32984439/gileads-chronic-hepatitis-delta-infection-treatment-shows-sustained-efficacy-safety-profile-at-tw,2023-06-23 14:38:16,Gilead Sciences Inc GILD announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for chronic hepatitis delta ( HDV ) infection. Bulevirtide is the only approved treatment for HDV in Europe and is not approved in the U.S.,GILD,0.479683,-0.20884,Somewhat-Bearish
GILD: 3 Biotech Stocks Every Investor Wants,https://stocknews.com/news/gild-biib-alks-3-biotech-stocks-every-investor-wants/,2023-06-21 16:19:43,"The biotech sector is expanding due to innovations and robust demand. Furthermore, the biotech sector enjoys inelastic demand for its products and services and is relatively stable in the face of economic uncertainty.",GILD,0.299022,0.27677,Somewhat-Bullish
Arcellx  ( RCLX )  Down on Hold for Lead Program CART-ddBCMA,https://www.zacks.com/stock/news/2111331/arcellx-rclx-down-on-hold-for-lead-program-cart-ddbcma,2023-06-21 14:38:00,Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.,GILD,0.151064,0.168445,Somewhat-Bullish
2 Biotech Stocks You Can Buy and Hold for the Next Decade,https://www.fool.com/investing/2023/06/21/2-biotech-stocks-you-can-buy-and-hold-for-the-next/,2023-06-21 12:22:00,Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.,GILD,0.08609,0.130467,Neutral
Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2110861/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know,2023-06-20 22:00:22,"Gilead Sciences (GILD) closed the most recent trading day at $77.71, moving -1.46% from the previous trading session.",GILD,0.48724,0.152852,Somewhat-Bullish
The 'Perfect Storm' That Led To A Patient Death And Arcellx's Dive,https://www.investors.com/news/technology/aclx-stock-plunges-after-perfect-storm-leads-to-patient-death-in-cancer-drug-study/,2023-06-20 14:38:00,ACLX Stock Plunges After 'Perfect Storm' Leads To Patient Death In ... Investor's Business Daily ...,GILD,0.136113,0.0,Neutral
"Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls - Arcellx  ( NASDAQ:ACLX ) ",https://www.benzinga.com/general/biotech/23/06/32918224/arcellxs-lead-product-candidate-hit-by-fda-clinical-hold-for-multiple-myeloma-stock-falls,2023-06-20 12:19:18,"The FDA has put a clinical hold on Arcellx Inc's ACLX iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for relapsed or refractory multiple myeloma. Arcellx's lead product candidate, CART-ddBCMA, has been granted Fast Track, Orphan Drug, and Regenerative Medicine ...",GILD,0.305058,0.0,Neutral
Veralox Names Jonathan Mow as Chief Executive Officer as the Company Advances Development of First-in-Class Therapies for Immune-Mediated Diseases in Conjunction with Financing,https://www.benzinga.com/pressreleases/23/06/g32918968/veralox-names-jonathan-mow-as-chief-executive-officer-as-the-company-advances-development-of-first,2023-06-20 11:00:00,-- New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX-1005 -- Company Prepares to Evaluate VLX-1005 in Heparin-Induced Thrombocytopenia ( HIT ),GILD,0.066784,-0.058092,Neutral
Is Johnson & Johnson Stock a Buy Now?,https://www.fool.com/investing/2023/07/09/is-johnson-johnson-stock-a-buy-now/,2023-07-09 11:45:00,Some businesses never go out of style.,GILD,0.059488,0.077996,Neutral
US Stocks Dip After Mixed Jobs Data,https://www.barrons.com/news/us-stocks-dip-after-mixed-jobs-data-da0d5c5b,2023-07-07 20:35:44,Wall Street stocks dipped Friday following data that showed slower hiring in the United States but which was seen as keeping the Federal Reserve on track to raise interest rates.,GILD,0.18967,0.053266,Neutral
"$1 Billion Deal For Moderna To Expand Product Pipeline In China - Gilead Sciences  ( NASDAQ:GILD ) , Moderna  ( NASDAQ:MRNA ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33145546/1-billion-deal-for-moderna-to-expand-product-pipeline-in-china,2023-07-07 12:45:17,The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in the money markets and where investors think we are in the business cycle.,GILD,0.157141,-0.041704,Neutral
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer,https://www.globenewswire.com/news-release/2023/07/05/2699908/0/en/Lyell-Immunopharma-Appoints-Matthew-Lang-as-Chief-Business-Officer.html,2023-07-05 20:05:00,"SOUTH SAN FRANCISCO, Calif., July 05, 2023 ( GLOBE NEWSWIRE ) -- Lyell Immunopharma, Inc. ( Nasdaq: LYEL ) , a clinicalâstage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the ...",GILD,0.066598,0.065286,Neutral
"NanoViricides Inc.  ( NYSE American: NNVC )  Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment - Nanoviricides  ( AMEX:NNVC ) ",https://www.benzinga.com/general/biotech/23/07/33113617/nanoviricides-inc-nyse-american-nnvc-begins-long-awaited-clinical-trials-for-its-anti-viral-nanom,2023-07-05 11:50:51,"NanoViricides NNVC is a drug development company working on a novel nanomedical treatment. It recently updated the world on the status of its long-awaited and now active trials into its lead drug candidate, NV-CoV-2.",GILD,0.137671,0.027658,Neutral
GILEAD SCIENCES AND IAS - THE INTERNATIONAL AIDS SOCIETY - HONOUR HEALTHCARE PROVIDERS GLOBALLY WHO CHAMPION STIGMA-FREE HIV SERVICES,https://www.prnewswire.com/apac/news-releases/gilead-sciences-and-ias--the-international-aids-society---honour-healthcare-providers-globally-who-champion-stigma-free-hiv-services-301869864.html,2023-07-05 03:00:00,GILEAD SCIENCES AND IAS - THE INTERNATIONAL AIDS SOCIETY - HONOUR HEALTHCARE PROVIDERS ... PR ...,GILD,0.199365,0.15493,Somewhat-Bullish
Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2116263/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know,2023-07-03 22:00:18,"Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a -0.46% move from the prior day.",GILD,0.6809,0.327844,Somewhat-Bullish
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,2023-07-03 21:01:00,Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...,GILD,0.020404,0.202125,Somewhat-Bullish
"Over $59M Bet On This Communication Services Stock? Check Out These 3 Stocks Insiders Are Buying - Asana  ( NYSE:ASAN ) , MediaAlpha  ( NYSE:MAX ) ",https://www.benzinga.com/trading-ideas/long-ideas/23/07/33096454/over-59m-bet-on-this-communication-services-stock-check-out-these-3-stocks-insiders-are-,2023-07-03 13:23:21,"Although US stocks closed higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.",GILD,0.114682,0.159386,Somewhat-Bullish
This Is What Whales Are Betting On Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/markets/options/23/06/33079869/this-is-what-whales-are-betting-on-gilead-sciences,2023-06-30 15:01:50,"A whale with a lot of money to spend has taken a noticeably bearish stance on Gilead Sciences. Looking at options history for Gilead Sciences GILD we detected 13 strange trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with ...",GILD,0.682689,0.056304,Neutral
3 American Mutual Funds Worth Buying for Long-Term Investing,https://www.zacks.com/stock/news/2115217/3-american-mutual-funds-worth-buying-for-long-term-investing,2023-06-30 11:22:00,"Given the prevailing market conditions, it would be wise for investors to consider allocating their investments to renowned American mutual funds such as RMFEX, WSHFX and FIFAX.",GILD,0.046907,0.049196,Neutral
Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2124129/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know,2023-07-19 22:00:19,"Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.",GILD,0.631282,0.246566,Somewhat-Bullish
Peering Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/07/33289199/peering-into-gilead-sciencess-recent-short-interest,2023-07-19 16:45:26,"Gilead Sciences's GILD short percent of float has risen 6.16% since its last report. The company recently reported that it has 17.34 million shares sold short, which is 1.55% of all regular shares that are available for trading.",GILD,0.221819,0.155473,Somewhat-Bullish
3 Healthcare Stocks to Buy and Hold for the Next 10 Years,https://www.fool.com/investing/2023/07/19/3-healthcare-stocks-to-buy-and-hold-for-the-next/,2023-07-19 12:15:00,It helps to offer products everyone needs.,GILD,0.308891,0.270539,Somewhat-Bullish
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2123401/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-07-19 10:20:07,Sector ETF report for ...,GILD,0.137278,0.072244,Neutral
"SARS-CoV-2 Is Not Done Yet - Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/23/07/33264588/sars-cov-2-is-not-done-yet-could-this-new-drug-in-clinical-trials-be-the-safest-option-for-treati,2023-07-18 12:07:40,"SARS-CoV-2 is not done yet - Although it is not grabbing as many headlines, the number of deaths arestill greater than even a pandemic influenza year at last count.",GILD,0.106541,0.05881,Neutral
"ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer",https://www.globenewswire.com/news-release/2023/07/18/2706277/0/en/ACELYRIN-INC-Appoints-Ken-Lock-as-Chief-Commercial-Officer.html,2023-07-18 11:00:00,Accomplished global leader brings 20 years of immunology sales and marketing expertise.,GILD,0.048919,0.090139,Neutral
Is SPDR Russell 1000 Yield Focus ETF  ( ONEY )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2122580/is-spdr-russell-1000-yield-focus-etf-oney-a-strong-etf-right-now,2023-07-18 10:20:06,Smart Beta ETF report for ONEY ...,GILD,0.114137,0.060868,Neutral
Price Over Earnings Overview: Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/07/33255587/price-over-earnings-overview-gilead-sciences,2023-07-17 20:00:18,"In the current market session, Gilead Sciences Inc. GILD share price is at $77.52, after a 0.42% spike. Moreover, over the past month, the stock fell by 0.25%, but in the past year, spiked by 24.78%.",GILD,0.421485,-0.062358,Neutral
Gilead's  ( GILD )  Veklury Gets FDA Nod for Label Expansion,https://www.zacks.com/stock/news/2122308/gileads-gild-veklury-gets-fda-nod-for-label-expansion,2023-07-17 15:40:00,"Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.",GILD,0.147818,0.110645,Neutral
Should IQ Chaikin U.S. Large Cap ETF  ( CLRG )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2121855/should-iq-chaikin-us-large-cap-etf-clrg-be-on-your-investing-radar,2023-07-17 10:20:06,Style Box ETF report for ...,GILD,0.124486,0.068857,Neutral
These 2 Numbers Should Scare Every Biogen Shareholder,https://www.fool.com/investing/2023/07/16/numbers-should-scare-every-biogen-shareholder/,2023-07-16 11:15:00,There are a couple of pieces of evidence that Biogen's long-term strategy isn't working.,GILD,0.056275,-0.044013,Neutral
FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/07/33232032/fda-approves-gileads-remdesivir-for-covid-19-treatment-patients-with-severe-renal-impairment,2023-07-14 15:23:57,"The FDA approved Gilead Sciences Inc's GILD supplemental new drug application for using Veklury ( remdesivir ) in COVID-19 patients with severe renal impairment, including those on dialysis.",GILD,0.433523,0.153506,Somewhat-Bullish
Gilead Sciences  ( GILD )  Gains But Lags Market: What You Should Know,https://www.zacks.com/stock/news/2120956/gilead-sciences-gild-gains-but-lags-market-what-you-should-know,2023-07-13 22:00:20,"In the latest trading session, Gilead Sciences (GILD) closed at $76.71, marking a +0.43% move from the previous day.",GILD,0.479683,0.316727,Somewhat-Bullish
"Stocks Run With Big Earnings, Nasdaq Rebalance Due",https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stocks-run-with-big-earnings-nasdaq-100-rebalance-due/,2023-07-13 20:40:00,"Dow Jones futures tilted lower after hours, along with S&P 500 futures and Nasdaq futures. JPMorgan Chase headlines big earnings Friday. Tech growth plays led another solid session for the stock market rally, with Treasury yields and the dollar continuing to slide.",GILD,0.04968,0.278397,Somewhat-Bullish
"The Hidden Winner Of Nasdaq's ""Great Rebalancing""",https://moneymorning.com/investing/the-hidden-winner-of-nasdaqs-great-rebalancing/,2023-07-13 19:13:02,"One of the most notable trends in the stock market this year has been the meteoric rise of mega-cap tech. These companies have outperformed all other sectors of the equity market, and their dominance has become increasingly concentrated. Currently, the seven largest companies account for over 54% ...",GILD,0.16117,0.425203,Bullish
Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies,https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/,2023-07-13 12:06:00,"One minute Dow Jones industrial average component Merck ( MRK ) might be doing battle with fellow drugmaker Bristol Myers Squibb ( BMY ) over drugs that can ward off cancer. The next, biotech giants like Amgen ( AMGN ) and Sanofi ( SNY ) are tussling in court over the fate of ...",GILD,0.366061,0.043641,Neutral
Is Now the Right Time to Embrace Biotech ETFs?,https://www.zacks.com/stock/news/2120021/is-now-the-right-time-to-embrace-biotech-etfs,2023-07-12 15:09:00,Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.,GILD,0.124164,0.04872,Neutral
ETFs in Focus as Nasdaq 100 Undergoes Rejiggering,https://www.zacks.com/stock/news/2119996/etfs-in-focus-as-nasdaq-100-undergoes-rejiggering,2023-07-12 14:42:00,The Nasdaq 100 is set to undergo a special rebalance on Jul 24 to address overconcentration issues posed by a handful of technology stocks on the index by redistributing the weights.,GILD,0.050254,0.047906,Neutral
Is IQ Chaikin U.S. Large Cap ETF  ( CLRG )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2119624/is-iq-chaikin-us-large-cap-etf-clrg-a-strong-etf-right-now,2023-07-12 10:20:05,Smart Beta ETF report for ...,GILD,0.116631,0.061379,Neutral
Explainer: What is Nasdaq's special rebalancing and its impact?,https://www.reuters.com/markets/us/what-is-nasdaqs-special-rebalancing-its-impact-2023-07-11/,2023-07-11 17:21:00,"July 11 ( Reuters ) - A ""special rebalance"" of the Nasdaq 100 index ( .NDX ) will take place later this month as exchange operator Nasdaq ( NDAQ.O ) looks to reduce the concentration of heavyweight companies that account for nearly half of the index's weight.",GILD,0.063425,0.099056,Neutral
Mega-cap tech stocks have gotten so big that the Nasdaq 100 is about to undergo a 'special rebalance' to address overconcentration,https://markets.businessinsider.com/news/stocks/mega-cap-tech-stocks-nasdaq-100-forcing-special-rebalance-winners-2023-7,2023-07-11 14:31:00,Mega-cap tech stocks are so big that the Nasdaq 100 is forcing a shake-up - Markets Insider ...,GILD,0.087824,0.17276,Somewhat-Bullish
"Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials - What Other Viruses Could This COVID Treatment Target? - Merck & Co  ( NYSE:MRK ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/23/07/33166416/novel-nanomedicine-platform-with-pipeline-of-antivirals-goes-to-human-trials-what-other-viruses-c,2023-07-10 13:13:14,"NanoViricides NNVC has begun trials for its new drug candidate, NV-CoV-2 - an exciting development for the biotech company, as it starts its first human trials with drug sponsor Karveer Meditech Pvt. Ltd. India, the company's licensee and co-developer in India.",GILD,0.099271,-0.045466,Neutral
3 Stocks Retirees Should Absolutely Love,https://www.fool.com/investing/2023/07/29/3-stocks-retirees-should-absolutely-love/,2023-07-29 10:14:00,These stocks offer solid income plus more.,GILD,0.175221,0.195826,Somewhat-Bullish
Gilead  ( GILD )  Gears Up to Report Q2 Earnings: What's in Store?,https://www.zacks.com/stock/news/2129602/gilead-gild-gears-up-to-report-q2-earnings-whats-in-store,2023-07-28 16:29:00,Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.,GILD,0.282777,0.297312,Somewhat-Bullish
GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030,https://www.prnewswire.com/apac/news-releases/gilead-launches-global-all4liver-grant-program-to-help-achieve-the-world-health-organizations-goal-of-viral-hepatitis-elimination-by-2030-301885938.html,2023-07-28 04:00:00,GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ... PR ...,GILD,0.341699,0.354796,Bullish
Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2128274/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know,2023-07-26 21:50:19,"In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day.",GILD,0.488777,0.17379,Somewhat-Bullish
"Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More",https://www.zacks.com/stock/news/2128013/biotech-stock-roundup-biib-gsks-q2-earnings-kod-faces-setback-more,2023-07-26 14:08:00,Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.,GILD,0.077845,0.122632,Neutral
Should SPDR Russell 1000 Yield Focus ETF  ( ONEY )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2127494/should-spdr-russell-1000-yield-focus-etf-oney-be-on-your-investing-radar,2023-07-26 10:20:07,Style Box ETF report for ONEY ...,GILD,0.12013,0.067797,Neutral
Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2127347/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know,2023-07-25 22:00:19,"In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day.",GILD,0.666827,0.376657,Bullish
Cognizant signs $800-mn deal with Gilead Sciences,https://www.financialexpress.com/industry/cognizant-signs-800-mn-deal-with-gilead-sciences/3185238/,2023-07-24 23:30:00,"In keeping with the recent trend of software majors bagging big deals, Cognizant on Monday said it is expanding its IT service partnership with Gilead Sciences for a total expected value of $800 million over the next five years.",GILD,0.124809,0.078175,Neutral
3 Top ETFs to Buy Right Now,https://www.fool.com/investing/2023/07/24/3-top-etfs-to-buy-right-now/,2023-07-24 21:45:00,These three exchange-traded funds could be winning plays for patient investors.,GILD,0.07423,0.039438,Neutral
"Stocks making the biggest moves midday: AMC Entertainment, Mattel, Chevron, Spotify and more",https://www.cnbc.com/2023/07/24/stocks-making-the-biggest-moves-midday-amc-mat-cvx-spot.html,2023-07-24 17:00:23,These are the stocks posting the largest moves in midday trading.,GILD,0.058903,-0.081065,Neutral
Gilead  ( GILD )  Ends Myelodysplastic Syndromes Study on Magrolimab,https://www.zacks.com/stock/news/2126211/gilead-gild-ends-myelodysplastic-syndromes-study-on-magrolimab,2023-07-24 14:44:00,"Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.",GILD,0.114956,0.123622,Neutral
Why Are Gilead Sciences  ( GILD )  Stock Trading Lower Today - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/07/33341414/trial-setback-for-gilead-sciences-shuts-late-stage-magrolimabazacitidine-combo-study-in-type-of-b,2023-07-24 12:36:32,Gilead Sciences Inc GILD decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes ( MDS ) due to futility based on a planned analysis. The Phase 3 study evaluated the combination of magrolimab plus azacitidine as first-line treatments for higher-risk ...,GILD,0.412298,0.226142,Somewhat-Bullish
"Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling - Bank of America  ( NYSE:BAC ) , Bank of New York Mellon  ( NYSE:BK ) ",https://www.benzinga.com/news/23/07/33343121/bank-of-america-bank-of-new-york-mellon-and-2-other-stocks-insiders-are-selling,2023-07-24 12:08:06,"The Nasdaq 100 closed slightly higher on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.",GILD,0.31482,0.043153,Neutral
Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million,https://www.prnewswire.com/news-releases/cognizant-and-gilead-extend-partnership-with-five-year-service-agreement-estimated-at-800-million-301883522.html,2023-07-24 12:00:00,Cognizant will manage Gilead's global IT infrastructure while leading digital transformation initiatives designed to enhance overall client experience and enable faster time to market for Gilead products.,GILD,0.113956,0.106617,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2125862/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-07-24 10:20:08,Smart Beta ETF report for ...,GILD,0.121959,0.061385,Neutral
"AMC shares surge after judge rejects APE conversion plan, Tesla stock slips on downgrade and other stocks on the move",https://www.marketwatch.com/story/amc-shares-surge-after-judge-rejects-ape-conversion-plan-tesla-stock-slips-on-downgrade-and-other-stocks-on-the-move-a6ac8ccd,2023-07-24 09:04:00,"Here are some of the biggest movers of the day: AMC Entertainment, Tesla and Gilead Sciences.",GILD,0.411176,0.0,Neutral
Drugmakers Are 'Throwing the Kitchen Sink' to Halt Medicare Price Negotiations,https://www.nytimes.com/2023/07/23/us/politics/medicare-drug-price-negotiations-lawsuits.html,2023-07-23 07:00:17,The government will soon announce the first 10 medications that will be subject to price negotiations with Medicare under a new law. Drugmakers are fighting the measure in court.,GILD,0.024053,-0.040908,Neutral
How a Drug Maker Profited by Slow-Walking a Promising H.I.V. Therapy,https://www.nytimes.com/2023/07/22/business/gilead-hiv-drug-tenofovir.html,2023-07-22 09:00:28,"Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.",GILD,0.025299,-0.121025,Neutral
Gilead scraps late-stage trial of blood cancer treatment,https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-stops-late-stage-trial-blood-cancer-treatment-2023-07-21/,2023-07-21 21:34:00,July 21 ( Reuters ) - Gilead Sciences Inc ( GILD.O ) said on Friday it was stopping a late-stage trial of its blood cancer combination treatment following an analysis that showed it would not be effective.,GILD,0.355588,-0.540177,Bearish
Stock Market Struggles To Stay Ahead; Dow Tries For A 10-Day Winning Streak,https://www.investors.com/market-trend/stock-market-today/stock-market-struggles-to-stay-ahead-dow-keeps-rally-going-auto-parts-stock-breaks-out/,2023-07-21 17:46:00,Stock Market Struggles To Stay Ahead. Dow Tries For A 10-Day Winning Streak Investor's Business Daily ...,GILD,0.144708,0.0,Neutral
Dow Jones Fades; Trump-Backed DWAC Surges As Cathie Wood Swoops On Battered Chip Leader,https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-trump-backed-dwac-surges-as-cathie-wood-swoops-down-on-battered-chip-leader/,2023-07-21 14:57:00,Dow Jones Fades. Trump-Backed DWAC Surges As Cathie Wood Swoops On Battered Chip Leader Investor's Business Daily ...,GILD,0.145583,0.0,Neutral
"Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years",https://www.fool.com/investing/2023/07/21/got-1000-buying-caribou-biosciences-stock-could/,2023-07-21 14:00:00,"It's still early going, but this small biotech shows great promise.",GILD,0.053153,-0.058994,Neutral
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/pressreleases/23/07/g33307586/center-for-disease-analysis-foundation-announces-receipt-of-an-8-million-grant-from-gilead-science,2023-07-20 16:00:00,"LAFAYETTE, Colo., July 20, 2023 ( GLOBE NEWSWIRE ) -- The Center for Disease Analysis Foundation ( CDA Foundation ) announced today that it received an $8 million grant from Gilead Sciences GILD as part of Gilead's Relink grant program.",GILD,0.215894,0.101132,Neutral
"2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street",https://www.fool.com/investing/2023/07/20/3-growth-stocks-that-could-rocket-to-higher-accord/,2023-07-20 15:35:00,The investment bank analysts who follow these stocks think they could deliver enormous gains in the not-so-distant future.,GILD,0.058759,0.056558,Neutral
Why Shares of Vir Biotechnology Are Plunging Thursday,https://www.fool.com/investing/2023/07/20/why-shares-of-vir-biotechnology-are-plunging-thurs/,2023-07-20 15:31:00,The company had disappointing trial news for one of its lead therapies.,GILD,0.135347,-0.216391,Somewhat-Bearish
"Pfizer, Gilead, GSK to capture 62% of $150 billion infectious diseases market | The Financial Express",https://www.financialexpress.com/healthcare/pharma-healthcare/pfizer-gilead-gsk-to-capture-62-of-150-billion-infectious-diseases-market/3178455/,2023-07-20 04:30:00,"Pfizer, Gilead, GSK to capture 62% of $150 billion infectious diseases market The Financial Express ...",GILD,0.258351,0.389872,Bullish
"GILD: 2 Biotech Stocks You Should Buy While You Can, 1 That Investors Are Avoiding",https://stocknews.com/news/gild-jazz-bngo-2-biotech-stocks-you-should-buy-while-you-can-1/,2023-08-08 15:58:36,"Despite the slowdown over the past year, the biotech sector is well-positioned for long-term growth due to increasing demand for agro-based products, personalized healthcare, and synthetic biology solutions. Additionally, government initiatives and growing healthcare needs reinforce its promising ...",GILD,0.211806,0.104154,Neutral
2 High-Yield Dividend Stocks to Buy on the Dip,https://www.fool.com/investing/2023/08/08/2-high-yield-dividend-stocks-to-buy-on-the-dip/,2023-08-08 09:26:00,The market may have been a bit too harsh on these stocks.,GILD,0.462648,0.287065,Somewhat-Bullish
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction,https://www.globenewswire.com/news-release/2023/08/07/2719566/0/en/Ikena-Oncology-Acquires-Pionyr-Immunotherapeutics-in-All-Stock-Transaction.html,2023-08-07 11:00:00,Ikena receives approximately $43 million in net cash at closing ...,GILD,0.086245,0.082227,Neutral
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction - Ikena Oncology  ( NASDAQ:IKNA ) ,https://www.benzinga.com/pressreleases/23/08/g33596881/ikena-oncology-acquires-pionyr-immunotherapeutics-in-all-stock-transaction,2023-08-07 11:00:00,"Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 ( GLOBE NEWSWIRE ) -- Ikena Oncology, Inc.",GILD,0.116161,0.088994,Neutral
Gilead Stock Jumps On Strong Q2 Performance Despite Lower Profit Outlook Amid Litigation - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/08/33576008/gilead-stock-jumps-on-strong-q2-performance-despite-lower-profit-outlook-amid-litigation,2023-08-04 17:55:42,"Gilead Sciences Inc's GILD Q2 FY23 sales increased 6% Y/Y to $6.60 billion, above the consensus of $6.43 billion, primarily driven by increased sales in HIV and Oncology, partially offset by lower Veklury ( remdesivir ) sales.",GILD,0.511256,0.24333,Somewhat-Bullish
"Gilead's  ( GILD )  Q2 Earnings Miss, Revenues Beat on Oncology",https://www.zacks.com/stock/news/2132850/gileads-gild-q2-earnings-miss-revenues-beat-on-oncology,2023-08-04 17:00:00,Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.,GILD,0.209004,-0.012346,Neutral
Market Rally Under Pressure As Yields Soar: Weekly Review,https://www.investors.com/news/market-rally-under-pressure-as-yields-soar-amazon-elf-caterpillar-are-earnings-winners/,2023-08-04 14:51:00,"The stock market rally came under pressure amid surging Treasury yields, fueled by a U.S. credit-rating downgrade as well, swelling Treasury issuance and improving U.S. economic growth. But yields pared gains following a mixed jobs report. Apple ( AAPL ) and Amazon ( AMZN ) capped a huge week of ...",GILD,0.032491,-0.016541,Neutral
The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... - PR Newswire,https://www.prnewswire.com/news-releases/the-pulmonary-embolism-therapeutics-market-size-to-grow-at-a-cagr-of-9-52-from-2022-to-2027the-advancement-in-the-healthcare-and-medical-sector-is-a-major-trend-technavio-301892623.html,2023-08-04 09:30:00,The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... PR ...,GILD,0.045569,0.139204,Neutral
Gilead Sciences  ( GILD )  Q2 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/08/04/gilead-sciences-gild-q2-2023-earnings-call-transcr/,2023-08-04 04:00:29,"GILD earnings call for the period ending June 30, 2023.",GILD,0.004845,0.086423,Neutral
Gilead Sciences  ( GILD )  Q2 Earnings Lag Estimates,https://www.zacks.com/stock/news/2132287/gilead-sciences-gild-q2-earnings-lag-estimates,2023-08-03 21:45:13,"Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",GILD,0.138464,0.117364,Neutral
"Gilead quarterly profit falls on COVID sales drop, legal settlement charge",https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-quarterly-profit-falls-covid-sales-drop-legal-settlement-charge-2023-08-03/,2023-08-03 21:12:00,"[1/2] Gilead Sciences is seen during the outbreak of the coronavirus disease ( COVID-19 ) , in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo",GILD,0.195025,-0.018094,Neutral
"Futures: Amazon, Apple Lead Earnings Late",https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-apple-amazon-lead-earnings-movers-late-jobs-report-on-tap/,2023-08-03 21:09:00,"Dow Jones Futures: Apple, Amazon Lead Earnings Movers Late. Jobs Report On Tap Investor's Business Daily ...",GILD,0.087291,0.205872,Somewhat-Bullish
Will An Earnings Miss Cloud Gilead's Massive Cancer Drug Growth?,https://www.investors.com/news/technology/gild-stock-gilead-earnings-q2-2023/,2023-08-03 20:23:00,"Two out of three of Gilead Sciences' ( GILD ) cancer drugs topped Wall Street's second-quarter sales expectations Thursday. But GILD stock was hamstrung on an earnings miss. Sales of Trodelvy, Yescarta and Tecartus - Gilead's cancer medicines - surged a combined 38% to $728 million.",GILD,0.484191,-0.170809,Somewhat-Bearish
"Gilead's profit lags consensus but sales beat, sending stock up after hours",https://www.marketwatch.com/story/gileads-stock-slides-2-after-q2-profit-lags-consensus-and-as-company-lowers-guidance-529efb68,2023-08-03 20:15:00,Gilead's quarterly revenue topped estimates and it tweaked guidance.,GILD,0.234684,0.157746,Somewhat-Bullish
"Cognizant  ( CTSH )  Q2 Earnings Beat Estimates, Revenues Down Y/Y",https://www.zacks.com/stock/news/2132168/cognizant-ctsh-q2-earnings-beat-estimates-revenues-down-yy,2023-08-03 16:54:00,Cognizant's (CTSH) second-quarter 2023 results benefit from strong Health Sciences revenues and acquisitions amid a challenging macro environment.,GILD,0.064797,0.091207,Neutral
"US Oil Inventories Drop By Most On Record - Apple  ( NASDAQ:AAPL ) , Ambev  ( NYSE:ABEV ) ",https://www.benzinga.com/economics/macro-economic-events/23/08/33551926/us-oil-inventories-drop-by-most-on-record,2023-08-03 14:56:37,"Billionaire hedge fund manager Bill Ackman is making a bold move! He's shorting 30-year Treasury bills using options, and he predicts yields could skyrocket to 5.5% 'soon'. His strategy is a hedge against the impact of long-term rates on stocks in ""a world with persistent 3% inflation.""",GILD,0.080458,0.0,Neutral
"US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month - Cars.com  ( NYSE:CARS ) , DraftKings  ( NASDAQ:DKNG ) , PayPal Holdings  ( NASDAQ:PYPL ) , Cheesecake Factory  ( NASDAQ:CAKE ) , Expedia Group  ( NASDAQ:EXPE ) , Hyatt Hotels  ( NYSE:H ) , Kellogg  ( NYSE:K ) , Amgen  ( NASDAQ:AMGN ) , DoorDash  ( NYSE:DASH ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Occidental Petroleum  ( NYSE:OXY ) , Etsy  ( NASDAQ:ETSY ) , Qualcomm  ( NASDAQ:QCOM ) , Warner Bros. Discovery  ( NASDAQ:WBD ) , EVgo  ( NASDAQ:EVGO ) , Atlassian  ( NASDAQ:TEAM ) , Gilead Sciences  ( NASDAQ:GILD ) , Hasbro  ( NASDAQ:HAS ) , Bausch Health Companies  ( NYSE:BHC ) , Moderna  ( NASDAQ:MRNA ) , Qorvo  ( NASDAQ:QRVO ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , SPDR S&P 500  ( ARCA:SPY ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/markets/equities/23/08/33543176/us-stock-futures-dip-as-apple-amazon-earnings-loom-analyst-warns-of-perfectly-normal-5-pullback-,2023-08-03 10:53:08,"As Fitch's U.S. ratings downgrade overhang persists and earnings new flow turns negative, stock futures are pulling back yet again on Thursday. Traders may find caution a virtue as a few profile tech names, including Apple, Inc. AAPL, are scheduled to report their quarterly results.",GILD,0.106541,0.0,Neutral
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors,https://www.prnewswire.com/news-releases/kyverna-therapeutics-extends-series-b-financing-round-to-145-million-and-brings-in-new-investors-301891039.html,2023-08-03 09:00:00,Proceeds to support clinical development of novel fully human anti-CD19 CAR T-cell therapies for autoimmune diseases,GILD,0.050044,-0.037797,Neutral
The Popular Miracle 'Off-Label' Weight Loss Drug for Diabetes Is Paralyzing Stomachs: 'This Medicine Made My Life Hell.',https://www.benzinga.com/news/23/08/33527068/the-popular-miracle-off-label-weight-loss-drug-for-diabetes-is-paralyzing-stomachs-this-medicine-mad,2023-08-02 17:01:16,"A July 25 CNN report shed light on severe gastroparesis, also known as stomach paralysis, experienced by some patients after taking Ozempic and Wegovy, medications known to result in weight loss in type 2 diabetes patients.",GILD,0.055109,0.143861,Neutral
GILD: 3 Biotech Stocks to Buy for August,https://stocknews.com/news/gild-regn-uthr-3-biotech-stocks-to-buy-for-august/,2023-08-02 12:43:37,"The biotechnology industry has emerged at the forefront as a vital industry harboring potential for innovation, economic development, and enhanced healthcare deliverables.",GILD,0.292657,0.140016,Neutral
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/earnings/23/07/33477554/1000-invested-in-gilead-sciences-20-years-ago-would-be-worth-this-much-today,2023-07-31 19:00:37,"Gilead Sciences GILD has outperformed the market over the past 20 years by 4.04% on an annualized basis producing an average annual return of 12.04%. Currently, Gilead Sciences has a market capitalization of $94.96 billion.",GILD,0.980595,0.386944,Bullish
Robert W. Baird Remains a Hold on Gilead Sciences  ( GILD ) ,https://markets.businessinsider.com/news/stocks/robert-w-baird-remains-a-hold-on-gilead-sciences-gild-1032494585,2023-07-31 09:45:15,Robert W. Baird Remains a Hold on Gilead Sciences (GILD) - Markets Insider ...,GILD,0.651499,-0.043652,Neutral
CTSH: Top 3 Tech Stocks in the A-Rated Industry on Wall Street,https://stocknews.com/news/ctsh-it-hckt-gild-now-top-3-tech-stocks-in-the-a-rated-industry-on-wall/,2023-08-17 18:40:29,"The U.S. tech industry is one of the most dynamic and innovative in the world. Companies in this space constantly develop new products and services and disrupt traditional industries. Despite facing multiple macroeconomic headwinds over the past two years, the sector is poised to rake in ...",GILD,0.05333,0.0,Neutral
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia - Autolus Therapeutics  ( NASDAQ:AUTL ) ,https://www.benzinga.com/general/biotech/23/08/33898135/autolus-therapeutics-obe-cels-shows-compelling-safety-over-gileads-drug-for-acute-lymphoblastic-l,2023-08-17 17:22:14,Truist has raised the price target for Autolus Therapeutics PLC AUTL from $6 to $9 with a Buy rating on Obe-cel's prospects. The analyst Asthika Goonewardene sees Obe-cel as poised to be a new standard of care and the preferred CAR-T in adults with acute lymphoblastic leukemia ( ALL ) over ...,GILD,0.285526,0.0,Neutral
"Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More",https://www.zacks.com/stock/news/2137533/biotech-stock-roundup-glto-plunges-on-setback-blue-offers-updates-more,2023-08-17 12:58:00,Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.,GILD,0.093108,-0.132014,Neutral
"Up 126% in 3 Days, Is Tango Therapeutics a Buy Right Now?",https://www.fool.com/investing/2023/08/17/up-126-in-3-days-is-tango-therapeutics-a-buy-right/,2023-08-17 09:05:00,Remember that past performance doesn't predict future returns.,GILD,0.06211,0.091165,Neutral
Two brands suspend advertising on X after their ads appeared next to pro-Nazi content | Business,https://edition.cnn.com/2023/08/16/tech/x-ads-pro-nazi-account-brand-safety/index.html,2023-08-16 23:39:00,Two brands suspend advertising on X after their ads appeared next to pro-Nazi content CNN International ...,GILD,0.04823,0.0,Neutral
Two brands suspend advertising on X after their ads appeared next to pro-Nazi content | Business,https://www.cnn.com/2023/08/16/tech/x-ads-pro-nazi-account-brand-safety/index.html,2023-08-16 23:39:00,Two brands suspend advertising on X after their ads appeared next to pro-Nazi content ...,GILD,0.04823,0.0,Neutral
"Gilead  ( GILD ) , Tentarix To Develop Cancer, Inflammation Therapies",https://www.zacks.com/stock/news/2137191/gilead-gild-tentarix-to-develop-cancer-inflammation-therapies,2023-08-16 17:21:00,Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.,GILD,0.192694,0.014766,Neutral
"Gilead ties up with Tentarix for cancer, inflammatory disease therapies",https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-ties-up-with-tentarix-cancer-inflammatory-disease-therapies-2023-08-15/,2023-08-15 12:49:00,"The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo Aug 15 ( Reuters ) - Gilead Sciences ( GILD.O ) said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop ...",GILD,0.690822,-0.296079,Somewhat-Bearish
"Biotechnology Market to Worth Around USD 3,995.22 Billion by 2032",https://www.benzinga.com/pressreleases/23/08/g33835844/biotechnology-market-to-worth-around-usd-3-995-22-billion-by-2032,2023-08-14 15:00:00,"Ottawa, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- The global biotechnology market size accounted for USD 1,224.31 billion in 2022, a study published by Towards Healthcare a sister firm of Precedence Research.",GILD,0.013202,0.0,Neutral
Is Vir Biotechnology Stock a Buy?,https://www.fool.com/investing/2023/08/11/is-vir-biotechnology-stock-a-buy/,2023-08-11 14:15:00,"The biotech is out to prove that it isn't just a ""pandemic stock."" ...",GILD,0.062597,0.137077,Neutral
Should You Invest in the VanEck Biotech ETF  ( BBH ) ?,https://www.zacks.com/stock/news/2135485/should-you-invest-in-the-vaneck-biotech-etf-bbh,2023-08-11 10:20:08,Sector ETF report for ...,GILD,0.13459,0.071501,Neutral
How Is The Market Feeling About Gilead Sciences? - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/08/33709999/how-is-the-market-feeling-about-gilead-sciences,2023-08-10 14:15:26,"Gilead Sciences's GILD short percent of float has risen 6.96% since its last report. The company recently reported that it has 18.84 million shares sold short, which is 1.69% of all regular shares that are available for trading.",GILD,0.221819,0.155473,Somewhat-Bullish
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/08/10/2722508/0/en/HOOKIPA-Pharma-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html,2023-08-10 11:01:00,"NEW YORK and VIENNA, Austria, Aug. 10, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the second quarter ...",GILD,0.02164,0.075115,Neutral
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors - Entrada Therapeutics  ( NASDAQ:TRDA ) ,https://www.benzinga.com/pressreleases/23/08/g33701692/entrada-therapeutics-appoints-gina-chapman-to-its-board-of-directors,2023-08-10 11:00:00,"BOSTON, Aug. 10, 2023 ( GLOBE NEWSWIRE ) -- Entrada Therapeutics, Inc. TRDA, a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle ( EEVâ¢ ) -therapeutics as a new class of medicines, today announced the appointment of Gina ...",GILD,0.066784,0.026221,Neutral
Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies,https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/,2023-08-09 12:06:00,"One minute Dow Jones industrial average component Merck ( MRK ) might be doing battle with fellow drugmaker Bristol Myers Squibb ( BMY ) over drugs that can ward off cancer. The next, biotech giants like Amgen ( AMGN ) and Sanofi ( SNY ) are tussling in court over the fate of ...",GILD,0.366061,0.043641,Neutral
A-Alpha Bio Nets $22.4M For Groundbreaking Protein Interaction Predictions,https://www.benzinga.com/news/23/08/34055486/a-alpha-bio-nets-22-4m-for-groundbreaking-protein-interaction-predictions,2023-08-26 12:00:11,"What do you get when you combine a revolutionary healthcare startup with artificial intelligence ( AI ) technology? In the case of A-Alpha Bio, the answer is simple: a $22.4 million funding round and a bright future.",GILD,0.092569,-0.040468,Neutral
GILD: 3 Biotech Stocks to Buy This Month and Beyond,https://stocknews.com/news/gild-jazz-alks-3-biotech-stocks-to-buy-this-month-and-beyond/,2023-08-25 17:49:15,"Biotech companies are making significant strides in developing new drugs and treatments for various diseases, including cancer, cardiovascular disease, and rare diseases. Positive clinical trial results and improved patient outcomes are driving the need for ongoing medical care and treatment.",GILD,0.173645,0.016451,Neutral
"MRNA: Is Now the Time to Buy Into Moderna, Inc.  ( MRNA ) ?",https://stocknews.com/news/mrna-alks-gild-otsky-is-now-the-time-to-buy-into-moderna-inc-mrna/,2023-08-25 16:41:32,"COVID-19-related hospitalizations are once again on the rise due to the onslaught of new subvariants. Vaccine-maker Moderna, Inc. ( MRNA ) announced that an initial study shows that its updated vaccine is effective against the EG.5 ( Eris ) and FL 1.5.1 ( Fornax ) subvariants.",GILD,0.051386,0.166452,Somewhat-Bullish
Gilead  ( GILD )  Gets FDA Nod for Veklury for Hepatic Impairment,https://www.zacks.com/stock/news/2140945/gilead-gild-gets-fda-nod-for-veklury-for-hepatic-impairment,2023-08-25 15:48:00,"Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.",GILD,0.113597,0.125294,Neutral
"The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics",https://www.zacks.com/stock/news/2140807/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-gilead-sciences-novavax-apellis-pharmaceuticals-and-fulcrum-therapeutics,2023-08-25 13:16:00,"Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.",GILD,0.10087,0.054348,Neutral
Stock buybacks spur wealth inequality and stifle innovation. Should they be banned?,https://www.marketwatch.com/story/stock-buybacks-spur-wealth-inequality-and-stifle-innovation-but-should-they-be-banned-13e963c0,2023-08-24 21:56:00,"Stock buybacks have become a major source of wealth inequality and have stifled innovation in the U.S., according to this academic.",GILD,0.07031,0.080602,Neutral
Biotech Stocks Rally After Roche's  ( RHHBY )  Accidental Data Leak,https://www.zacks.com/stock/news/2140458/biotech-stocks-rally-after-roches-rhhby-accidental-data-leak,2023-08-24 15:30:00,Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.,GILD,0.084127,0.042916,Neutral
"Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More",https://www.zacks.com/stock/news/2140318/biotech-stock-roundup-regn-up-on-approval-apls-nvax-gain-on-updates-more,2023-08-24 14:15:00,Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.,GILD,0.071463,0.112486,Neutral
Roche  ( RHHBY )  Up on Upbeat Data From Combo Drug Cancer Study,https://www.zacks.com/stock/news/2140250/roche-rhhby-up-on-upbeat-data-from-combo-drug-cancer-study,2023-08-24 13:02:00,Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.,GILD,0.059935,-0.047035,Neutral
PM360 Announces 2023 Trailblazer Award Finalists,https://www.prnewswire.com/news-releases/pm360-announces-2023-trailblazer-award-finalists-301907769.html,2023-08-24 13:00:00,"Top Companies, Marketers, CEOs, Products, and Initiatives to be Honored During Gala on October 3rd NEW YORK, Aug. 24, 2023 /PRNewswire/ -- PM360 has announced the finalists for its 15th annual Trailblazer Awards.",GILD,0.013876,0.0,Neutral
Indexes end sharply higher; AI chip maker Nvidia jumps again after the bell,https://www.moneycontrol.com/news/business/markets/indexes-end-sharply-higher-ai-chip-maker-nvidia-jumps-again-after-the-bell-11247481.html,2023-08-24 00:39:52,"Shares of Nvidia, which reported results after the closing bell, jumped 9%, extending a gain of 3.2% during the regular session.",GILD,0.081552,0.043283,Neutral
"Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",https://www.benzinga.com/general/biotech/23/08/34010167/who-are-other-players-gaining-from-roches-accidental-lung-cancer-data-update,2023-08-23 19:05:15,"Earlier today, Roche Holdings AG RHHBY announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq ( atezolizumab ) versus Tecentriq alone as an initial ( first-line ) treatment for ...",GILD,0.375251,0.357725,Bullish
How Roche's Accidental Update Lifted An Entire Group Of Stocks,https://www.investors.com/news/technology/roche-stock-surges-on-accidental-lung-cancer-update-boosting-iteos-and-arcus/,2023-08-23 13:24:00,Roche Stock Surges On Accidental Lung Cancer Update. Boosting ... Investor's Business Daily ...,GILD,0.305058,0.451642,Bullish
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It,https://www.fool.com/investing/2023/08/23/looking-next-big-biopharma-stock-nash-novo/,2023-08-23 09:31:00,"NASH is a surprisingly common ailment, and the first treatments are on the way.",GILD,0.046006,0.039626,Neutral
Gilead's  ( GILD )  Leukemia Study Progress Put on Clinical Hold,https://www.zacks.com/stock/news/2139160/gileads-gild-leukemia-study-progress-put-on-clinical-hold,2023-08-22 15:47:00,Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.,GILD,0.113597,0.174783,Somewhat-Bullish
FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/08/33964646/fda-pauses-gileads-investigational-magrolimab-study-in-blood-cancer-patients,2023-08-21 15:46:30,FDA has placed a partial clinical hold on Gilead Sciences Inc GILD initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia ( AML ) . The FDA action follows the previously announced discontinuation of Phase 3 ENHANCE study of magrolimab in higher-risk ...,GILD,0.488777,0.554837,Bullish
US FDA puts Gilead Sciences blood cancer drug studies on hold,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-puts-gilead-sciences-blood-cancer-drug-studies-hold-2023-08-21/,2023-08-21 12:55:26,"The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo/File Photo Acquire Licensing Rights",GILD,0.421485,-0.274929,Somewhat-Bearish
HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... - PR Newswire,https://www.prnewswire.com/news-releases/hiv-drugs-market-size-to-grow-by-usd-10-47-biilion-from-2022-to-2027--expanding-access-to-hiv-treatment-is-a-major-trend--technavio-301905076.html,2023-08-21 11:30:00,HIV Drugs Market size to grow by USD 10.47 biilion from 2022 to 2027 | Expanding access to HIV treatment is a major ... PR ...,GILD,0.064973,0.102266,Neutral
3 Under-the-Radar Biotech Stocks to Buy in 2023,https://www.fool.com/investing/2023/08/19/3-under-the-radar-biotech-stocks-to-buy-in-2023/,2023-08-19 11:40:00,All three biotech companies focus on oncology therapies.,GILD,0.04872,-0.274181,Somewhat-Bearish
Gilead Sciences  ( GILD )  Dips More Than Broader Markets: What You Should Know,https://www.zacks.com/stock/news/2146319/gilead-sciences-gild-dips-more-than-broader-markets-what-you-should-know,2023-09-07 22:00:17,"Gilead Sciences (GILD) closed at $73.94 in the latest trading session, marking a -0.4% move from the prior day.",GILD,0.601928,0.238828,Somewhat-Bullish
"$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/earnings/23/09/34326865/1000-invested-in-this-stock-20-years-ago-would-be-worth-9-000-today,2023-09-07 16:30:40,"Gilead Sciences GILD has outperformed the market over the past 20 years by 4.42% on an annualized basis producing an average annual return of 11.97%. Currently, Gilead Sciences has a market capitalization of $92.51 billion.",GILD,0.980595,0.386944,Bullish
GILD: 3 Biotech Stocks with Breakout Growth Potential,https://stocknews.com/news/gild-sgioy-thtx-3-biotech-stocks-with-breakout-growth-potential/,2023-09-07 14:48:43,"Innovative technology is propelling the biotech sector to new heights. Therefore, I present quality biotech stocks Theratechnologies Inc. ( THTX ) , Shionogi & Co., Ltd. ( SGIOY ) , and Gilead Sciences, Inc. ( GILD ) , which show solid signs of breakout growth potential.",GILD,0.243498,0.127085,Neutral
Why One Drug Company Held Back a Better Drug,https://www.nytimes.com/2023/09/07/podcasts/the-daily/gilead-hiv-drug.html,2023-09-07 10:00:12,"Edited by Liz O. Baylen and Paige Cowett Original music by Rowan Niemisto, Dan Powell, Elisheba Ittoop and Marion Lozano For decades, drugmakers have argued that patents are critical to bringing new drugs to the market.",GILD,0.09439,0.018497,Neutral
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,2023-09-06 21:01:00,"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period ( 2023-2032 ) , Examines ... PR ...",GILD,0.022494,0.023078,Neutral
 ( GILD )  - Analyzing Gilead Sciences's Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/09/34238663/gild-analyzing-gilead-sciencess-short-interest,2023-09-05 14:30:21,"Gilead Sciences's GILD short percent of float has risen 4.14% since its last report. The company recently reported that it has 19.63 million shares sold short, which is 1.76% of all regular shares that are available for trading.",GILD,0.221819,0.155473,Somewhat-Bullish
"MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead's Nomination of a Bispecific Research Program - Macrogenics  ( NASDAQ:MGNX ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/pressreleases/23/09/g34228797/macrogenics-announces-achievement-of-15-million-milestone-related-to-gileads-nomination-of-a-bispe,2023-09-05 11:00:00,"ROCKVILLE, MD, Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- MacroGenics, Inc. MGNX, a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that its partner, Gilead Sciences, Inc.",GILD,0.093108,0.079693,Neutral
3 No-Brainer Dividend Stocks to Buy in September,https://www.fool.com/investing/2023/09/02/3-no-brainer-dividend-stocks-to-buy-in-september/,2023-09-02 10:55:00,Income investors should really like these biopharma stocks with juicy dividends.,GILD,0.436691,0.299708,Somewhat-Bullish
Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2143965/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know,2023-09-01 21:50:12,"In the latest trading session, Gilead Sciences (GILD) closed at $76.65, marking a +0.22% move from the previous day.",GILD,0.668563,0.35468,Bullish
CTSH: Top 3 Tech Stocks You Would Regret Not Buying in September,https://stocknews.com/news/ctsh-tdc-hckt-gild-now-top-3-tech-stocks-you-would-regret-not-buying-in/,2023-09-01 16:10:37,"Cloud migrations and digitization trends across industries fuel the tech industry's growth. Given the industry's steady prospects, investors could consider quality tech stocks Cognizant Technology Solutions Corporation ( CTSH ) , Teradata Corporation ( TDC ) , and The Hackett Group, Inc. ( HCKT ) ...",GILD,0.089909,0.075541,Neutral
Cognizant  ( CTSH )  Up 1.6% Since Last Earnings Report: Can It Continue?,https://www.zacks.com/stock/news/2143797/cognizant-ctsh-up-16-since-last-earnings-report-can-it-continue,2023-09-01 15:31:39,Cognizant (CTSH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,GILD,0.053449,0.107915,Neutral
GILD: 3 Best Biotech Stocks for Growth in September,https://stocknews.com/news/gild-jazz-alks-teva-bbh-3-best-biotech-stocks-for-growth-in-september/,2023-08-30 17:06:35,"Despite the macroeconomic challenges, the biotech industry is primed for long-term growth. An aging population and the need for quality treatments for rare and common diseases underpins this positive outlook.",GILD,0.2589,0.152917,Somewhat-Bullish
Nearing Retirement? These Stocks Will Pay You For Life,https://www.fool.com/investing/2023/08/29/nearing-retirement-these-stocks-will-pay-you-for/,2023-08-29 13:45:00,These companies are passive income machines.,GILD,0.304428,0.279454,Somewhat-Bullish
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer - Pliant Therapeutics  ( NASDAQ:PLRX ) ,https://www.benzinga.com/pressreleases/23/09/g34612138/pliant-therapeutics-appoints-minnie-kuo-as-chief-development-officer,2023-09-15 12:00:00,"SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 ( GLOBE NEWSWIRE ) -- Pliant Therapeutics, Inc. PLRX, a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development ...",GILD,0.048621,-0.037608,Neutral
"Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates",https://www.zacks.com/stock/news/2148988/biotech-stock-roundup-mrnas-pipeline-news-rckt-bcyc-rally-on-study-updates,2023-09-14 14:12:00,Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.,GILD,0.057628,-0.016084,Neutral
Cipla founding family's stake sale in jeopardy over $13 bn valuation target,https://www.business-standard.com/companies/news/cipla-founding-family-s-stake-sale-in-jeopardy-over-13-bn-valuation-target-123091400368_1.html,2023-09-14 07:08:14,"The sale of a stake in Cipla Ltd. is in jeopardy as potential buyers have balked at the Rs 1.09 trillion ( $13.1 billion ) valuation members of the founding family are targeting for the Indian firm in a deal, according to people familiar with the matter.",GILD,0.089797,0.049613,Neutral
Gilead Sciences  ( GILD )  Stock Moves -0.31%: What You Should Know,https://www.zacks.com/stock/news/2148041/gilead-sciences-gild-stock-moves--031-what-you-should-know,2023-09-12 21:50:17,"In the latest trading session, Gilead Sciences (GILD) closed at $76.80, marking a -0.31% move from the previous day.",GILD,0.649828,0.163752,Somewhat-Bullish
Time for Gilead Sciences-Heavy ETFs?,https://www.zacks.com/stock/news/2147978/time-for-gilead-sciences-heavy-etfs,2023-09-12 18:00:00,"Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.",GILD,0.255641,-0.01583,Neutral
"CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer",https://www.benzinga.com/pressreleases/23/09/g34487555/cargo-therapeutics-announces-appointment-of-michael-ports-phd-as-chief-scientific-officer,2023-09-12 13:05:51,- Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development -,GILD,0.051999,0.058896,Neutral
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/09/34447206/gileads-breast-cancer-drug-shows-promise-when-combined-with-mercks-treatment,2023-09-11 16:45:07,"Gilead Sciences Inc GILD revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy. The study saw a combination with Merck & Co Inc's MRK Keytruda ( pembrolizumab ) with or without platinum agents in patients with previously untreated advanced or metastatic non-small ...",GILD,0.357293,0.183117,Somewhat-Bullish
Nurix  ( NRIX )  Stock Increases 9% in a Month: Here's Why,https://www.zacks.com/stock/news/2147375/nurix-nrix-stock-increases-9-in-a-month-heres-why,2023-09-11 16:10:00,The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.,GILD,0.185781,0.177066,Somewhat-Bullish
Gilead's  ( GILD )  Trodelvy Combo Shows Promise in NSCLC Study,https://www.zacks.com/stock/news/2147280/gileads-gild-trodelvy-combo-shows-promise-in-nsclc-study,2023-09-11 15:20:00,"Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.",GILD,0.112269,-0.154782,Somewhat-Bearish
S&P 500 closes up slightly ahead of US inflation data,https://www.moneycontrol.com/news/business/markets/sp-500-closes-up-slightly-ahead-of-us-inflation-data-11337721.html,2023-09-09 03:19:33,"The Dow Jones Industrial Average rose 75.86 points, or 0.22%, to 34,576.59, the SP 500 gained 6.35 points, or 0.14%, to 4,457.49 and the Nasdaq Composite added 12.69 points, or 0.09%, to 13,761.53.",GILD,0.055751,0.321008,Somewhat-Bullish
Oral Antiviral Market Report 2023: Demand for Novel Therapeutics Boosts Opportunities,https://www.prnewswire.com/news-releases/oral-antiviral-market-report-2023-demand-for-novel-therapeutics-boosts-opportunities-301921979.html,2023-09-09 01:15:00,"DUBLIN, Sept. 8, 2023 /PRNewswire/ -- The ""Oral Antiviral Market by Indication, Drug Class, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031"" report has been added to ResearchAndMarkets.com's offering.",GILD,0.085022,0.079948,Neutral
How To Earn $500 A Month From Gilead Sciences Stock - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34366120/how-to-earn-500-a-month-from-gilead-sciences-stock,2023-09-08 18:31:54,"Shares of Gilead Sciences, Inc GILD are trading higher during Friday's trading session, bolstered by the Bank of America Securities bullish outlook on the stock. Bank of America's nod of confidence drew attention to the underappreciated growth avenues within Gilead Sciences' core HIV segment and ...",GILD,0.820009,0.564662,Bullish
Why Vir Biotechnology  ( VIR )  Shares Are Falling Today - Vir Biotechnology  ( NASDAQ:VIR ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34363871/infectious-disease-player-vir-biotech-has-limited-near-term-upside-analyst-downgrad,2023-09-08 18:15:00,"BofA Securities has downgraded Vir Biotechnology Inc VIR to Neutral from Buy with a price target of $14, down from $23.",GILD,0.271274,-0.13787,Neutral
The Unexpected Reason Gilead Notched Its Biggest Single-Day Move In A Month,https://www.investors.com/news/technology/gild-stock-nabs-biggest-single-day-move-in-a-month-here-is-why/,2023-09-08 16:42:00,GILD Stock Nabs Biggest Single-Day Move In A Month. Here's Why Investor's Business Daily ...,GILD,0.50186,0.214434,Somewhat-Bullish
"Stocks making the biggest moves midday: Kroger, DocuSign, Planet Labs, First Solar and more",https://www.cnbc.com/2023/09/08/stocks-making-the-biggest-moves-midday-kroger-docusign-planet-labs-first-solar-and-more.html,2023-09-08 15:58:02,These are the stocks posting the largest moves in midday trading.,GILD,0.09439,0.085317,Neutral
Could A Gilead Sciences' Next-Generation Asset Be The Key To Bullish Analyst Upgrade? - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34362892/gilead-sciences-shares-trade-higher-after-bullish-analyst-upgrades-stock,2023-09-08 15:28:26,"Shares of Gilead Sciences, Inc. GILD are trading higher into Friday's trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in its core HIV business and emerging hematology/oncology franchises.",GILD,0.936251,0.657953,Bullish
"Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday - Adobe  ( NASDAQ:ADBE ) , ABM Indus  ( NYSE:ABM ) ",https://www.benzinga.com/news/23/09/34360130/adobe-to-rally-over-12-here-are-10-other-analyst-forecasts-for-friday,2023-09-08 12:24:11,"B of A Securities cut the price target for DigitalOcean Holdings, Inc. DOCN from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean shares fell 6% to $24.98 in pre-market trading.",GILD,0.276909,0.142114,Neutral
"Stocks making the biggest moves before the bell: Kroger, DocuSign, Snowflake, Adobe and more",https://www.cnbc.com/2023/09/08/premarket-movers-kroger-docusign-snowflake-adobe-and-more.html,2023-09-08 12:18:34,These are the stocks posting the largest moves in premarket trading.,GILD,0.07913,0.041067,Neutral
"Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields - Gilead Sciences  ( NASDAQ:GILD ) , Pfizer  ( NYSE:PFE ) ",https://www.benzinga.com/news/23/09/34947896/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields,2023-09-27 13:03:32,"During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.",GILD,0.103778,0.0,Neutral
Gilead Sciences  ( GILD )  Gains As Market Dips: What You Should Know,https://www.zacks.com/stock/news/2155735/gilead-sciences-gild-gains-as-market-dips-what-you-should-know,2023-09-26 22:00:19,"Gilead Sciences (GILD) closed the most recent trading day at $75.53, moving +0.94% from the previous trading session.",GILD,0.670305,0.243891,Somewhat-Bullish
"Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.",https://www.cnbc.com/2023/09/26/miami-man-pleads-guilty-to-selling-misbranded-hiv-drugs.html,2023-09-26 19:31:39,"The misbranded HIV drugs, which included Truvada and Biktarvy, were distributed to pharmacies across the U.S. and dispensed to unsuspecting patients.",GILD,0.130926,-0.020614,Neutral
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,2023-09-25 21:01:00,"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key ... PR ...",GILD,0.018757,0.012868,Neutral
AstraZeneca's  ( AZN )  Dato-DXd Meets Goal in Breast Cancer Study,https://www.zacks.com/stock/news/2154945/astrazenecas-azn-dato-dxd-meets-goal-in-breast-cancer-study,2023-09-25 15:05:00,"AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.",GILD,0.105836,0.217231,Somewhat-Bullish
"THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON - PR Newswire",https://www.prnewswire.com/news-releases/the-black-womens-agenda-inc-hosts-46th-annual-symposium-town-hall--awards-luncheon-301936600.html,2023-09-22 20:27:00,"THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON PR ...",GILD,0.075161,0.096641,Neutral
"Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Eli Lilly, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG",https://www.prnewswire.com/news-releases/chronic-lower-back-pain-market-to-showcase-tremendous-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---eli-lilly-camurus-braeburn-inc-scilex-holding-mesoblast-limited-anges-mg-301934365.html,2023-09-21 21:01:00,"Chronic Lower Back Pain Market to Showcase Tremendous Growth by 2032, Predicts DelveInsight | Key Companies to ... PR ...",GILD,0.02275,0.014186,Neutral
CAAN AND GILEAD SCIENCES CANADA IGNITE HOPE WITH NEW INDIGENOUS HEALTH GRANT - Canada NewsWire,https://www.newswire.ca/news-releases/caan-and-gilead-sciences-canada-ignite-hope-with-new-indigenous-health-grant-800507084.html,2023-09-21 20:00:00,CAAN AND GILEAD SCIENCES CANADA IGNITE HOPE WITH NEW INDIGENOUS HEALTH GRANT Canada ...,GILD,0.302346,0.401423,Bullish
How Is The Market Feeling About Gilead Sciences? - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/09/34803110/how-is-the-market-feeling-about-gilead-sciences,2023-09-21 18:15:31,"Gilead Sciences's GILD short percent of float has fallen 6.82% since its last report. The company recently reported that it has 18.25 million shares sold short, which is 1.64% of all regular shares that are available for trading.",GILD,0.221819,0.083071,Neutral
3 Bargain Stocks to Buy in a Market That's Priced for Perfection,https://www.fool.com/investing/2023/09/21/3-bargain-stocks-to-buy-in-a-market-thats-priced-f/,2023-09-21 17:54:00,Many stocks have nosebleed valuations. But not these.,GILD,0.40348,0.291742,Somewhat-Bullish
Big pharma can't get enough of one class of cancer drugs,https://www.economist.com/business/2023/09/21/big-pharma-cant-get-enough-of-one-class-of-cancer-drugs,2023-09-21 12:51:46,A spate of dealmaking suggests high expectations for antibody-drug conjugates ...,GILD,0.0699,0.157028,Somewhat-Bullish
"Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development",https://www.benzinga.com/pressreleases/23/09/g34789158/bluejay-therapeutics-expands-management-team-and-hired-christopher-holterhoff-as-senior-vice-presi,2023-09-21 11:55:00,"SAN MATEO, Calif., Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the appointment of Christopher Holterhoff as Senior Vice President, Head of Business Development.",GILD,0.03853,0.153119,Somewhat-Bullish
Gilead Sciences Unusual Options Activity - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/markets/options/23/09/34772999/gilead-sciences-unusual-options-activity,2023-09-20 20:15:48,"A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences GILD we detected 10 strange trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with ...",GILD,0.743681,0.405647,Bullish
Gilead's  ( GILD )  Veklury Gets CHMP Nod in Damaged Liver Patients,https://www.zacks.com/stock/news/2152969/gileads-gild-veklury-gets-chmp-nod-in-damaged-liver-patients,2023-09-20 11:51:00,"Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.",GILD,0.203215,0.083354,Neutral
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2152870/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-09-20 10:20:05,Sector ETF report for ...,GILD,0.138066,0.072464,Neutral
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know,https://www.fool.com/investing/2023/09/19/1-huge-risk-that-gene-editing-stock-investors-desp/,2023-09-19 11:35:00,Good medicines aren't always good business.,GILD,0.103331,-0.272132,Somewhat-Bearish
Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2152175/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know,2023-09-18 22:00:18,"Gilead Sciences (GILD) closed the most recent trading day at $75.62, moving -0.07% from the previous trading session.",GILD,0.531019,0.24678,Somewhat-Bullish
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/earnings/23/09/34700117/100-invested-in-gilead-sciences-20-years-ago-would-be-worth-this-much-today,2023-09-18 18:30:32,"Gilead Sciences GILD has outperformed the market over the past 20 years by 4.95% on an annualized basis producing an average annual return of 12.68%. Currently, Gilead Sciences has a market capitalization of $94.47 billion.",GILD,0.980595,0.386944,Bullish
"GILD: Bionano Genomics  ( BNGO )  vs. Gilead Sciences  ( GILD ) : Buy, Hold or Sell these Biotech Stocks?",https://stocknews.com/news/gild-bngo-mrk-bionano-genomics-bngo-vs-gilead-sciences-gild-buy-hold-or/,2023-09-18 15:53:09,GILD: Bionano Genomics ( BNGO ) vs. Gilead Sciences ( GILD ) : Buy ... ...,GILD,0.557513,0.263808,Somewhat-Bullish
"Black Diamond Therapeutics Announces CEO Transition - Black Diamond Therapeutic  ( NASDAQ:BDTX ) , G1 Therapeutics  ( NASDAQ:GTHX ) ",https://www.benzinga.com/pressreleases/23/09/g34682997/black-diamond-therapeutics-announces-ceo-transition,2023-09-18 11:00:00,"Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Black Diamond Therapeutics, Inc.",GILD,0.058903,-0.061986,Neutral
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,2023-09-18 09:15:00,"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... PR ...",GILD,0.043108,0.0,Neutral
Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire,https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html,2023-09-18 08:35:00,Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...,GILD,0.052685,0.0,Neutral
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/earnings/23/10/35114040/heres-how-much-100-invested-in-gilead-sciences-20-years-ago-would-be-worth-today,2023-10-05 17:30:50,"Gilead Sciences GILD has outperformed the market over the past 20 years by 4.82% on an annualized basis producing an average annual return of 12.02%. Currently, Gilead Sciences has a market capitalization of $93.13 billion.",GILD,0.980595,0.386944,Bullish
Strides Pharma Science trades marginally lower despite USFDA nod,https://www.moneycontrol.com/news/business/stocks/strides-pharma-science-trades-marginally-lower-despite-usfda-nod-11478241.html,2023-10-05 04:11:48,"The company has received approval for Efavirenz ( 600mg ) , Emtricitabine ( 200mg ) , Tenofovir Disproxil Fumurate ( 300mg ) , ( EET ) tablets from the United States Food Drug Administration ( USFDA ) .",GILD,0.172097,0.0,Neutral
CTSH: Supercharge Your October Portfolio With These 3 Promising Tech Stocks,https://stocknews.com/news/ctsh-it-hckt-supercharge-your-october-portfolio-with-these-3-promising-tech-stocks/,2023-10-04 13:43:09,CTSH: Supercharge Your October Portfolio With These 3 Promising ... ...,GILD,0.095138,0.150134,Somewhat-Bullish
Lilly Announces Leadership Transitions,https://markets.businessinsider.com/news/stocks/lilly-announces-leadership-transitions-1032677321,2023-10-04 10:45:00,"INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced changes to its executive leadership team. Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company.",GILD,0.028023,-0.049462,Neutral
Lilly Announces Leadership Transitions,https://www.prnewswire.com/news-releases/lilly-announces-leadership-transitions-301946467.html,2023-10-04 10:45:00,"INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced changes to its executive leadership team. Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company.",GILD,0.027667,-0.049386,Neutral
"Breast Cancer Therapeutics Market to Hit $63.96 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners",https://www.benzinga.com/pressreleases/23/10/g35082720/breast-cancer-therapeutics-market-to-hit-63-96-billion-globally-by-2030-exclusive-report-by-the-in,2023-10-04 09:57:03,"Pune, India, Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Breast cancer is one of the most common types of cancer and has a sizable market for therapies. According to the Centers for Disease Control and Prevention, in 2020, in the US, 239,612 new cases of breast cancer were reported among women, of which ...",GILD,0.036643,-0.119027,Neutral
AMGN: Top 3 Biotech Stocks Leading the Way This October,https://stocknews.com/news/amgn-gild-jazz-top-3-biotech-stocks-leading-the-way-this-october/,2023-10-03 16:44:08,"The biotech industry is thriving, driven by innovation and stable demand, positioning it for sustained growth. Despite macroeconomic challenges, this positive outlook is supported by an aging population and the demand for quality treatments for both rare and common diseases.",GILD,0.169335,0.147264,Neutral
Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: What You Should Know,https://www.zacks.com/stock/news/2158894/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know,2023-10-02 22:00:18,"In the latest trading session, Gilead Sciences (GILD) closed at $74.10, marking a -1.12% move from the previous day.",GILD,0.538782,0.270872,Somewhat-Bullish
"Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD",https://www.globenewswire.com/news-release/2023/10/02/2753011/0/en/Message-from-Renovaro-Biosciences-CEO-The-Hon-Mark-Dybul-MD.html,2023-10-02 16:05:00,AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine ...,GILD,0.017072,0.107168,Neutral
AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine - Renovaro Biosciences  ( NASDAQ:RENB ) ,https://www.benzinga.com/pressreleases/23/10/g35031585/ai-company-gedicube-and-renovaro-biosciences-sign-definitive-agreement-to-combine,2023-10-02 13:25:00,"LOS ANGELES, Oct. 02, 2023 ( GLOBE NEWSWIRE ) -- Renovaro Biosciences Inc. RENB",GILD,0.017496,0.104397,Neutral
AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine,https://www.globenewswire.com/news-release/2023/10/02/2752845/0/en/AI-Company-GEDiCube-and-Renovaro-Biosciences-Sign-Definitive-Agreement-to-Combine.html,2023-10-02 13:25:00,"Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD ...",GILD,0.017072,0.107168,Neutral
3 Magnificent Dividend Stocks to Buy in October,https://www.fool.com/investing/2023/09/30/3-magnificent-dividend-stocks-to-buy-in-october/,2023-09-30 10:55:00,These stocks come with great dividends and more.,GILD,0.179788,0.03029,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2157520/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-09-29 10:20:05,Smart Beta ETF report for ...,GILD,0.122894,0.068464,Neutral
Two Trial Halts In A Row - Gilead Sciences Stops Late Stage COVID-19 Study - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/23/09/34982869/two-trial-halts-in-a-row-gilead-sciences-stops-late-stage-covid-19-study,2023-09-28 17:35:28,"Gilead Sciences Inc GILD said it has stopped patient enrollment in BIRCH ( Study GS-US-611-6273 ) , a Phase 3 study evaluating the efficacy and safety of obeldesivir compared with placebo in non-hospitalized participants who are at high risk for developing severe COVID-19.",GILD,0.479683,0.069836,Neutral
TRDA: 3 Biotech Stocks for Long-Term Value,https://stocknews.com/news/trda-mgnx-gnft-gild-3-biotech-stocks-for-long-term-value/,2023-10-17 17:19:44,"Innovative biotech companies are making remarkable progress in creating novel medications and therapies for a diverse array of conditions, such as cancer, heart disease, and rare ailments. Encouraging trial outcomes and enhanced patient well-being are spurring the demand for continuous medical ...",GILD,0.086975,0.119542,Neutral
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why - Assembly Biosciences  ( NASDAQ:ASMB ) ,https://www.benzinga.com/general/biotech/23/10/35286090/hepatitis-focused-assembly-biosciences-stock-trading-over-100-higher-heres-why,2023-10-17 13:51:16,"Gilead Sciences Inc GILD and Assembly Biosciences Inc ASMB have entered into a 12-year partnership. Their goal is to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio's established areas of herpesviruses, hepatitis B virus ( HBV ) and ...",GILD,0.21686,0.0,Neutral
Gilead Sciences  ( GILD )  Beats Stock Market Upswing: What Investors Need to Know,https://www.zacks.com/stock/news/2166772/gilead-sciences-gild-beats-stock-market-upswing-what-investors-need-to-know,2023-10-16 22:00:20,"Gilead Sciences (GILD) reachead $79.20 at the closing of the latest trading day, reflecting a +2% change compared to its last close.",GILD,0.573213,0.294515,Somewhat-Bullish
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,2023-10-16 21:01:00,"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period ( 2019-2032 ) , Assesses ... PR ...",GILD,0.051663,-0.028928,Neutral
GILD: 4 Promising Biotech Stocks for Smart Investment Strategies,https://stocknews.com/news/gild-vrtx-uthr-jazz-4-promising-biotech-stocks-for-smart-investment-strategies/,2023-10-16 19:25:31,"The biotechnology sector has thrived exceptionally over the past few years, catalyzed by continued innovations that fortify its status as a vanguard in crucial sectors like healthcare, agriculture, and the environment.",GILD,0.12342,0.218092,Somewhat-Bullish
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html,2023-10-16 11:50:00,"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... PR ...",GILD,0.044386,-0.061069,Neutral
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html,2023-10-16 11:50:00,"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... Canada ...",GILD,0.044386,-0.061069,Neutral
2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now,https://www.fool.com/investing/2023/10/15/2-dirt-cheap-high-yield-dividend-stocks-to-buy/,2023-10-15 14:00:00,These companies aren't getting the respect they deserve.,GILD,0.330286,0.317256,Somewhat-Bullish
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/earnings/23/10/35248115/heres-how-much-100-invested-in-gilead-sciences-20-years-ago-would-be-worth-today,2023-10-13 20:00:20,"Gilead Sciences GILD has outperformed the market over the past 20 years by 5.07% on an annualized basis producing an average annual return of 12.39%. Currently, Gilead Sciences has a market capitalization of $96.67 billion.",GILD,0.980595,0.386944,Bullish
Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics,https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html,2023-10-13 15:45:00,Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...,GILD,0.036643,0.067285,Neutral
GILD: How to Enhance Your Own Strategies with POWR Ratings,https://stocknews.com/news/gild-amgn-uthr-biib-regn-how-to-enhance-your-own-strategies-with-powr-ratings/,2023-10-12 16:29:47,"One thing Wall Street is never short of is ideas. Technical strategies, fundamental strategies, seasonal investing, and the list goes on and on and on.",GILD,0.139467,0.121564,Neutral
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032,https://investingnews.com/global-car-t-cell-therapy-market-projected-to-reach-83-billion-by-2032/,2023-10-12 13:39:21,"FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines.",GILD,0.084796,0.055474,Neutral
Gene Siskel Film Center of The School of the Art Institute of Chicago Announces the Full Program for the 29th Annual Black Harvest Film Festival,https://www.benzinga.com/pressreleases/23/10/n35203301/gene-siskel-film-center-of-the-school-of-the-art-institute-of-chicago-announces-the-full-program-f,2023-10-11 19:51:00,"CHICAGO, Oct. 11, 2023 /PRNewswire/ -- The School of the Art Institute of Chicago's Gene Siskel Film Center is pleased to announce the complete festival program and schedule for its 29th Annual Black Harvest Film Festival.",GILD,0.040348,0.180164,Somewhat-Bullish
Nurix  ( NRIX )  to Report Q3 Earnings: What's in Store?,https://www.zacks.com/stock/news/2164117/nurix-nrix-to-report-q3-earnings-whats-in-store,2023-10-11 11:09:00,"On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.",GILD,0.157141,0.165995,Somewhat-Bullish
Should You Invest in the VanEck Biotech ETF  ( BBH ) ?,https://www.zacks.com/stock/news/2164069/should-you-invest-in-the-vaneck-biotech-etf-bbh,2023-10-11 10:20:06,Sector ETF report for ...,GILD,0.134968,0.071604,Neutral
"Northrop Grumman  ( NYSE:NOC )  Lowered to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/10/11/northrop-grumman-nysenoc-lowered-to-hold-at-stocknews-com.html,2023-10-11 08:40:53,StockNews.com downgraded shares of Northrop Grumman ( NYSE:NOC - Free Report ) from a buy rating to a hold rating in a research note published on Tuesday. NOC has been the topic of several other reports.,GILD,0.049526,0.114672,Neutral
"F.N.B.  ( NYSE:FNB )  Upgraded to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/10/11/f-n-b-nysefnb-upgraded-to-hold-at-stocknews-com.html,2023-10-11 08:08:42,StockNews.com upgraded shares of F.N.B. ( NYSE:FNB - Free Report ) from a sell rating to a hold rating in a research note released on Tuesday. Several other equities analysts have also weighed in on the stock.,GILD,0.061315,0.13113,Neutral
Mobileye Global  ( NASDAQ:MBLY )  Upgraded to Hold at StockNews.com,https://www.defenseworld.net/2023/10/11/mobileye-global-nasdaqmbly-upgraded-to-hold-at-stocknews-com.html,2023-10-11 08:08:42,Mobileye Global ( NASDAQ:MBLY ) Upgraded to Hold at StockNews ... Defense World ...,GILD,0.055236,0.215,Somewhat-Bullish
"Eltek  ( NASDAQ:ELTK )  Downgraded by StockNews.com to ""Buy""",https://www.defenseworld.net/2023/10/11/eltek-nasdaqeltk-downgraded-by-stocknews-com-to-buy.html,2023-10-11 08:04:50,StockNews.com lowered shares of Eltek ( NASDAQ:ELTK - Free Report ) from a strong-buy rating to a buy rating in a research note released on Tuesday. NASDAQ ELTK opened at $11.35 on Tuesday. Eltek has a 12-month low of $3.57 and a 12-month high of $11.49.,GILD,0.090474,0.105801,Neutral
Protagonist Therapeutics  ( NASDAQ:PTGX )  Upgraded to Hold at StockNews.com,https://www.defenseworld.net/2023/10/11/protagonist-therapeutics-nasdaqptgx-upgraded-to-hold-at-stocknews-com-2.html,2023-10-11 08:04:50,Protagonist Therapeutics ( NASDAQ:PTGX ) Upgraded to Hold at ... Defense World ...,GILD,0.071784,-0.02337,Neutral
"Bright Horizons Family Solutions  ( NYSE:BFAM )  Upgraded to ""Hold"" by StockNews.com",https://www.defenseworld.net/2023/10/11/bright-horizons-family-solutions-nysebfam-upgraded-to-hold-by-stocknews-com.html,2023-10-11 08:02:44,"Bright Horizons Family Solutions ( NYSE:BFAM ) Upgraded to ""Hold ... Defense World ...",GILD,0.045743,0.223204,Somewhat-Bullish
Johnson & Johnson  ( NYSE:JNJ )  Upgraded by StockNews.com to Strong-Buy,https://www.defenseworld.net/2023/10/11/johnson-johnson-nysejnj-upgraded-by-stocknews-com-to-strong-buy.html,2023-10-11 08:02:44,Johnson & Johnson ( NYSE:JNJ ) Upgraded by StockNews.com to ... Defense World ...,GILD,0.040829,0.094895,Neutral
Rite Aid  ( NYSE:RAD )  Now Covered by StockNews.com,https://www.defenseworld.net/2023/10/11/rite-aid-nyserad-now-covered-by-stocknews-com.html,2023-10-11 08:02:43,"StockNews.com began coverage on shares of Rite Aid ( NYSE:RAD - Get Free Report ) in a research report issued to clients and investors on Wednesday. The brokerage set a ""sell"" rating on the stock. Shares of NYSE:RAD opened at $0.74 on Wednesday. Rite Aid has a 1-year low of $0.38 and a 1-year ...",GILD,0.095899,0.211208,Somewhat-Bullish
Empire State Realty OP  ( NYSE:ESBA )  Now Covered by Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/empire-state-realty-op-nyseesba-now-covered-by-analysts-at-stocknews-com-2.html,2023-10-11 08:02:43,Empire State Realty OP ( NYSE:ESBA ) Now Covered by Analysts at ... Defense World ...,GILD,0.089797,0.192356,Somewhat-Bullish
Enservco  ( NYSEAMERICAN:ENSV )  Earns Sell Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/enservco-nyseamericanensv-earns-sell-rating-from-analysts-at-stocknews-com.html,2023-10-11 07:30:41,Enservco ( NYSEAMERICAN:ENSV ) Earns Sell Rating from Analysts ... Defense World ...,GILD,0.088147,0.268426,Somewhat-Bullish
Espey Mfg. & Electronics  ( NYSEAMERICAN:ESP )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/10/11/espey-mfg-electronics-nyseamericanesp-coverage-initiated-at-stocknews-com.html,2023-10-11 07:30:41,Espey Mfg. & Electronics ( NYSEAMERICAN:ESP ) Coverage ... Defense World ...,GILD,0.082963,0.122723,Neutral
PNM Resources  ( NYSE:PNM )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/10/11/pnm-resources-nysepnm-upgraded-at-stocknews-com.html,2023-10-11 07:30:41,"PNM Resources ( NYSE:PNM - Get Free Report ) was upgraded by investment analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued to investors on Wednesday.",GILD,0.072217,0.15822,Somewhat-Bullish
Corporate Office Properties Trust  ( NYSE:OFC )  Receives New Coverage from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/corporate-office-properties-trust-nyseofc-receives-new-coverage-from-analysts-at-stocknews-com.html,2023-10-11 07:30:41,Corporate Office Properties Trust ( NYSE:OFC ) Receives New ... Defense World ...,GILD,0.060541,0.219103,Somewhat-Bullish
Birks Group  ( NYSEAMERICAN:BGI )  Receives New Coverage from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/birks-group-nyseamericanbgi-receives-new-coverage-from-analysts-at-stocknews-com.html,2023-10-11 07:30:41,Birks Group ( NYSEAMERICAN:BGI ) Receives New Coverage from ... Defense World ...,GILD,0.124164,0.278381,Somewhat-Bullish
Westwood Holdings Group  ( NYSE:WHG )  Earns Buy Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/westwood-holdings-group-nysewhg-earns-buy-rating-from-analysts-at-stocknews-com.html,2023-10-11 07:28:59,Westwood Holdings Group ( NYSE:WHG ) Earns Buy Rating from ... Defense World ...,GILD,0.082963,0.185506,Somewhat-Bullish
"Teekay Tankers  ( NYSE:TNK )  Downgraded to ""Buy"" at StockNews.com",https://www.defenseworld.net/2023/10/11/teekay-tankers-nysetnk-downgraded-to-buy-at-stocknews-com.html,2023-10-11 07:28:59,"Teekay Tankers ( NYSE:TNK - Get Free Report ) was downgraded by research analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a research note issued to investors on Wednesday.",GILD,0.076847,0.088476,Neutral
Zovio  ( NYSE:ZVO )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/10/11/zovio-nysezvo-coverage-initiated-at-stocknews-com-2.html,2023-10-11 07:28:59,"Analysts at StockNews.com assumed coverage on shares of Zovio ( NYSE:ZVO - Get Free Report ) in a research note issued to investors on Wednesday. The brokerage set a ""hold"" rating on the stock. Zovio has a twelve month low of $0.08 and a twelve month high of $1.79.",GILD,0.209365,0.175948,Somewhat-Bullish
StockNews.com Begins Coverage on Flexible Solutions International  ( NYSE:FSI ) ,https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-flexible-solutions-international-nysefsi-2.html,2023-10-11 07:16:43,StockNews.com Begins Coverage on Flexible Solutions ... Defense World ...,GILD,0.078611,0.19911,Somewhat-Bullish
StockNews.com Begins Coverage on Phoenix New Media  ( NYSE:FENG ) ,https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-phoenix-new-media-nysefeng.html,2023-10-11 07:16:43,StockNews.com Begins Coverage on Phoenix New Media ( NYSE ... Defense World ...,GILD,0.126119,0.153564,Somewhat-Bullish
Culp  ( NYSE:CULP )  Receives New Coverage from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/culp-nyseculp-receives-new-coverage-from-analysts-at-stocknews-com.html,2023-10-11 07:16:42,Culp ( NYSE:CULP ) Receives New Coverage from Analysts at ... Defense World ...,GILD,0.075874,0.110628,Neutral
"Fortis  ( NYSE:FTS )  Raised to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/10/11/fortis-nysefts-raised-to-hold-at-stocknews-com.html,2023-10-11 07:16:42,"Fortis ( NYSE:FTS - Get Free Report ) was upgraded by investment analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued to investors on Wednesday. Other research analysts have also issued reports about the stock.",GILD,0.072435,0.122881,Neutral
Cedar Fair  ( NYSE:FUN )  Rating Lowered to Hold at StockNews.com,https://www.defenseworld.net/2023/10/11/cedar-fair-nysefun-rating-lowered-to-hold-at-stocknews-com.html,2023-10-11 07:16:42,"Cedar Fair ( NYSE:FUN - Get Free Report ) was downgraded by equities researchers at StockNews.com from a ""buy"" rating to a ""hold"" rating in a report issued on Wednesday. Other equities analysts also recently issued research reports about the company.",GILD,0.053153,0.175709,Somewhat-Bullish
"Eagle Materials  ( NYSE:EXP )  Cut to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/10/11/eagle-materials-nyseexp-cut-to-hold-at-stocknews-com.html,2023-10-11 07:16:42,"Eagle Materials ( NYSE:EXP - Get Free Report ) was downgraded by equities researchers at StockNews.com from a ""buy"" rating to a ""hold"" rating in a research report issued on Wednesday.",GILD,0.042723,0.146292,Neutral
StockNews.com Initiates Coverage on China Pharma  ( NYSE:CPHI ) ,https://www.defenseworld.net/2023/10/11/stocknews-com-initiates-coverage-on-china-pharma-nysecphi.html,2023-10-11 07:16:42,"Analysts at StockNews.com started coverage on shares of China Pharma ( NYSE:CPHI - Get Free Report ) in a note issued to investors on Wednesday. The firm set a ""hold"" rating on the stock. NYSE CPHI opened at $0.13 on Wednesday. China Pharma has a one year low of $0.11 and a one year high of ...",GILD,0.144275,0.175242,Somewhat-Bullish
StockNews.com Initiates Coverage on Global Cord Blood  ( NYSE:CO ) ,https://www.defenseworld.net/2023/10/11/stocknews-com-initiates-coverage-on-global-cord-blood-nyseco.html,2023-10-11 07:14:56,"Research analysts at StockNews.com started coverage on shares of Global Cord Blood ( NYSE:CO - Get Free Report ) in a research note issued to investors on Wednesday. The firm set a ""strong-buy"" rating on the medical research company's stock. Shares of CO stock opened at $1.24 on Wednesday.",GILD,0.092569,0.13364,Neutral
Brooklyn ImmunoTherapeutics  ( NYSE:BTX )  Research Coverage Started at StockNews.com,https://www.defenseworld.net/2023/10/11/brooklyn-immunotherapeutics-nysebtx-research-coverage-started-at-stocknews-com.html,2023-10-11 07:14:56,Brooklyn ImmunoTherapeutics ( NYSE:BTX ) Research Coverage ... Defense World ...,GILD,0.116348,0.234414,Somewhat-Bullish
Brunswick  ( NYSE:BC )  Upgraded by StockNews.com to Buy,https://www.defenseworld.net/2023/10/11/brunswick-nysebc-upgraded-by-stocknews-com-to-buy-2.html,2023-10-11 07:14:55,"Brunswick ( NYSE:BC - Get Free Report ) was upgraded by StockNews.com from a ""hold"" rating to a ""buy"" rating in a research note issued on Wednesday. BC has been the subject of several other research reports.",GILD,0.064276,0.119123,Neutral
Bluerock Residential Growth REIT  ( NYSE:BRG )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/bluerock-residential-growth-reit-nysebrg-coverage-initiated-by-analysts-at-stocknews-com.html,2023-10-11 07:14:55,Bluerock Residential Growth REIT ( NYSE:BRG ) Coverage Initiated ... Defense World ...,GILD,0.173333,0.211729,Somewhat-Bullish
AngloGold Ashanti  ( NYSE:AU )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/anglogold-ashanti-nyseau-coverage-initiated-by-analysts-at-stocknews-com.html,2023-10-11 07:14:53,AngloGold Ashanti ( NYSE:AU ) Coverage Initiated by Analysts at ... Defense World ...,GILD,0.062271,0.148159,Neutral
Ampio Pharmaceuticals  ( NYSE:AMPE )  Receives New Coverage from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/ampio-pharmaceuticals-nyseampe-receives-new-coverage-from-analysts-at-stocknews-com.html,2023-10-11 07:14:52,Ampio Pharmaceuticals ( NYSE:AMPE ) Receives New Coverage ... Defense World ...,GILD,0.083541,0.058399,Neutral
AutoNation  ( NYSE:AN )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/10/11/autonation-nysean-upgraded-at-stocknews-com.html,2023-10-11 07:14:52,"AutoNation ( NYSE:AN - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a research note issued on Wednesday.",GILD,0.046816,0.113135,Neutral
StockNews.com Begins Coverage on American Equity Investment Life  ( NYSE:AEL ) ,https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-american-equity-investment-life-nyseael.html,2023-10-11 07:14:51,StockNews.com Begins Coverage on American Equity Investment ... Defense World ...,GILD,0.045054,0.144637,Neutral
Air Industries Group  ( NYSE:AIRI )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/10/11/air-industries-group-nyseairi-coverage-initiated-at-stocknews-com.html,2023-10-11 07:14:51,Air Industries Group ( NYSE:AIRI ) Coverage Initiated at StockNews ... Defense World ...,GILD,0.117486,0.171327,Somewhat-Bullish
WW International  ( NASDAQ:WW )  Rating Increased to Hold at StockNews.com,https://www.defenseworld.net/2023/10/11/ww-international-nasdaqww-rating-increased-to-hold-at-stocknews-com.html,2023-10-11 07:14:50,WW International ( NASDAQ:WW ) Rating Increased to Hold at ... Defense World ...,GILD,0.061159,0.182199,Somewhat-Bullish
United-Guardian  ( NASDAQ:UG )  Earns Buy Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/united-guardian-nasdaqug-earns-buy-rating-from-analysts-at-stocknews-com.html,2023-10-11 07:14:45,United-Guardian ( NASDAQ:UG ) Earns Buy Rating from Analysts at ... Defense World ...,GILD,0.072217,0.177184,Somewhat-Bullish
ENGlobal  ( NASDAQ:ENG )  Receives New Coverage from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/englobal-nasdaqeng-receives-new-coverage-from-analysts-at-stocknews-com-2.html,2023-10-11 07:14:44,ENGlobal ( NASDAQ:ENG ) Receives New Coverage from Analysts ... Defense World ...,GILD,0.086556,0.229488,Somewhat-Bullish
StockNews.com Begins Coverage on OpGen  ( NASDAQ:OPGN ) ,https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-opgen-nasdaqopgn.html,2023-10-11 07:14:44,"Equities research analysts at StockNews.com started coverage on shares of OpGen ( NASDAQ:OPGN - Get Free Report ) in a report issued on Wednesday. The brokerage set a ""hold"" rating on the medical research company's stock.",GILD,0.082393,0.115379,Neutral
"Manhattan Bridge Capital  ( NASDAQ:LOAN )  Upgraded to ""Strong-Buy"" at StockNews.com",https://www.defenseworld.net/2023/10/11/manhattan-bridge-capital-nasdaqloan-upgraded-to-strong-buy-at-stocknews-com.html,2023-10-11 07:14:44,"Manhattan Bridge Capital ( NASDAQ:LOAN ) Upgraded to ""Strong ... Defense World ...",GILD,0.076115,0.124003,Neutral
Heron Therapeutics  ( NASDAQ:HRTX )  Upgraded to Hold at StockNews.com,https://www.defenseworld.net/2023/10/11/heron-therapeutics-nasdaqhrtx-upgraded-to-hold-at-stocknews-com.html,2023-10-11 07:14:44,Heron Therapeutics ( NASDAQ:HRTX ) Upgraded to Hold at ... Defense World ...,GILD,0.06211,0.170259,Somewhat-Bullish
"Intuitive Surgical  ( NASDAQ:ISRG )  Downgraded to ""Hold"" at StockNews.com",https://www.defenseworld.net/2023/10/11/intuitive-surgical-nasdaqisrg-downgraded-to-hold-at-stocknews-com.html,2023-10-11 07:14:44,"Intuitive Surgical ( NASDAQ:ISRG ) Downgraded to ""Hold"" at ... Defense World ...",GILD,0.04303,0.065888,Neutral
ObsEva  ( NASDAQ:OBSV )  Now Covered by Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/obseva-nasdaqobsv-now-covered-by-analysts-at-stocknews-com-2.html,2023-10-11 07:14:43,ObsEva ( NASDAQ:OBSV ) Now Covered by Analysts at StockNews ... Defense World ...,GILD,0.099066,0.133757,Neutral
"Intevac  ( NASDAQ:IVAC )  Lowered to ""Sell"" at StockNews.com",https://www.defenseworld.net/2023/10/11/intevac-nasdaqivac-lowered-to-sell-at-stocknews-com-2.html,2023-10-11 07:14:43,"Intevac ( NASDAQ:IVAC - Get Free Report ) was downgraded by stock analysts at StockNews.com from a ""hold"" rating to a ""sell"" rating in a research note issued on Wednesday. Separately, Benchmark lowered shares of Intevac from a ""buy"" rating to a ""hold"" rating in a report on Wednesday, June 14th.",GILD,0.097062,0.157224,Somewhat-Bullish
ContraFect  ( NASDAQ:CFRX )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/10/11/contrafect-nasdaqcfrx-coverage-initiated-at-stocknews-com-3.html,2023-10-11 07:14:43,"Equities researchers at StockNews.com initiated coverage on shares of ContraFect ( NASDAQ:CFRX - Get Free Report ) in a research report issued on Wednesday. The brokerage set a ""sell"" rating on the biotechnology company's stock. Shares of ContraFect stock opened at $0.48 on Wednesday.",GILD,0.082963,0.127692,Neutral
ProPhase Labs  ( NASDAQ:PRPH )  Lifted to Hold at StockNews.com,https://www.defenseworld.net/2023/10/11/prophase-labs-nasdaqprph-lifted-to-hold-at-stocknews-com.html,2023-10-11 07:14:43,"ProPhase Labs ( NASDAQ:PRPH - Get Free Report ) was upgraded by stock analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research note issued to investors on Wednesday. Separately, HC Wainwright reissued a ""buy"" rating and issued a $14.00 price target on shares of ProPhase ...",GILD,0.081001,0.186043,Somewhat-Bullish
EMCORE  ( NASDAQ:EMKR )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/emcore-nasdaqemkr-coverage-initiated-by-analysts-at-stocknews-com.html,2023-10-11 07:14:43,EMCORE ( NASDAQ:EMKR ) Coverage Initiated by Analysts at ... Defense World ...,GILD,0.077343,0.149085,Neutral
PFSweb  ( NASDAQ:PFSW )  Earns Hold Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/pfsweb-nasdaqpfsw-earns-hold-rating-from-analysts-at-stocknews-com.html,2023-10-11 07:14:43,PFSweb ( NASDAQ:PFSW ) Earns Hold Rating from Analysts at ... Defense World ...,GILD,0.073321,0.172605,Somewhat-Bullish
Rigel Pharmaceuticals  ( NASDAQ:RIGL )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/10/11/rigel-pharmaceuticals-nasdaqrigl-upgraded-at-stocknews-com.html,2023-10-11 07:14:43,"Rigel Pharmaceuticals ( NASDAQ:RIGL - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a ""hold"" rating to a ""buy"" rating in a note issued to investors on Wednesday.",GILD,0.068112,0.089021,Neutral
Global Indemnity Group  ( NASDAQ:GBLI )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/10/11/global-indemnity-group-nasdaqgbli-coverage-initiated-at-stocknews-com.html,2023-10-11 07:14:43,Global Indemnity Group ( NASDAQ:GBLI ) Coverage Initiated at ... Defense World ...,GILD,0.067536,0.001013,Neutral
Gladstone Investment  ( NASDAQ:GAIN )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/10/11/gladstone-investment-nasdaqgain-upgraded-at-stocknews-com.html,2023-10-11 07:14:43,"Gladstone Investment ( NASDAQ:GAIN - Get Free Report ) was upgraded by analysts at StockNews.com from a ""sell"" rating to a ""hold"" rating in a research report issued to clients and investors on Wednesday. GAIN opened at $12.58 on Wednesday.",GILD,0.067158,0.092797,Neutral
Allied Healthcare Products  ( NASDAQ:AHPI )  Now Covered by Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/allied-healthcare-products-nasdaqahpi-now-covered-by-analysts-at-stocknews-com.html,2023-10-11 07:14:43,Allied Healthcare Products ( NASDAQ:AHPI ) Now Covered by ... Defense World ...,GILD,0.116348,0.184734,Somewhat-Bullish
China Jo-Jo Drugstores  ( NASDAQ:CJJD )  Now Covered by Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/china-jo-jo-drugstores-nasdaqcjjd-now-covered-by-analysts-at-stocknews-com-2.html,2023-10-11 07:14:43,China Jo-Jo Drugstores ( NASDAQ:CJJD ) Now Covered by Analysts ... Defense World ...,GILD,0.114682,0.134711,Neutral
StockNews.com Begins Coverage on ARCA biopharma  ( NASDAQ:ABIO ) ,https://www.defenseworld.net/2023/10/11/stocknews-com-begins-coverage-on-arca-biopharma-nasdaqabio.html,2023-10-11 07:14:42,StockNews.com Begins Coverage on ARCA biopharma ( NASDAQ ... Defense World ...,GILD,0.096671,0.182865,Somewhat-Bullish
Athersys  ( NASDAQ:ATHX )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/athersys-nasdaqathx-coverage-initiated-by-analysts-at-stocknews-com.html,2023-10-11 07:14:42,Athersys ( NASDAQ:ATHX ) Coverage Initiated by Analysts at ... Defense World ...,GILD,0.084127,0.104935,Neutral
Brainstorm Cell Therapeutics  ( NASDAQ:BCLI )  Earns Hold Rating from Analysts at StockNews.com,https://www.defenseworld.net/2023/10/11/brainstorm-cell-therapeutics-nasdaqbcli-earns-hold-rating-from-analysts-at-stocknews-com.html,2023-10-11 07:14:42,Brainstorm Cell Therapeutics ( NASDAQ:BCLI ) Earns Hold Rating ... Defense World ...,GILD,0.081276,0.160878,Somewhat-Bullish
AstroNova  ( NASDAQ:ALOT )  Research Coverage Started at StockNews.com,https://www.defenseworld.net/2023/10/11/astronova-nasdaqalot-research-coverage-started-at-stocknews-com.html,2023-10-11 07:14:42,AstroNova ( NASDAQ:ALOT ) Research Coverage Started at ... Defense World ...,GILD,0.078099,0.139058,Neutral
Aethlon Medical  ( NASDAQ:AEMD )  Coverage Initiated at StockNews.com,https://www.defenseworld.net/2023/10/11/aethlon-medical-nasdaqaemd-coverage-initiated-at-stocknews-com.html,2023-10-11 07:14:42,Aethlon Medical ( NASDAQ:AEMD ) Coverage Initiated at StockNews ... Defense World ...,GILD,0.077593,0.016798,Neutral
StockNews.com Initiates Coverage on Heritage-Crystal Clean  ( NASDAQ:HCCI ) ,https://www.defenseworld.net/2023/10/11/stocknews-com-initiates-coverage-on-heritage-crystal-clean-nasdaqhcci.html,2023-10-11 07:14:42,StockNews.com Initiates Coverage on Heritage-Crystal Clean ... Defense World ...,GILD,0.059636,0.047174,Neutral
Tango Therapeutics  ( TNGX )  Rises 20% in a Month: Here's Why,https://www.zacks.com/stock/news/2163685/tango-therapeutics-tngx-rises-20-in-a-month-heres-why,2023-10-10 15:28:00,The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.,GILD,0.10607,-0.112528,Neutral
"Russell Reynolds Associates, World 50 Group To Help Accelerate Executive Diversity With Third Cohort of ""Next Generation Director"" Development Program",https://www.prnewswire.com/news-releases/russell-reynolds-associates-world-50-group-to-help-accelerate-executive-diversity-with-third-cohort-of-next-generation-director-development-program-301951425.html,2023-10-10 13:00:00,"Russell Reynolds Associates, World 50 Group To Help Accelerate Executive Diversity With Third Cohort of ""Next ... PR ...",GILD,0.04161,0.089247,Neutral
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip,https://www.fool.com/investing/2023/10/10/a-bull-market-is-coming-1-beaten-down-growth-stock/,2023-10-10 09:40:00,Wall Street price targets suggest this stock can rocket more than 400% higher.,GILD,0.110973,-0.140828,Neutral
Gilead Sciences  ( GILD )  Ascends But Remains Behind Market: Some Facts to Note,https://www.zacks.com/stock/news/2162984/gilead-sciences-gild-ascends-but-remains-behind-market-some-facts-to-note,2023-10-09 22:00:20,"In the closing of the recent trading day, Gilead Sciences (GILD) stood at $75.06, denoting a +0.43% change from the preceding trading day.",GILD,0.532556,0.273258,Somewhat-Bullish
"Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 - Exclusive Study by The Insight Partners",https://www.benzinga.com/pressreleases/23/10/g35143608/antibody-drug-conjugates-market-revenue-to-hit-29-6-billion-globally-by-2030-exclusive-study-by-th,2023-10-09 12:04:10,"Pune, India, Oct. 09, 2023 ( GLOBE NEWSWIRE ) -- Antibody drug conjugates ( ADC ) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody ( mAbs ) covalently attached to a cytotoxic drug via a chemical linker.",GILD,0.087985,0.057624,Neutral
"Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51 ... - PR Newswire",https://www.prnewswire.com/news-releases/non-alcoholic-steatohepatitis-market-to-grow-by-usd-11-22-billion--from-2022-to-2027--north-america-to-account-for-51-of-market-growth--technavio-301969658.html,2023-10-27 18:30:00,"Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51 ... PR ...",GILD,0.068112,0.0,Neutral
"Merck  ( MRK )  Q3 Earnings Top Estimates, COVID Drug Boosts Sales",https://www.zacks.com/stock/news/2172963/merck-mrk-q3-earnings-top-estimates-covid-drug-boosts-sales,2023-10-26 15:13:00,Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.,GILD,0.106423,0.165144,Somewhat-Bullish
3 Pharma Stocks That Are Screaming Buys in October,https://www.fool.com/investing/2023/10/26/3-pharma-stocks-that-are-screaming-buys-in-october/,2023-10-26 11:30:00,Each company delivers an above-average dividend and revenue growth.,GILD,0.076115,-0.044986,Neutral
USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day,https://www.zacks.com/stock/news/2171221/usa-compression-and-disney-have-been-highlighted-as-zacks-bull-and-bear-of-the-day,2023-10-25 08:49:00,"Chicago, IL - October 25, 2023 - Zacks Equity Research shares USA Compression Partners ( USAC Quick QuoteUSAC - ) as the Bull of the Day and Disney ( DIS Quick QuoteDIS - ) as the Bear of the Day.",GILD,0.273705,0.255919,Somewhat-Bullish
Gilead Sciences Getting Closer To Key Technical Benchmark,https://www.investors.com/ibd-data-stories/gilead-sciences-getting-closer-to-key-technical-benchmark/,2023-10-25 07:00:00,"Gilead Sciences ( GILD ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 70 to 73. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",GILD,0.579393,0.549012,Bullish
Gilead Sciences  ( GILD )  Exceeds Market Returns: Some Facts to Consider,https://www.zacks.com/stock/news/2171075/gilead-sciences-gild-exceeds-market-returns-some-facts-to-consider,2023-10-24 21:50:19,"Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close.",GILD,0.584103,0.343208,Somewhat-Bullish
3 Biotech Stocks With Decent Dividend for a Steady Return,https://www.zacks.com/stock/news/2170733/3-biotech-stocks-with-decent-dividend-for-a-steady-return,2023-10-24 13:15:00,"Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.",GILD,0.451494,0.422583,Bullish
Gilead Sciences  ( GILD )  Falls More Steeply Than Broader Market: What Investors Need to Know,https://www.zacks.com/stock/news/2170500/gilead-sciences-gild-falls-more-steeply-than-broader-market-what-investors-need-to-know,2023-10-23 22:00:19,"Gilead Sciences (GILD) concluded the recent trading session at $77.56, signifying a -0.31% move from its prior day's close.",GILD,0.516073,0.280244,Somewhat-Bullish
A 27-year-old investor building a $2 million retirement portfolio in 8 years shares why he's buying a fund that's up 324% since inception and made up of cheap stocks with strong competitive advantages,https://markets.businessinsider.com/news/stocks/fund-etf-with-high-return-since-inception-investor-retirement-portfolio-2023-10,2023-10-21 09:17:02,"At the turn of the year, personal finance content creator Austin Hankwitz decided to start a public challenge: amass a $2 million retirement portfolio in eight years, or up to 15 years in the event of a stock market slowdown or if he has low-income years.",GILD,0.113062,0.008966,Neutral
A 27-year-old investor building a $2 million retirement portfolio in 8 years shares why he's buying a fund that's up 324% since inception and made up of cheap stocks with strong competitive advantages,https://www.businessinsider.com/fund-etf-with-high-return-since-inception-investor-retirement-portfolio-2023-10,2023-10-21 09:17:00,Fund With 324% Return Since Inception in Investor's Retirement Portfolio - Business Insider ...,GILD,0.113062,0.008966,Neutral
Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/10/35353698/comparative-study-gilead-sciences-and-industry-competitors-in-biotechnology-industry,2023-10-20 16:02:41,"Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts.",GILD,0.586322,0.321102,Somewhat-Bullish
Torrent lines up at least $5 billion funding to buy 33% stake in Cipla,https://www.business-standard.com/companies/news/torrent-lines-up-at-least-5-billion-funding-to-buy-33-stake-in-cipla-123102000660_1.html,2023-10-20 10:31:56,"Torrent Pharmaceuticals Ltd. has lined up at least $5 billion in funding as the company is seeking to buy a stake in Mumbai-listed drugmaker Cipla Ltd., according to people familiar with the matter.",GILD,0.113062,0.050223,Neutral
GILD or VRTX: Which Is the Better Value Stock Right Now?,https://www.zacks.com/stock/news/2169033/gild-or-vrtx-which-is-the-better-value-stock-right-now,2023-10-19 15:40:12,GILD vs. VRTX: Which Stock Is the Better Value Option?,GILD,0.77735,0.575786,Bullish
"Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase - Pfizer  ( NYSE:PFE ) ",https://www.benzinga.com/general/biotech/23/10/35323628/pfizer-decides-to-raise-covid-19-treatment-pill-price-defends-itself-amid-criticism-for-cost-incr,2023-10-19 12:45:10,"Pfizer Inc PFE is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529. Pfizer's decision to raise the price has garnered criticism from doctors and patient advocates who fear limited ...",GILD,0.266828,-0.237603,Somewhat-Bearish
"Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling - Gilead Sciences  ( NASDAQ:GILD ) , HubSpot  ( NYSE:HUBS ) ",https://www.benzinga.com/news/23/10/35326531/vertex-pharmaceuticals-gilead-sciences-and-2-other-stocks-insiders-are-selling,2023-10-19 11:42:01,"The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.",GILD,0.421485,0.130694,Neutral
SAP Announces Q3 2023 Results,https://www.prnewswire.com/news-releases/sap-announces-q3-2023-results-301961175.html,2023-10-18 20:05:00,"in â¬ millions, unless otherwise stated.",GILD,0.02013,0.075425,Neutral
Why AstraZeneca's Lung Cancer Update Also Tripped Gilead Stock,https://www.investors.com/news/technology/astrazeneca-stock-dives-pulling-gilead-with-it-on-a-disappointing-update-in-lung-cancer-treatment/,2023-10-18 15:35:00,"AstraZeneca Stock Dives, Pulling Gilead With It, On A Disappointing ... Investor's Business Daily ...",GILD,0.119532,0.008141,Neutral
Pharmaceutical Pellets Market Major Driver - Increasing Prevalence Of Chronic Diseases As Per The Business Research Company's Pharmaceutical Pellets Global Market Report 2023,https://www.benzinga.com/pressreleases/23/10/g35312139/pharmaceutical-pellets-market-major-driver-increasing-prevalence-of-chronic-diseases-as-per-the-bu,2023-10-18 15:30:00,"LONDON, Oct. 18, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Pharmaceutical Pellets Global Market Report 2023, the global pharmaceutical pellets market is set to undergo remarkable growth.",GILD,0.064276,0.050309,Neutral
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus  ( HBV )  therapeutic vaccine developed in collaboration with Gilead Sciences,https://www.globenewswire.com/news-release/2023/10/18/2762210/0/en/HOOKIPA-Pharma-announces-publication-of-preclinical-data-of-hepatitis-B-virus-HBV-therapeutic-vaccine-developed-in-collaboration-with-Gilead-Sciences.html,2023-10-18 11:01:00,"NEW YORK and VIENNA, Austria, Oct. 18, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that The Journal of Infectious Diseases has published ...",GILD,0.080323,-0.089207,Neutral
"The Zacks Analyst Blog Highlights Walmart, NIKE, TJX, Gilead Sciences and Schlumberger",https://www.zacks.com/stock/news/2167708/the-zacks-analyst-blog-highlights-walmart-nike-tjx-gilead-sciences-and-schlumberger,2023-10-18 10:56:00,"Walmart, NIKE, TJX, Gilead Sciences and Schlumberger are included in this Analyst Blog.",GILD,0.129516,0.0,Neutral
Is American Century U.S. Quality Value ETF  ( VALQ )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2167684/is-american-century-us-quality-value-etf-valq-a-strong-etf-right-now,2023-10-18 10:20:06,Smart Beta ETF report for ...,GILD,0.114682,0.04541,Neutral
GILD: Gilead Sciences  ( GILD )  Earnings Forecast and Gameplan,https://stocknews.com/news/gild-otsky-alxn-cort-gilead-sciences-gild-earnings-forecast-and-gameplan/,2023-11-06 19:01:49,GILD: Gilead Sciences ( GILD ) Earnings Forecast and ...,GILD,0.573091,0.390296,Bullish
Momentum Monday: Don't Miss the Year End Rally,https://www.zacks.com/stock/news/2179513/momentum-monday-dont-miss-the-year-end-rally,2023-11-06 18:20:00,Want to start the week ahead of the pack? Check out Momentum Monday to get the scoop on market leading stocks and major economic news ...,GILD,0.090134,0.0,Neutral
"If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/23/11/35622438/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-1-200-today,2023-11-06 15:30:23,"Gilead Sciences GILD has outperformed the market over the past 20 years by 5.88% on an annualized basis producing an average annual return of 13.18%. Currently, Gilead Sciences has a market capitalization of $101.86 billion.",GILD,0.980595,0.386944,Bullish
"Biotech/Drug Stocks Q3 Earnings Due Nov 7: GILD, PRGO, VTRS & More",https://www.zacks.com/stock/news/2179006/biotechdrug-stocks-q3-earnings-due-nov-7-gild-prgo-vtrs-more,2023-11-06 13:26:00,"Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.",GILD,0.181956,0.048847,Neutral
Active Pharmaceutical Ingredients Market Set to Surge USD 363.68 Billion by 2032 | Precedence Research,https://www.prnewswire.com/news-releases/active-pharmaceutical-ingredients-market-set-to-surge-usd-363-68-billion-by-2032--precedence-research-301978434.html,2023-11-06 11:38:00,"OTAWA,ON, Nov. 6, 2023 /PRNewswire/ -- The active pharmaceutical ingredients ( API ) market size was valued at USD 204.04 billion in 2023 and likely to hit around USD 363.68 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. An active pharmaceutical ingredient ( API ) is a drug's ...",GILD,0.018554,0.078226,Neutral
"Disney and other entertainment giants report after upbeat results from peers, but investors are getting harsher on companies that don't deliver",https://www.marketwatch.com/story/disney-and-other-entertainment-giants-report-after-upbeat-results-from-peers-but-investors-are-getting-harsher-on-companies-that-dont-deliver-c7318fa7,2023-11-05 15:31:00,"Walt Disney Co., Warner Bros. Discovery Inc., Lions Gate Entertainment Corp. and AMC Entertainment Holdings Inc. all report results this week.",GILD,0.076847,0.0,Neutral
"Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... - PR Newswire",https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-to-account-for-39-of-market-growth--technavio-301976707.html,2023-11-03 22:35:00,"Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... PR ...",GILD,0.074692,0.0,Neutral
"Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",https://www.benzinga.com/markets/equities/23/11/35601229/fed-holds-rates-steady-powells-cautious-stance-soothes-investors-labor-market-softens-the-week-i,2023-11-03 20:03:39,"Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and bonds, with investors embracing the Federal Reserve's decision to hold steady on interest rates.",GILD,0.129168,-0.093536,Neutral
Which Corporations Pay The Most Federal Income Tax?,https://www.forbes.com/sites/taxnotes/2023/11/03/which-corporations-pay-the-most-federal-income-tax/,2023-11-03 14:31:05,"Corporations report their total cash payments of income tax - federal, state, and foreign combined - but they don't identify, nor does the IRS reveal, how much federal income tax they pay. We believe, however, that we can make reasonable estimates from information reported by publicly traded ...",GILD,0.0367,0.036094,Neutral
Stocks Flashing Renewed Technical Strength: Gilead Sciences,https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-gilead-sciences/,2023-11-03 08:00:00,"When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Gilead Sciences ( GILD ) , which had its Relative Strength ( RS ) Rating upgraded from 78 to 81 Friday.",GILD,0.582526,0.368754,Bullish
This Is What Whales Are Betting On Gilead Sciences - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/markets/options/23/11/35574505/this-is-what-whales-are-betting-on-gilead-sciences,2023-11-02 19:20:16,"Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences GILD. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",GILD,0.658003,0.336161,Somewhat-Bullish
Earnings Preview: Illumina  ( ILMN )  Q3 Earnings Expected to Decline,https://www.zacks.com/stock/news/2177328/earnings-preview-illumina-ilmn-q3-earnings-expected-to-decline,2023-11-02 14:00:49,Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,GILD,0.087185,0.038018,Neutral
REGN: Regeneron Pharmaceuticals  ( REGN )  Earnings Analysis -- Should Investors Brace for Impact?,https://stocknews.com/news/regn-otsky-gild-jazz-regeneron-pharmaceuticals-regn-earnings-analysis-should-investors-brace-for/,2023-11-01 18:02:55,REGN: Regeneron Pharmaceuticals ( REGN ) Earnings Analysis ... ...,GILD,0.054114,0.172807,Somewhat-Bullish
Gilead Sciences  ( GILD )  Earnings Expected to Grow: Should You Buy?,https://www.zacks.com/stock/news/2175549/gilead-sciences-gild-earnings-expected-to-grow-should-you-buy,2023-10-31 14:01:30,Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,GILD,0.087663,0.088507,Neutral
Gilead Sciences Sees RS Rating Improve To 71,https://www.investors.com/ibd-data-stories/gilead-sciences-sees-rs-rating-improve-to-71/,2023-10-31 08:00:00,"The Relative Strength ( RS ) Rating for Gilead Sciences ( GILD ) jumped into a higher percentile Tuesday, as it got a lift from 67 to 71. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",GILD,0.524949,0.41869,Bullish
Gilead Sciences  ( GILD )  Outperforms Broader Market: What You Need to Know,https://www.zacks.com/stock/news/2174854/gilead-sciences-gild-outperforms-broader-market-what-you-need-to-know,2023-10-30 21:50:10,"Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day.",GILD,0.463792,0.322689,Somewhat-Bullish
Gilead  ( GILD )  Gears Up to Report Q3 Earnings: What's in Store?,https://www.zacks.com/stock/news/2174771/gilead-gild-gears-up-to-report-q3-earnings-whats-in-store,2023-10-30 15:59:00,Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 results.,GILD,0.236205,0.267495,Somewhat-Bullish
AMGN: Amgen  ( AMGN )  Earnings Watch: Buy or Sell?,https://stocknews.com/news/amgn-gild-jazz-alks-amgen-amgn-earnings-watch-buy-or-sell/,2023-10-30 15:34:04,"Pharmaceutical major Amgen Inc. ( AMGN ) is scheduled to report its third-quarter earnings on October 31. In this piece, I have discussed why it could be wise to buy the stock now. Wall Street expects a year-over-year decline in earnings on higher revenues when AMGN reports results for the ...",GILD,0.072108,0.071115,Neutral
Pfizer's  ( PFE )  Key Drugs to Drive Q3 Earnings Amid COVID Decline?,https://www.zacks.com/stock/news/2174310/pfizers-pfe-key-drugs-to-drive-q3-earnings-amid-covid-decline,2023-10-30 12:49:00,"Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.",GILD,0.247208,0.276957,Somewhat-Bullish
IBM to pause ad spending on X after its ads ran on pro-Nazi accounts | Business,https://www.cnn.com/2023/11/16/tech/ibm-to-pause-ad-spending-on-x/index.html,2023-11-16 23:00:00,IBM suspends advertising on Elon Musk's X after its ad appeared next to pro-Nazi content ...,GILD,0.052112,-0.002993,Neutral
IBM to pause ad spending on X after its ads ran on pro-Nazi accounts | Business,https://edition.cnn.com/2023/11/16/tech/ibm-to-pause-ad-spending-on-x/index.html,2023-11-16 23:00:00,IBM to pause ad spending on X after its ads ran on pro-Nazi accounts CNN International ...,GILD,0.052112,-0.002993,Neutral
Arcellx  ( ACLX )  Up 5% on Partnership Expansion With Gilead,https://www.zacks.com/stock/news/2185410/arcellx-aclx-up-5-on-partnership-expansion-with-gilead,2023-11-16 15:10:00,Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.,GILD,0.153961,0.07588,Neutral
Dow Jones Jumps Another 160 Points Amid More Evidence Inflation Is Waning,https://www.investors.com/market-trend/stock-market-today/dow-jones-jumps-another-200-points-amid-more-evidence-inflation-is-waning/,2023-11-15 21:29:00,Dow Jones Jumps Another 160 Points Amid More Evidence Inflation ... Investor's Business Daily ...,GILD,0.089629,0.049155,Neutral
Gilead Sciences's Options: A Look at What the Big Money is Thinking - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/markets/options/23/11/35810554/gilead-sciencess-options-a-look-at-what-the-big-money-is-thinking,2023-11-15 17:16:53,"Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences GILD revealed 12 unusual trades. Delving into the details, we found 41% of traders were bullish, while 58% showed bearish tendencies.",GILD,0.636698,0.01476,Neutral
"Small Caps Lead Stock Market As Retail Sector Shines, Except For These Laggards",https://www.investors.com/market-trend/stock-market-today/stock-market-extends-gains-as-retail-sector-shines-except-for-these-laggards/,2023-11-15 15:39:00,"Small Caps Lead Stock Market As Retail Sector Shines, Except For ... Investor's Business Daily ...",GILD,0.109455,-0.148966,Neutral
Top 2% Biotech Breaks Out On $285 Million Gilead Tie-Up,https://www.investors.com/news/technology/aclx-stock-breaks-out-after-inking-a-deal-with-gilead-kite/,2023-11-15 15:04:00,ACLX Stock Breaks Out After Inking A $285 Million Deal With ... Investor's Business Daily ...,GILD,0.201523,-0.267769,Somewhat-Bearish
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP,https://www.prnewswire.com/news-releases/arcellx-and-kite-announce-expansion-in-strategic-partnership-301988865.html,2023-11-15 11:00:00,-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas --,GILD,0.060035,0.049113,Neutral
Analysts Offer Insights on Healthcare Companies: Gilead Sciences  ( GILD )  and Vertex  ( VERX ) ,https://markets.businessinsider.com/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-vertex-verx-1032808809,2023-11-11 08:48:53,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Vertex (VERX) - Markets Insider ...,GILD,0.47672,0.231974,Somewhat-Bullish
"Biological threats exacerbated in Africa, Asia",https://www.financialexpress.com/opinion/biological-threats-exacerbated-in-africa-asia/3304827/,2023-11-11 06:48:03,"Considering recent stages of the world's development, modern technology creates new threats emerging from developing biological technologies and outlines existing ones. Global division between already developed and developing countries is exacerbated.",GILD,0.0367,-0.017545,Neutral
VRTX: Vertex Pharmaceuticals  ( VRTX )  Post-Earnings Analysis: Is It Time to Buy the Stock?,https://stocknews.com/news/vrtx-gild-otsky-cort-vertex-pharmaceuticals-vrtx-post-earnings-analysis-is-it-time-to-buy/,2023-11-10 19:29:32,VRTX: Vertex Pharmaceuticals ( VRTX ) Post-Earnings Analysis: Is It ... ...,GILD,0.048278,0.124896,Neutral
WHO's new COVID guidelines see fewer patients requiring hospitalization,https://www.marketwatch.com/story/whos-new-covid-guidelines-see-fewer-patients-requiring-hospitalization-f4703057,2023-11-10 13:43:00,Groups previously deemed high-risk are now at moderate risk of getting severe disease or dying.,GILD,0.179121,0.008884,Neutral
Market Rally Pauses As Yields Rebound: Weekly Review,https://www.investors.com/news/stock-market-rally-pauses-as-yields-rebound-datadog-affirm-among-earnings-winners-weekly-review/,2023-11-10 12:00:00,"The stock market rally saw the Dow Jones, S&P 500 and Nasdaq snap long win streaks, slashing or erasing weekly gains. The Russell 2000 tumbled amid weak breadth. Earnings generally remained positive.",GILD,0.046724,0.006,Neutral
A Closer Look at Gilead Sciences's Options Market Dynamics - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/markets/options/23/11/35708450/a-closer-look-at-gilead-sciencess-options-market-dynamics,2023-11-09 18:32:52,"Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",GILD,0.549988,0.209883,Somewhat-Bullish
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates,https://www.zacks.com/stock/news/2181433/4-biotech-stocks-likely-to-outpace-q3-earnings-estimates,2023-11-09 12:05:00,"Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.",GILD,0.082677,0.100716,Neutral
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights,https://www.globenewswire.com/news-release/2023/11/09/2777198/0/en/HOOKIPA-Pharma-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html,2023-11-09 12:01:00,"NEW YORK and VIENNA, Austria, Nov. 09, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the third quarter ...",GILD,0.047371,0.024943,Neutral
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates - Assembly Biosciences  ( NASDAQ:ASMB ) ,https://www.benzinga.com/pressreleases/23/11/g35684422/assembly-biosciences-reports-third-quarter-2023-financial-results-and-recent-updates,2023-11-08 21:05:00,"Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond Now anticipate four development candidates from expanded pipeline in clinical development by the end of 2024 Named Anuj Gaggar, MD, PhD, as chief medical officer",GILD,0.049526,0.0,Neutral
"Gilead  ( GILD )  Q3 Earnings Beat, Trodelvy Fuels Oncology Sales",https://www.zacks.com/stock/news/2180900/gilead-gild-q3-earnings-beat-trodelvy-fuels-oncology-sales,2023-11-08 14:52:00,Gilead (GILD) reports better-than-expected results for the third quarter as Trodelvy boosts oncology sales and Biktarvy maintains momentum in the HIV franchise.,GILD,0.167554,0.172633,Somewhat-Bullish
"Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer - Assembly Biosciences  ( NASDAQ:ASMB ) ",https://www.benzinga.com/pressreleases/23/11/g35670938/assembly-biosciences-names-anuj-gaggar-md-phd-as-chief-medical-officer,2023-11-08 13:00:00,"-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 ( GLOBE NEWSWIRE ) -- Assembly Biosciences, Inc.",GILD,0.065506,0.068172,Neutral
Futures: Five Stocks In Buy Areas From This Hot Sector,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-is-market-rally-due-for-pause-tesla-rivals-report/,2023-11-08 03:08:00,Dow Jones Futures: Is Market Rally Due For A Pause? Tesla Rivals ... Investor's Business Daily ...,GILD,0.090588,-0.249486,Somewhat-Bearish
Gilead Sciences  ( GILD )  Q3 2023 Earnings Call Transcript,https://www.fool.com/earnings/call-transcripts/2023/11/07/gilead-sciences-gild-q3-2023-earnings-call-transcr/,2023-11-08 02:15:17,"GILD earnings call for the period ending September 30, 2023.",GILD,0.004527,0.085,Neutral
After-Hours Selling to Challenge Winning Streak Wednesday,https://www.zacks.com/stock/news/2180387/after-hours-selling-to-challenge-winning-streak-wednesday,2023-11-07 22:57:00,"Gilead, eBay and Rivian all beat on the bottom line in Q3, but all three are selling the news.",GILD,0.19661,0.364399,Bullish
Win Streak Continues As This Sector Soars; TSLA Rivals Report,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-win-streak-continues-as-this-sector-soars-tsla-rivals-report/,2023-11-07 22:28:00,Win Streak Continues As This Sector Soars. TSLA Rivals Report Investor's Business Daily ...,GILD,0.091509,-0.268354,Somewhat-Bearish
Gilead Sciences  ( GILD )  Tops Q3 Earnings and Revenue Estimates,https://www.zacks.com/stock/news/2180365/gilead-sciences-gild-tops-q3-earnings-and-revenue-estimates,2023-11-07 22:15:02,"Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?",GILD,0.138464,0.095763,Neutral
Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/earnings/23/11/35659653/gilead-sciences-stock-slides-after-hours-on-q3-report-heres-why,2023-11-07 21:36:37,"Gilead Sciences, Inc. GILD shares are volatile in Tuesday's after-hours session on the heels of the company's third-quarter earnings report. What To Know: Gilead reported quarterly earnings of $2.29 per share, which beat the analyst consensus estimate of $1.92, a 20.53% increase over earnings of ...",GILD,0.449503,0.275867,Somewhat-Bullish
Gilead quarterly results beat Street estimates as profit up on lower taxes,https://www.reuters.com/business/healthcare-pharmaceuticals/gilead-quarterly-results-beat-street-estimates-profit-up-lower-taxes-2023-11-07/,2023-11-07 21:02:00,"Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo Acquire Licensing Rights Nov 7 ( Reuters ) - Drugmaker Gilead Sciences ( GILD.O ) on Tuesday said third-quarter sales were little changed from a year earlier, but ...",GILD,0.25168,-0.111247,Neutral
BIIB: Biogen  ( BIIB )  Earnings Spotlight: Is the Biotech Stock a Buy or Sell?,https://stocknews.com/news/biib-gild-jazz-alks-biogen-biib-earnings-spotlight-is-the-biotech-stock-a-buy/,2023-11-07 17:02:10,BIIB: Biogen ( BIIB ) Earnings Spotlight: Is the Biotech Stock a Buy or ... ...,GILD,0.076115,0.006126,Neutral
"Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity - Arcus Biosciences  ( NYSE:RCUS ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/23/11/35638777/positive-news-for-gastric-cancers-gileadarcus-biosciences-combination-cancer-therapy-shows-encour,2023-11-07 16:17:25,Gilead Sciences Inc GILD and Arcus Biosciences Inc RCUS announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate ( ORR ) and six-month progression-free survival ( PFS ) rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.,GILD,0.27432,0.244726,Somewhat-Bullish
Markets Await Consumer Credit Report,https://www.zacks.com/stock/news/2180194/markets-await-consumer-credit-report,2023-11-07 15:52:00,"Pre-market futures are trying to push out of the red this morning, having opened the early trading day decidedly down after rare winning streaks now extended to 6 days on the Dow and 7 on the Nasdaq. In fact, the Nasdaq is already trading higher in the early session, +20 points at this hour.",GILD,0.148731,0.034768,Neutral
Can Markets Keep the Winning Streak Intact?,https://www.zacks.com/stock/news/2180187/can-markets-keep-the-winning-streak-intact,2023-11-07 15:32:00,"Uber missed on headline although business was good, D.R. Horton beat and raised, and the U.S. trade deficit got slimmer.",GILD,0.146025,0.03569,Neutral
"S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto - Celsius Holdings  ( NASDAQ:CELH ) , Matterport  ( NASDAQ:MTTR ) , Choice Hotels Intl  ( NYSE:CHH ) , TripAdvisor  ( NASDAQ:TRIP ) ",https://www.benzinga.com/news/earnings/23/11/35640681/s-p-500-nasdaq-set-to-break-6-day-rally-today-traders-await-fed-cues-analyst-says-seasonal-rally-ha,2023-11-07 12:15:27,"Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum. Reaction to earnings has been mixed, adding to the prevailing uncertainty.",GILD,0.075635,0.0,Neutral
"Arbutus Announces CEO, William Collier, to Retire December 31, 2023 - Arbutus Biopharma  ( NASDAQ:ABUS ) ",https://www.benzinga.com/pressreleases/23/11/g35640675/arbutus-announces-ceo-william-collier-to-retire-december-31-2023,2023-11-07 12:15:00,"WARMINSTER, Pa., Nov. 07, 2023 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ABUS ( ""Arbutus"" or the ""Company"" ) , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus ( cHBV ) infection, today ...",GILD,0.030759,-0.016534,Neutral
A wall of debt rolling over: Here's what's scaring Bridgewater's co-CIO,https://www.marketwatch.com/story/a-wall-of-debt-rolling-over-heres-whats-scaring-bridgewaters-co-cio-ea1e6852,2023-11-07 11:52:00,Bridgewater's co chief investment officer says investors need to start thinking about a wall of U.S. debt that's coming.,GILD,0.076115,0.130557,Neutral
Anti-Infective Drugs Market to Hit USD 177.9 billion by 2031 | Transparency Market Research Inc.,https://www.benzinga.com/pressreleases/23/11/g35637643/anti-infective-drugs-market-to-hit-usd-177-9-billion-by-2031-transparency-market-research-inc,2023-11-07 10:30:00,"Wilmington, Delaware, United States, Nov. 07, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global anti-infective drugs market is projected to flourish at a CAGR of 4.0% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 117.9 billion is anticipated for ...",GILD,0.043658,-0.109878,Neutral
S&P 500 futures dip after six-day winning streak,https://www.marketwatch.com/story/s-p-500-futures-dip-after-six-day-winning-streak-8d539d83,2023-11-07 09:48:00,U.S. stock futures inched lower as traders adopted a more cautious stance following a six-day winning streak.,GILD,0.142565,0.0,Neutral
CIIE to share China's enormous market with world - PR Newswire,https://www.prnewswire.com/apac/news-releases/ciie-to-share-chinas-enormous-market-with-world-301979539.html,2023-11-07 07:13:44,CIIE to share China's enormous market with world PR ...,GILD,0.039745,0.065645,Neutral
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later,https://www.fool.com/investing/2023/11/26/3-fantastic-dividend-stocks-to-buy-sooner-rather-t/,2023-11-26 11:55:00,There's no time like the present to buy these stocks.,GILD,0.225321,0.13405,Neutral
"Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals",https://www.zacks.com/stock/news/2188966/zacks-industry-outlook-highlights-gilead-sciences-crispr-therapeutics-acadia-pharmaceuticals-dynavax-and-ligand-pharmaceuticals,2023-11-24 14:10:00,"Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.",GILD,0.0854,0.090184,Neutral
"A Hollywood director took millions of dollars in Netflix funding and used it to trade options and crypto, report says. Here's a closer look at how he used the cash.",https://markets.businessinsider.com/news/stocks/netflix-director-trades-gilead-sciences-stock-spx-options-dogecoin-crypto-2023-11,2023-11-23 15:02:00,"Hollywood Director Used Netflix Cash for Gilead, S&P 500, Dogecoin Bets - Markets Insider ...",GILD,0.141726,0.015182,Neutral
Looking Into Gilead Sciences's Recent Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/11/35922792/looking-into-gilead-sciencess-recent-short-interest,2023-11-22 18:45:26,"Gilead Sciences's GILD short percent of float has fallen 4.37% since its last report. The company recently reported that it has 19.50 million shares sold short, which is 1.75% of all regular shares that are available for trading.",GILD,0.221819,0.083071,Neutral
Authorities warn that fake HIV drugs are found in Kenya despite a crackdown on counterfeits,https://apnews.com/article/kenya-us-hiv-counterfeit-medication-6420b710aa4f0e72f449410077e8103b,2023-11-22 15:25:00,"NAIROBI, Kenya ( AP ) - Kenyan authorities issued a warning Wednesday about the sale of counterfeit HIV prevention drugs in the country, saying their ""safety, quality and efficacy cannot be assured.""",GILD,0.147818,-0.283542,Somewhat-Bearish
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright,https://www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright,2023-11-22 13:07:00,"New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.",GILD,0.066908,0.125817,Neutral
Top 5 U.S. Giants for 2024 That Have Failed to Deliver in 2023,https://www.zacks.com/stock/news/2187699/top-5-us-giants-for-2024-that-have-failed-to-deliver-in-2023,2023-11-22 13:04:00,"We have narrowed our search to five U.S. corporate giants that have failed to deliver in 2023. These are: PEP, PG, MMM, XOM, GILD.",GILD,0.207928,0.307865,Somewhat-Bullish
"$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/23/11/35903134/100-invested-in-this-stock-20-years-ago-would-be-worth-1-000-today,2023-11-21 18:30:21,"Gilead Sciences GILD has outperformed the market over the past 20 years by 4.81% on an annualized basis producing an average annual return of 12.32%. Currently, Gilead Sciences has a market capitalization of $93.34 billion.",GILD,0.980595,0.386944,Bullish
"The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics",https://www.zacks.com/stock/news/2187239/the-zacks-analyst-blog-highlights-gilead-sciences-legend-biotech-beigene-exact-sciences-and-sarepta-therapeutics,2023-11-21 14:43:00,"Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.",GILD,0.199365,0.201812,Somewhat-Bullish
These Stocks Are Exploding In November Rally,https://www.investors.com/research/these-stocks-explode-in-november-stock-market-rally/,2023-11-21 13:00:00,The November stock market rally is picking up steam and expanding into more than just the Magnificent Seven stocks. We created an IBD MarketSmith screen that identified stocks that rocked the most in the past month. Each has gained over 50% for the month.,GILD,0.143843,-0.214803,Somewhat-Bearish
Best Penny Stocks To Buy This Week? 4 To Watch Now,https://pennystocks.com/featured/2023/11/20/best-penny-stocks-to-buy-this-week-4-to-watch-now/,2023-11-20 15:17:26,"Whether you're looking at the ""Magnificent Seven stocks,"" or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday's Thanksgiving Holiday and one of the ""Magnificent Seven"" could become a major catalyst.",GILD,0.031822,0.040484,Neutral
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024,https://www.zacks.com/stock/news/2186479/5-biotechnology-stocks-to-buy-for-a-stable-portfolio-in-2024,2023-11-20 13:02:00,"We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.",GILD,0.169378,0.283412,Somewhat-Bullish
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus,https://www.globenewswire.com/news-release/2023/11/20/2783124/0/en/HOOKIPA-Pharma-Announces-FDA-Clearance-of-its-Investigational-New-Drug-Application-for-HB-500-for-the-Treatment-of-Human-Immunodeficiency-Virus.html,2023-11-20 12:01:00,"NEW YORK and VIENNA, Austria, Nov. 20, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance from the U.S.",GILD,0.038969,0.056707,Neutral
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus - HOOKIPA Pharma  ( NASDAQ:HOOK ) ,https://www.benzinga.com/pressreleases/23/11/g35869897/hookipa-pharma-announces-fda-clearance-of-its-investigational-new-drug-application-for-hb-500-for-,2023-11-20 12:01:00,"Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. ( 'Gilead' ) , to be evaluated as a potential curative regimen for human immunodeficiency virus ( HIV ) Phase 1 trial to commence in the first half of 2024",GILD,0.038345,-0.022637,Neutral
"Major advertisers flee X, deepening crisis at Elon Musk's social media site | Business",https://www.cnn.com/2023/11/17/tech/lionsgate-suspends-advertising-x-musk,2023-11-18 00:09:00,Disney and Warner Bros. Discovery stop advertising on X as antisemitism crisis grows at Elon Musk's company ...,GILD,0.066598,0.0,Neutral
Lionsgate suspends all advertising on Elon Musk's X | Business,https://www.cnn.com/2023/11/17/tech/lionsgate-suspends-advertising-x-musk/index.html,2023-11-17 20:28:00,Lionsgate suspends all advertising on Elon Musk's X ...,GILD,0.107016,0.0,Neutral
"If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/23/12/36113449/if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-11-000-today,2023-12-06 14:30:37,"Gilead Sciences GILD has outperformed the market over the past 20 years by 5.36% on an annualized basis producing an average annual return of 12.88%. Currently, Gilead Sciences has a market capitalization of $98.54 billion.",GILD,0.980595,0.386944,Bullish
"Hospital Infection Therapeutics Market to be Worth USD 14.4 billion by 2031| Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/23/12/g36087772/hospital-infection-therapeutics-market-to-be-worth-usd-14-4-billion-by-2031-transparency-market-re,2023-12-05 12:00:00,"Wilmington, Delaware, United States, Dec. 05, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global hospital infection therapeutics market was estimated to have acquired US$ 11.3 billion in 2022.",GILD,0.044551,0.0,Neutral
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate TrodelvyÂ® and IDE397 Combination in MTAP-Deletion Bladder Cancer,https://www.prnewswire.com/news-releases/ideaya-announces-clinical-study-collaboration-with-gilead-sciences-to-evaluate-trodelvy-and-ide397-combination-in-mtap-deletion-bladder-cancer-302003940.html,2023-12-04 11:00:00,IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate TrodelvyÂ® and IDE397 Combination ... PR ...,GILD,0.058615,0.136018,Neutral
"Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... - PR Newswire",https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-613-9-million-from-2022-to-2027--growing-research-in-gene-therapy-for-cvds-and-orphan-diseases-is-the-major-market-trend--technavio-302002646.html,2023-12-01 07:35:00,"Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... PR ...",GILD,0.048523,0.017903,Neutral
2 Biotech Stocks You Can Buy and Hold for the Next Decade,https://www.fool.com/investing/2023/11/30/2-biotech-stocks-you-can-buy-and-hold-for-the-next/,2023-11-30 13:30:00,"These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.",GILD,0.366832,0.261516,Somewhat-Bullish
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies,https://www.zacks.com/stock/news/2190744/car-t-cell-therapies-under-fda-watch-on-reports-of-malignancies,2023-11-29 13:37:00,"The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.",GILD,0.093289,0.057718,Neutral
GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV PROJECTS IN ASIA PACIFIC,https://www.prnewswire.com/apac/news-releases/gilead-sciences-awards-over-us1-5-million-to-strengthen-support-for-community-led-hiv-projects-in-asia-pacific-302000007.html,2023-11-29 03:00:00,GILEAD SCIENCES AWARDS OVER US$1.5 MILLION TO STRENGTHEN SUPPORT FOR COMMUNITY-LED HIV ... PR ...,GILD,0.197682,0.235055,Somewhat-Bullish
US FDA investigating safety risk of CAR-T cancer therapies,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-investigating-safety-risk-car-t-cancer-therapies-2023-11-28/,2023-11-28 18:42:00,"Signage is seen outside of the Food and Drug Administration ( FDA ) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Acquire Licensing Rights Nov 28 ( Reuters ) - The U.S.",GILD,0.113062,-0.247011,Somewhat-Bearish
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD,https://www.zacks.com/stock/news/2189596/gsk-key-drugs-vaccines-help-stock-outperform-industry-ytd,2023-11-27 13:46:00,"Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.",GILD,0.19331,0.083423,Neutral
Patients Regain Weight After They Quit Using Ozempic Rival Zepbound. Here's Why That Makes Eli Lilly Stock an Even Better Buy.,https://www.fool.com/investing/2023/12/16/ozempic-zepbound-eli-lilly-stock-better-buy/,2023-12-16 10:55:00,Lilly's weight loss drug appears to be on the way to becoming a megablockbuster.,GILD,0.165409,0.170712,Somewhat-Bullish
Gilead  ( GILD )  Outperforms Industry in 6 Months: What Lies Ahead?,https://www.zacks.com/stock/news/2198930/gilead-gild-outperforms-industry-in-6-months-what-lies-ahead,2023-12-15 17:49:00,Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.,GILD,0.194242,0.095526,Neutral
Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: Here's Why,https://www.zacks.com/stock/news/2198306/gilead-sciences-gild-stock-sinks-as-market-gains-heres-why,2023-12-14 22:50:04,"In the closing of the recent trading day, Gilead Sciences (GILD) stood at $81.78, denoting a -1.58% change from the preceding trading day.",GILD,0.659949,0.300743,Somewhat-Bullish
Envista Holdings Corporation Appoints Three New Members to Leadership Team,https://www.prnewswire.com/news-releases/envista-holdings-corporation-appoints-three-new-members-to-leadership-team-302015992.html,2023-12-14 21:10:00,"BREA, Calif., Dec. 14, 2023 /PRNewswire/ -- Envista Holdings Corporation ( NYSE: NVST ) today announced the expansion of its leadership team, with the recent appointments of Robert Befidi as President, Diagnostics. Suraj Satpathy as Chief Human Resources Officer. and Andrew Chen as Chief ...",GILD,0.058047,0.018019,Neutral
"Pediatric Health Care Products and Services Market Set to Surge at 6.9% CAGR, to Reach USD 173.5 billion by 2031| Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/23/12/g36201229/pediatric-health-care-products-and-services-market-set-to-surge-at-6-9-cagr-to-reach-usd-173-5-bil,2023-12-12 16:30:00,"Wilmington, Delaware, United States, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The market for pediatric health care products and services is projected to thrive with an anticipated CAGR of 6.9% between 2023 and 2031.",GILD,0.033562,0.0,Neutral
10 Best Tech Stocks For 2024,https://www.forbes.com/sites/investor-hub/article/best-tech-stocks-for-2024/,2023-12-12 15:38:42,"In this article, I look at the power and potential of technology stocks in shaping your investment portfolio. Read on to discover the compelling benefits of owning tech stocks, their dynamic nature, their ability to drive substantial growth and how to navigate the ever-evolving landscape in 2024.",GILD,0.010915,0.173467,Somewhat-Bullish
"A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street",https://www.fool.com/investing/2023/12/12/a-bull-market-is-coming-1-stock-that-could-rocket/,2023-12-12 10:29:00,There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.,GILD,0.052685,-0.074158,Neutral
"Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/23/12/36179349/gilead-sciences-battles-rising-threat-of-drug-counterfeiting-initiates-legal-actions,2023-12-11 17:11:51,"Gilead Sciences Inc GILD faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion in counterfeit drugs annually.",GILD,0.375251,-0.274068,Somewhat-Bearish
Fraud in a bottle: How Big Pharma takes on criminals who make millions off counterfeit drugs,https://www.cnbc.com/2023/12/11/fraud-in-a-bottle-big-pharma-takes-on-counterfeit-drugs.html,2023-12-11 14:00:01,A CNBC investigation found criminal networks altering pill bottles of lifesaving drugs and then selling them back to pharmacies at large discounts.,GILD,0.018243,-0.078369,Neutral
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks,https://www.fool.com/investing/2023/12/10/emerging-risk-problem-big-pharma-stocks/,2023-12-10 18:48:00,"Regulators are already on the case, and their findings will have financial impacts.",GILD,0.090304,0.027038,Neutral
Gilead Sciences  ( GILD )  Outpaces Stock Market Gains: What You Should Know,https://www.zacks.com/stock/news/2195772/gilead-sciences-gild-outpaces-stock-market-gains-what-you-should-know,2023-12-08 22:50:05,"In the latest trading session, Gilead Sciences (GILD) closed at $79.02, marking a +1.24% move from the previous day.",GILD,0.576289,0.31023,Somewhat-Bullish
"Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights",https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html,2023-12-08 07:14:00,"BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.",GILD,0.028833,0.001897,Neutral
Why Is Gilead  ( GILD )  Up 1.9% Since Last Earnings Report?,https://www.zacks.com/stock/news/2194972/why-is-gilead-gild-up-19-since-last-earnings-report,2023-12-07 16:30:57,Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,GILD,0.068112,0.142095,Neutral
A Look Into Gilead Sciences Inc's Price Over Earnings - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/12/36135209/a-look-into-gilead-sciences-incs-price-over-earnings,2023-12-07 15:00:29,"Looking into the current session, Gilead Sciences Inc. GILD shares are trading at $79.44, after a 0.10% increase. Moreover, over the past month, the stock increased by 5.57%, but in the past year, fell by 10.01%.",GILD,0.340915,-0.01236,Neutral
Merck's lung cancer drug combo fails to meet trial goal,https://www.reuters.com/business/healthcare-pharmaceuticals/mercks-lung-cancer-drug-combo-fails-meet-trial-goal-2023-12-07/,2023-12-07 11:13:00,Dec 7 ( Reuters ) - Merck ( MRK.N ) said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not meet the main goal in a mid-stage study.,GILD,0.218817,0.036954,Neutral
Harpoon Therapeutics Strengthens Leadership Team - Harpoon Therapeutics  ( NASDAQ:HARP ) ,https://www.benzinga.com/pressreleases/23/12/g36382813/harpoon-therapeutics-strengthens-leadership-team,2023-12-26 12:30:00,"James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 ( GLOBE NEWSWIRE ) -- Harpoon Therapeutics, Inc.",GILD,0.049221,0.066801,Neutral
Harpoon Therapeutics Strengthens Leadership Team,https://www.globenewswire.com/news-release/2023/12/26/2801063/0/en/Harpoon-Therapeutics-Strengthens-Leadership-Team.html,2023-12-26 12:30:00,"James Bucher, J.D. joins as Chief Legal Officer ...",GILD,0.040011,0.065714,Neutral
"$100 Invested In This Stock 20 Years Ago Would Be Worth $1,100 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/news/23/12/36379733/100-invested-in-this-stock-20-years-ago-would-be-worth-1-100-today,2023-12-25 18:00:57,"Gilead Sciences GILD has outperformed the market over the past 20 years by 5.22% on an annualized basis producing an average annual return of 12.73%. Currently, Gilead Sciences has a market capitalization of $99.26 billion.",GILD,0.980595,0.386944,Bullish
A Look Into Gilead Sciences Inc's Price Over Earnings - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/23/12/36364654/a-look-into-gilead-sciences-incs-price-over-earnings,2023-12-22 16:00:26,"Looking into the current session, Gilead Sciences Inc. GILD shares are trading at $79.75, after a 1.03% increase. Moreover, over the past month, the stock spiked by 5.79%, but in the past year, fell by 6.19%.",GILD,0.340915,-0.046641,Neutral
"Nasdaq Gains 100 Points; CarMax Earnings Top Views - Clene  ( NASDAQ:CLNN ) , Annexon  ( NASDAQ:ANNX ) ",https://www.benzinga.com/news/earnings/23/12/36350420/nasdaq-gains-100-points-carmax-earnings-top-views,2023-12-21 19:23:03,"U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76. The S&P 500 also rose, gaining, 0.50% to 4,721.72. Materials shares jumped by 0.7% on Thursday.",GILD,0.06211,0.197164,Somewhat-Bullish
"Crude Oil Moves Lower; Micron Issues Strong Forecast - DMK Pharmaceuticals  ( NASDAQ:DMK ) , Clene  ( NASDAQ:CLNN ) ",https://www.benzinga.com/news/earnings/23/12/36347681/crude-oil-moves-lower-micron-issues-strong-forecast,2023-12-21 16:59:53,"U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37,296.40 while the NASDAQ rose 0.77% to 14,891.87. The S&P 500 also rose, gaining, 0.68% to 4,730.26. Health care shares jumped by 1% on Thursday.",GILD,0.062434,0.197188,Somewhat-Bullish
"Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More",https://www.zacks.com/stock/news/2201158/biotech-stock-roundup-cgen-up-on-gild-deal-mrna-gains-on-study-data-more,2023-12-21 16:39:00,"Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.",GILD,0.136113,0.05447,Neutral
Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today? - HOOKIPA Pharma  ( NASDAQ:HOOK ) ,https://www.benzinga.com/general/biotech/23/12/36341713/why-is-immunotherapy-focused-hookipa-pharma-stock-soaring-today,2023-12-21 16:02:18,"Gilead Sciences Inc GILD announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc HOOK for approximately $21.25 million, at $1.4167 per share. In addition, HOOKIPA has the right to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata ...",GILD,0.443626,0.481409,Bullish
"Dow Jumps 250 Points; US Weekly Jobless Claims Edge Higher - DMK Pharmaceuticals  ( NASDAQ:DMK ) , Clene  ( NASDAQ:CLNN ) ",https://www.benzinga.com/news/earnings/23/12/36344590/dow-jumps-250-points-us-weekly-jobless-claims-edge-higher,2023-12-21 14:48:30,"U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. Following the market opening Thursday, the Dow traded up 0.72% to 37,348.90 while the NASDAQ rose 0.96% to 14,919.80. The S&P 500 also rose, gaining, 0.78% to 4,734.96.",GILD,0.080728,0.201193,Somewhat-Bullish
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences,https://www.globenewswire.com/news-release/2023/12/21/2799897/0/en/HOOKIPA-Pharma-Announces-21-25-Million-Equity-Investment-from-Gilead-Sciences.html,2023-12-21 12:01:00,"NEW YORK and VIENNA, Austria, Dec. 21, 2023 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK, 'HOOKIPA' ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Gilead Sciences ( 'Gilead' ) has purchased 15 million ...",GILD,0.032871,0.040987,Neutral
Gilead Stock Could Finally Have a Breakout Year. Here's Why.,https://www.barrons.com/amp/articles/gilead-stock-breakout-year-2024-1dbb7728,2023-12-21 07:30:00,"Investors have been waiting years for Gilead Sciences to finally recover from its blowup in 2016. Will 2024 be the year it finally does? It's hard to remember now, but Gilead was once the hottest of biotech stocks. That was back in the 2010s, when it cured hepatitis C.",GILD,0.140896,0.209919,Somewhat-Bullish
Gilead Sciences  ( GILD )  Stock Moves -1.13%: What You Should Know,https://www.zacks.com/stock/news/2200767/gilead-sciences-gild-stock-moves--113-what-you-should-know,2023-12-20 22:50:12,"In the closing of the recent trading day, Gilead Sciences (GILD) stood at $78.59, denoting a -1.13% change from the preceding trading day.",GILD,0.596978,0.25759,Somewhat-Bullish
Why Is RedHill Biopharma  ( RDHL )  Stock Surging Today? - Redhill Biopharma  ( NASDAQ:RDHL ) ,https://www.benzinga.com/general/biotech/23/12/36327726/redhills-investigational-covid-19-drugs-combined-with-gileads-show-effect-against-ebola,2023-12-20 18:01:31,RedHill Biopharma Ltd RDHL says opaganib and RHB-107 ( upamostat ) demonstrated robust synergistic effects when combined individually with Gilead Sciences Inc GILD Veklury ( remdesivir ) in a new U.S. Army-funded and conducted Ebola virus in vitro study.,GILD,0.269776,-0.032663,Neutral
"Gilead  ( GILD ) , Compugen Collaborate for Immunotherapy Program",https://www.zacks.com/stock/news/2200585/gilead-gild-compugen-collaborate-for-immunotherapy-program,2023-12-20 15:33:00,Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.,GILD,0.365166,0.092221,Neutral
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola,https://www.prnewswire.com/news-releases/redhill-and-us-army-announce-opaganib-and-rhb-107-combinations-with-remdesivir-show-distinct-synergistic-effect-against-ebola-302020104.html,2023-12-20 13:45:00,RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic ... PR ...,GILD,0.028138,-0.057413,Neutral
Is American Century U.S. Quality Value ETF  ( VALQ )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2200357/is-american-century-us-quality-value-etf-valq-a-strong-etf-right-now,2023-12-20 11:20:06,Smart Beta ETF report for ...,GILD,0.115787,0.044463,Neutral
Compugen's stock rockets on deal with Gilead for anti-tumor drug,https://www.marketwatch.com/story/compugen-stock-rockets-on-anti-tumor-drug-deal-with-gilead-411f9617,2023-12-19 15:52:00,Shares are halted for volatility but rise to highest levels since mid-2022 on resumed trading.,GILD,0.488777,0.189445,Somewhat-Bullish
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? - Compugen  ( NASDAQ:CGEN ) ,https://www.benzinga.com/general/biotech/23/12/36302707/why-is-cancer-immunotherapy-focused-compugen-stock-is-trading-higher-today,2023-12-19 15:36:45,"Gilead Sciences Inc GILD announced an agreement with Compugen Ltd CGEN to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the COM503 drug candidate.",GILD,0.285526,0.248491,Somewhat-Bullish
 ( GILD )  - Analyzing Gilead Sciences's Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/23/12/36290043/gild-analyzing-gilead-sciencess-short-interest,2023-12-18 19:30:39,"Gilead Sciences's GILD short percent of float has fallen 4.29% since its last report. The company recently reported that it has 17.42 million shares sold short, which is 1.56% of all regular shares that are available for trading.",GILD,0.221819,0.083071,Neutral
Gilead Sciences  ( GILD )  Stock Falls Amid Market Uptick: What Investors Need to Know,https://www.zacks.com/stock/news/2206596/gilead-sciences-gild-stock-falls-amid-market-uptick-what-investors-need-to-know,2024-01-05 23:00:19,"In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.",GILD,0.504646,0.212063,Somewhat-Bullish
"This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns - Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36473452/this-analyst-downgrades-bristol-myers-squibb-cautions-amid-product-launch-and-reven,2024-01-03 17:29:30,"BofA Securities downgraded Bristol-Myers Squibb & Co BMY, noting that initially, the analyst believed that Bristol's loss of exclusivity ( LOEs ) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate for these losses and boost ...",GILD,0.303175,0.282842,Somewhat-Bullish
 ( GILD )  - Analyzing Gilead Sciences's Short Interest - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/short-sellers/24/01/36468482/gild-analyzing-gilead-sciencess-short-interest,2024-01-03 13:30:19,"Gilead Sciences's GILD short percent of float has risen 6.41% since its last report. The company recently reported that it has 18.50 million shares sold short, which is 1.66% of all regular shares that are available for trading.",GILD,0.221819,0.155473,Somewhat-Bullish
Galapagos signs agreement to transfer JyselecaÂ® business to Alfasigma,https://www.globenewswire.com/news-release/2024/01/02/2802388/0/en/Galapagos-signs-agreement-to-transfer-Jyseleca-business-to-Alfasigma.html,2024-01-02 06:00:00,"Mechelen, Belgium. 02 January 2024, 07:00 CET. Galapagos NV ( Euronext & NASDAQ: GLPG ) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' JyselecaÂ® ( filgotinib ) business to Alfasigma, marking a significant milestone in Galapagos' transformation into ...",GILD,0.032382,0.151775,Somewhat-Bullish
Galapagos signs agreement to transfer JyselecaÂ® business to Alfasigma - Galapagos  ( NASDAQ:GLPG ) ,https://www.benzinga.com/pressreleases/24/01/g36446176/galapagos-signs-agreement-to-transfer-jyseleca-business-to-alfasigma,2024-01-02 06:00:00,"Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos' Chief Commercial Officer, to join Alfasigma Mechelen, Belgium. 02 January 2024, 07:00 CET.",GILD,0.031446,0.151309,Somewhat-Bullish
Gilead Sciences  ( GILD )  Stock Moves -0.16%: What You Should Know,https://www.zacks.com/stock/news/2203937/gilead-sciences-gild-stock-moves--016-what-you-should-know,2023-12-29 23:00:18,"In the latest trading session, Gilead Sciences (GILD) closed at $81.01, marking a -0.16% move from the previous day.",GILD,0.523451,0.195074,Somewhat-Bullish
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/news/24/01/36612997/1000-invested-in-gilead-sciences-20-years-ago-would-be-worth-this-much-today,2024-01-12 16:00:48,"Gilead Sciences GILD has outperformed the market over the past 20 years by 5.26% on an annualized basis producing an average annual return of 12.66%. Currently, Gilead Sciences has a market capitalization of $107.43 billion.",GILD,0.980595,0.386944,Bullish
Gilead Sciences  ( GILD )  Increases Despite Market Slip: Here's What You Need to Know,https://www.zacks.com/stock/news/2209192/gilead-sciences-gild-increases-despite-market-slip-heres-what-you-need-to-know,2024-01-11 23:00:19,"In the closing of the recent trading day, Gilead Sciences (GILD) stood at $85.39, denoting a +1.05% change from the preceding trading day.",GILD,0.629492,0.263205,Somewhat-Bullish
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report,https://www.prnewswire.com/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-302027294.html,2024-01-08 08:00:00,"Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies",GILD,0.020266,-0.125978,Neutral
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report,https://www.newswire.ca/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-802561925.html,2024-01-08 08:00:00,"Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies",GILD,0.020266,-0.125978,Neutral
Behind the Scenes of Gilead Sciences's Latest Options Trends - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/insights/options/24/01/36788587/behind-the-scenes-of-gilead-sciencess-latest-options-trends,2024-01-25 19:46:30,"Whales with a lot of money to spend have taken a noticeably bearish stance on Gilead Sciences. Looking at options history for Gilead Sciences GILD we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish ...",GILD,0.634884,0.003648,Neutral
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2215507/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2024-01-25 11:20:04,Sector ETF report for ...,GILD,0.138066,0.072464,Neutral
"Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More",https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more,2024-01-24 15:42:00,Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.,GILD,0.134841,-0.19626,Somewhat-Bearish
"Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of ""Risks Of Secondary Cancer' - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/24/01/36760938/gileads-tecartus-dropped-from-fda-list-of-car-t-therapy-with-updated-label-warning-of-risks-of-se,2024-01-24 15:36:09,"Tuesday, the FDA announced to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.",GILD,0.353898,-0.336118,Somewhat-Bearish
"Immunotherapy Drugs Market Size Anticipated to Surge to USD 237.4 billion at 7.1% CAGR by 2031 - Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/01/g36754138/immunotherapy-drugs-market-size-anticipated-to-surge-to-usd-237-4-billion-at-7-1-cagr-by-2031-tran,2024-01-24 11:14:00,"Wilmington, Delaware, United States, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global immunotherapy drugs market is estimated to flourish at a CAGR of 7.1% from 2023 to 2031.",GILD,0.101725,0.322411,Somewhat-Bullish
Gilead Sciences  ( GILD )  Outperforms Broader Market: What You Need to Know,https://www.zacks.com/stock/news/2214622/gilead-sciences-gild-outperforms-broader-market-what-you-need-to-know,2024-01-23 23:00:18,"Gilead Sciences (GILD) concluded the recent trading session at $79.48, signifying a +1.34% move from its prior day's close.",GILD,0.612033,0.275728,Somewhat-Bullish
"If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today - Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/insights/news/24/01/36746523/if-you-invested-100-in-this-stock-20-years-ago-you-would-have-1-000-today,2024-01-23 21:05:36,"Gilead Sciences GILD has outperformed the market over the past 20 years by 5.49% on an annualized basis producing an average annual return of 13.02%. Currently, Gilead Sciences has a market capitalization of $98.72 billion.",GILD,0.980595,0.386944,Bullish
Gilead  ( GILD )  Down as NSCLC Study Fails to Meet Primary Goal,https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal,2024-01-23 16:37:00,Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.,GILD,0.184363,-0.120509,Neutral
"Company News for Jan 23, 2024",https://www.zacks.com/stock/news/2214086/company-news-for-jan-23-2024,2024-01-23 14:04:00,Companies In The Article ...,GILD,0.570165,-0.399008,Bearish
"Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment - Johnson & Johnson  ( NYSE:JNJ ) , Novartis  ( NYSE:NVS ) , Gilead Sciences  ( NASDAQ:GILD ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-,2024-01-23 13:19:18,"In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies. In its January 19 notification letters, the agency stressed that the potential risk applies to all ...",GILD,0.175859,0.007437,Neutral
"FDA Demands ""Boxed Warning"" to CAR T-Cell Therapy Labels",https://www.zacks.com/stock/news/2214008/fda-demands-boxed-warning-to-car-t-cell-therapy-labels,2024-01-23 13:08:00,"The FDA directs companies like NVS, BMY, GILD and others to add ""boxed warning"" to the labels of their CAR T-cell immunotherapies after it identified adverse events.",GILD,0.167322,0.034274,Neutral
Gilead sinks after lung cancer drug fails to improve survival,https://www.financialexpress.com/healthcare/pharma-healthcare/gilead-sinks-after-lung-cancer-drug-fails-to-improve-survival/3372692/,2024-01-23 08:31:27,"Gilead Sciences Inc.'s Trodelvy failed to significantly improve survival in a trial of patients with advanced lung cancer, a blow to the targeted treatment that's in one of the most promising classes in oncology.",GILD,0.098255,0.004662,Neutral
Why Gilead Sciences Stock Got Mashed on Monday,https://www.fool.com/investing/2024/01/22/why-gilead-sciences-stock-got-mashed-on-monday/,2024-01-22 23:08:02,A late-stage trial of an otherwise successful cancer drug failed to produce the desired results.,GILD,0.27432,0.138927,Neutral
"Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer",https://www.prnewswire.com/news-releases/non-alcoholic-fatty-liver-disease-market-to-observe-impressive-growth-by-2032-evaluates-delveinsight--key-companies---medicinova-eli-lilly-and-company-astrazeneca-madrigal-pharmaceuticals-biomarin-pharmaceutical-glaxosmithk-302040349.html,2024-01-22 22:01:00,"Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key ... PR ...",GILD,0.043381,0.059524,Neutral
Stock Market Today: Stocks Build on Broad-Based Gains,https://www.kiplinger.com/investing/stocks/stock-market-today-stocks-build-on-broad-based-gains,2024-01-22 21:10:10,"Stocks continued to build on their record levels Monday even as expectations for future interest rate cuts have become less optimistic. After notching its first new closing high in more than two years on Friday, the S&P 500 celebrated the confirmation of its new bull market by adding another 0.2% ...",GILD,0.261117,-0.078344,Neutral
"Dow Gains Over 100 Points; Archer-Daniels-Midland Shares Plunge - Digital World Acq  ( NASDAQ:DWAC ) , Archer-Daniels Midland  ( NYSE:ADM ) ",https://www.benzinga.com/news/earnings/24/01/36722779/dow-gains-over-100-points-archer-daniels-midland-shares-plunge,2024-01-22 19:19:48,"U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.27% to 37,967.81 while the NASDAQ rose 0.31% to 15,358.70. The S&P 500 also rose, gaining, 0.23% to 4,850.71. Industrials shares rose by 0.7% on Monday.",GILD,0.146469,-0.243344,Somewhat-Bearish
"Stock Indexes Trade At All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday? - Abbott Laboratories  ( NYSE:ABT ) , Archer-Daniels Midland  ( NYSE:ADM ) ",https://www.benzinga.com/news/earnings/24/01/36721881/stock-indexes-trade-at-all-time-highs-ahead-of-key-earnings-this-week-whats-driving-markets-monday,2024-01-22 18:34:49,"Following a record-breaking week for the S&P 500, U.S. stocks continue to be on the rise as investors eagerly await this week's key earnings reports with optimism.",GILD,0.186738,-0.180388,Somewhat-Bearish
"Crude Oil Surges Over 2%; US Leading Economic Index Falls In December - Digital World Acq  ( NASDAQ:DWAC ) , Archer-Daniels Midland  ( NYSE:ADM ) ",https://www.benzinga.com/news/earnings/24/01/36720255/crude-oil-surges-over-2-us-leading-economic-index-falls-in-december,2024-01-22 17:18:12,"U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Monday. The Dow traded up 0.41% to 38,018.23 while the NASDAQ rose 0.30% to 15,356.67. The S&P 500 also rose, gaining, 0.25% to 4,851.78. Real estate shares rose by 0.7% on Monday.",GILD,0.158,-0.254413,Somewhat-Bearish
Stock Market Can't Be Held Back; S&P 500 Delights Investors,https://www.investors.com/market-trend/stock-market-today/stock-market-cant-be-held-sp-500-delights-investors/,2024-01-22 15:51:00,Stock Market Can't Be Held Back. S&P 500 Delights Investors Investor's Business Daily ...,GILD,0.117486,-0.083338,Neutral
Gilead's stock tumbles toward biggest selloff in more than nine years as lung-cancer trial disappoints,https://www.marketwatch.com/story/gileads-stock-tumbles-toward-biggest-selloff-in-more-than-9-years-after-lung-cancer-treatment-trial-disappoints-785e6886,2024-01-22 15:04:00,Shares of Gilead Sciences tumbled 9.7% early Monday after the company reported disappointing lung-cancer trial results.,GILD,0.212115,-0.239508,Somewhat-Bearish
Why Is HIV Drug Giant Gilead Stock Trading Lower Today? - Gilead Sciences  ( NASDAQ:GILD ) ,https://www.benzinga.com/general/biotech/24/01/36716385/why-is-hiv-drug-giant-gilead-stock-falling-monday,2024-01-22 14:23:31,Gilead Sciences Inc GILD said its Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival ( OS ) in previously treated metastatic non-small cell lung cancer ( NSCLC ) . EVOKE-01 is evaluating Trodelvy ( sacituzumab govitecan-hziy.,GILD,0.397098,-0.011056,Neutral
Gilead Stock Crashes 9% After Cancer Drug Fails A Key Test,https://www.investors.com/news/technology/gild-stock-topples-as-trodelvy-fails-to-pass-muster-in-lung-cancer-test/,2024-01-22 14:02:00,GILD Stock Topples As Trodelvy Fails To Pass Muster In Lung Cancer Test Investor's Business Daily ...,GILD,0.598621,-0.647459,Bearish
"The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker - Ansys  ( NASDAQ:ANSS ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",https://www.benzinga.com/markets/equities/24/01/36685633/exclusive-the-buy-everything-market-is-over-synopsys-ansys-merger-provides-fertile-ground-for-th,2024-01-18 20:54:52,"The Federal Reserve is driving the market bus. Rate cut expectations have been re-drawn, and the ""buy everything"" sentiment that powered equity indices higher in the final quarter of 2023 is over. This is now a stock picker's market.",GILD,0.162802,0.114804,Neutral
List Price Of Ozempic And Other Drugs Reportedly Rise: Here's What That Means For Consumers,https://www.forbes.com/sites/ariannajohnson/2024/01/18/list-price-of-ozempic-and-other-drugs-reportedly-rise-heres-what-that-means-for-consumers/,2024-01-18 19:49:30,"Almost 800 medications-including Ozempic and Mounjaro-had a median list price increase of 4.5% this month, according to a Wall Street Journal report, meaning copays may increase for consumers.",GILD,0.056808,0.046999,Neutral
Medicare drug price negotiations hit critical phase,https://www.marketwatch.com/story/medicare-drug-price-negotiations-hit-critical-phase-1f52a7e2,2024-01-18 15:32:00,"The federal government is set to make its opening offers in Medicare drug price negotiations, as courts prepare to weigh in on the process.",GILD,0.071357,0.072962,Neutral
"AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' - Arch Capital Group  ( NASDAQ:ACGL ) , AbbVie  ( NYSE:ABBV ) ",https://www.benzinga.com/trading-ideas/long-ideas/24/01/36673096/abbvie-arch-capital-gilead-sciences-and-a-telecom-giant-on-cnbcs-final-trades,2024-01-18 14:36:18,"On CNBC's ""Halftime Report Final Trades,"" Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. GILD is an inexpensive way to give biotech exposure. Gilead Sciences, last month, said that it has purchased 15 million shares of HOOKIPA Pharma Inc HOOK for approximately $21.25 million, at $1.4167 ...",GILD,0.522333,0.426395,Bullish
Gilead Sciences  ( GILD )  Rises As Market Takes a Dip: Key Facts,https://www.zacks.com/stock/news/2211770/gilead-sciences-gild-rises-as-market-takes-a-dip-key-facts,2024-01-17 23:00:17,"In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.",GILD,0.549988,0.190998,Somewhat-Bullish
Can AI and a supercomputer beat the markets? This is one of the hedge funds trying to find out.,https://www.marketwatch.com/story/can-ai-and-a-supercomputer-beat-the-markets-this-is-one-of-the-hedge-funds-trying-to-find-out-25283664,2024-01-17 17:47:00,Castle Ridge is tiny and based in a hedge fund backwater. But Adrian de Valois Franklin is betting artificial intelligence will give it an edge.,GILD,0.063341,0.053015,Neutral
"Cell Therapy Market Global Surge to Over USD 26.8 Billion by 2033, Fueled by Growing Demand in United States",https://www.benzinga.com/pressreleases/24/01/g36658512/cell-therapy-market-global-surge-to-over-usd-26-8-billion-by-2033-fueled-by-growing-demand-in-unit,2024-01-17 13:21:47,"New York, Jan. 17, 2024 ( GLOBE NEWSWIRE ) -- According to Market.us, the global Cell Therapy Market size is forecasted to exceed USD 26.8 Billion by 2033, with a promising CAGR of 16.9% from 2024 to 2033.",GILD,0.056363,0.182015,Somewhat-Bullish
"Disney, Caterpillar, McDonald's, Ford: Investing Action Plan",https://www.investors.com/research/investing-action-plan/disney-stock-caterpillar-mcdonalds-ford-investing-action-plan/,2024-02-02 23:00:00,"Disney Stock, Caterpillar, McDonald's, Ford: Investing Action Plan Investor's Business Daily ...",GILD,0.053931,0.11074,Neutral
Gilead  ( GILD )  Gears Up to Report Q4 Earnings: Whats in Store?,https://www.zacks.com/stock/news/2220108/gilead-gild-gears-up-to-report-q4-earnings-whats-in-store,2024-02-02 13:28:00,Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.,GILD,0.25168,0.237815,Somewhat-Bullish
"Exploring Analyst Estimates for Gilead  ( GILD )  Q4 Earnings, Beyond Revenue and EPS",https://www.zacks.com/stock/news/2219377/exploring-analyst-estimates-for-gilead-gild-q4-earnings-beyond-revenue-and-eps,2024-02-01 14:15:24,"Evaluate the expected performance of Gilead (GILD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",GILD,0.143415,0.093043,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2219196/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2024-02-01 11:20:06,Smart Beta ETF report for ...,GILD,0.122894,0.06159,Neutral
"$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - Peoples Financial  ( OTC:PFBX ) , Amrep  ( NYSE:AXR ) ",https://www.benzinga.com/trading-ideas/long-ideas/24/02/36883775/320m-bet-on-this-healthcare-stock-check-out-these-3-stocks-insiders-are-buying,2024-02-01 11:09:28,"Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.",GILD,0.118064,0.17713,Somewhat-Bullish
Gilead Sciences  ( GILD )  Earnings Expected to Grow: Should You Buy?,https://www.zacks.com/stock/news/2218016/gilead-sciences-gild-earnings-expected-to-grow-should-you-buy,2024-01-30 15:00:47,Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,GILD,0.101154,0.091829,Neutral
"Why Is Arcus Biosciences Stock Trading Higher Today? - Arcus Biosciences  ( NYSE:RCUS ) , Gilead Sciences  ( NASDAQ:GILD ) ",https://www.benzinga.com/general/biotech/24/01/36840331/pharma-giant-gilead-raises-stake-in-cancer-focused-arcus-biosciences-stock-soars,2024-01-30 11:27:56,Arcus Biosciences Inc RCUS shares are trading higher after Gilead Sciences Inc GILD amended their collaboration agreement and announced a separate equity investment of $320 million in Arcus stock at $21.00 per share.,GILD,0.421485,0.451638,Bullish
"Microsoft, UPS, GM, Pfizer, Super Micro Computer, Calix, Sanmina, and More Stock Market Movers",https://www.barrons.com/amp/articles/stock-market-movers-67acb5bd,2024-01-30 09:25:00,"Microsoft, Alphabet, Super Micro Computer, Calix, Sanmina, and More Market Movers ...",GILD,0.075635,0.220979,Somewhat-Bullish
Gilead Sciences  ( GILD )  Stock Sinks As Market Gains: Here's Why,https://www.zacks.com/stock/news/2217470/gilead-sciences-gild-stock-sinks-as-market-gains-heres-why,2024-01-29 22:50:19,"Gilead Sciences (GILD) reachead $79.07 at the closing of the latest trading day, reflecting a -0.57% change compared to its last close.",GILD,0.601928,0.243924,Somewhat-Bullish
Why Is HOOKIPA Pharma Stock Trading Lower Today? - HOOKIPA Pharma  ( NASDAQ:HOOK ) ,https://www.benzinga.com/general/biotech/24/01/36830043/roche-walks-away-from-hookipa-pharma-partnered-kras-focused-cancer-deal,2024-01-29 17:55:20,HOOKIPA Pharma Inc HOOK will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive ( HPV16+ ) head and neck squamous cell carcinoma ( HNSCC ) and its two Gilead Science Inc GILD-partnered infectious disease ...,GILD,0.258351,0.10518,Neutral
"Medicare patients with highest COVID risks were less likely to get treatment, study finds",https://www.marketwatch.com/story/medicare-patients-with-highest-covid-risks-were-less-likely-to-get-treatment-study-finds-831ae6ed,2024-01-26 16:00:00,"Medicare patients who were at the highest risk of severe COVID-19 infections were less likely to get Paxlovid or other treatments, according to new research.",GILD,0.089965,0.006338,Neutral
Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarketsâ¢.,https://www.prnewswire.com/news-releases/regenerative-medicine-market-worth-49-0-billion--marketsandmarkets-302044495.html,2024-01-26 15:30:00,"CHICAGO, Jan. 26, 2024 /PRNewswire/ -- Regenerative Medicine Market in terms of revenue was estimated to be worth $16.0 billion in 2023 and is poised to reach $49.0 billion by 2028, growing at a CAGR of 25.1% from 2023 to 2028 according to a new report by MarketsandMarketsâ¢.",GILD,0.073773,0.107998,Neutral
The Slow Saucer Base Has Quick Returns,https://www.investors.com/how-to-invest/investors-corner/how-to-invest-the-slow-saucer-base-can-produce-quick-returns/,2024-01-26 13:00:00,How To Invest: Slow Saucer Base Has Quick Returns Investor's Business Daily ...,GILD,0.167322,-0.080079,Neutral
